CA2832266A1 - Method of profiling gene expression in a human subject having diabetes - Google Patents

Abstract

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers.
The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Description

METHOD OF PROFILING GENE EXPRESSION IN A HUMAN
SUBJECT HAVING DIABETES
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to the molecular biology of human diseases. More specifically, the present invention relates to a process using the genetic information contained in human peripheral whole blood for the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body.
Description of the Related Art The blood is a vital part of the human circulatory system for the human body. Numerous cell types make up the blood tissue including monocytes, leukocytes, lymphocytes and erythrocytes. Although many blood cell types have been described, there are likely many as yet undiscovered cell types in the human blood. Some of these undiscovered cells may exist transiently, such as those derived from tissues and organs that are constantly interacting with the circulating blood in health and disease. Thus, the blood can provide an immediate picture of what is happening in the human body at any given time.

The turnover of cells in the hematopoietic system is enormous. It was reported that over one trillion cells, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes, turn over each day in the human body (Ogawa 1993). As a consequence of continuous interactions between the blood and the body, genetic changes that occur within the cells or tissues of the body will trigger specific changes in gene expression within blood. It is the goal of the present invention that these genetic alterations be harnessed for diagnostic and prognostic purposes, which may lead to the development of therapeutics for ameliorating disease.
The complete profile of gene expression in the circulating blood remains totally unexplored. It is hypothesized that gene expression in the blood is reflective of body state and, as such, the resultant disruption of homeostasis under conditions of disease can be detected through analysis of transcripts differentially expressed in the blood alone. Thus, the identification of several key transcripts or genetic markers in blood will provide information about the genetic state of the cells, tissues, organs and systems of the human body in health and disease.
The prior art is deficient in non-invasive methods of screening for tissue-specific diseases. The present invention fulfills this long-standing need and desire in the art.
SUMMARY OF THE INVENTION
This present invention discloses a process of using the genetic information contained in human peripheral whole blood in the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body. The process described herein requires a simple blood sample and is, therefore, non-invasive compared to conventional practices used to detect tissue specific disease, such as biopsies.

2 One object of the present invention is to provide a non-invasive method for the diagnosis, prognosis and monitoring of genetic and infectious disease in humans and animals.
In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject. comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood.
In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the genes are tissue-specific genes.
In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA
fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.
In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of

3 the therapeutic treatment: and repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms.
In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:
a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject: d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.
In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising:
a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s).
Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.
In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.
Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

4 Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification.
It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.not be considered to limit the scope of the invention.
Figure 1 shows the following RNA samples prepared from human blood; Figure 1A: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene;

Lane 3, PCR on APP gene; Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC
gene; Figure 1B: Lanes 1 and 2. RT-PCR and PCR off3MyHC, respectively; Lanes 3 and 4, RT-PCR of 13MyHC from RNA prepared from human fetal and human adult heart, respectively; Lane 5, Molecular weight marker.
Figure 2 shows quantitative RT-PCR analysis performed on RNA
samples extracted from a drop of blood. Forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3", SEQ ID No. 2) of exons 1 and 2 of insulin gene.
Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and 7 represent overnight "fasting" blood sample and lanes 2, 4, 6 and 8 represent "non-fasting"
samples.

5 Figure 3 shows quantitative RT-PCR analysis performed on RNA
samples extracted from a drop of blood. Lanes 1 and 2 represent normal healthy person and lane 3 represents late-onset diabetes (Type II) and lane 4 represents asymptomatic diabetes.
Figure 4 shows multiple RT-PCR assay in a drop of blood. Primers were derived from insulin gene (INS), zinc-finger protein gene (ZFP) and house-keeping gene (GADH). Lane 1 represents normal person. Lane 2 represents late-onset diabetes and lane 3 represents asymptomatic diabetes.
Figure 5 shows standardized levels of insulin gene (Figure 5A) and ZFP gene (Figure 5B) expressed in a drop of blood. The first three subjects were normal, second two subjects showed normal glucose tolerance, and the last subject had late onset diabetes type II. Figure 5C shows standardized levels of insulin gene expressed in each fractionated cell from whole blood.
Figure 6 shows the differential screening of human blood cell cDNA
library with different cDNA probes of heart and brain tissue. Figure 6A shows blood cell cDNA probes vs. adult heart cDNA probes. Figure 6B shows blood cell cDNA
probes vs. human brain cDNA probes.
Figure 7 graphically shows the 1,800 unique genes in human blood and in the human fetal heart grouped into seven cellular functions.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed.

1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

6 Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture"
[R.I.
Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)); B.

Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.
A " cDNA" is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. "RT-PCR"
refers to reverse transcription polymerase chain reaction and results in production of cDNAs that are complementary to the mRNA template(s).
The term "oligonucleotide" is defined as a molecule comprised of two or more deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The factors involved in determining the appropriate length of primer are readily known to one of ordinary skill in the art.
As used herein, random sequence primers refer to a composition of primers of random sequence, i.e. not directed towards a specific sequence.
These

7 sequences possess sufficient complementary to hybridize with a polynucleotide and the primer sequence need not reflect the exact sequence of the template.
"Restriction fragment length polymorphism" refers to variations in DNA sequence detected by variations in the length of DNA fragments generated by restriction endonuclease digestion.
A standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue obtained from plant or other tissue, in accordance with conventional Northern hybridization techniques known to those persons of ordinary skill in the art. The Northern blot uses a hybridization probe, e.g.
radiolabelled cDNA, either containing the full-length, single stranded DNA or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length).
The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art. The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untxaviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from 3H, 14C, 32p, 35s, 36C1, 51Cr, 57Co, 58Co, 59Fe, 90y, 1251, 1311, and 186Re. Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like.
Many enzymes which can be used in these procedures are known and can be utilized.

8

9 The preferred are peroxidase, P-glucuronidase, P-D-glucosidase, 13-D-ga1actosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos.
3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.
As used herein, "individual" refers to human subjects as well as non-human subjects. The examples herein are not meant to limit the methodology of the present invention to human subjects only, as the instant methodology is useful in the fields of veterinary medicine, animal sciences and such.
In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood. An example of the quantifying method is by mass spectrometry.
In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the subject is a fetus, an embryo, a child, an adult or a non-human animal. The genes are non-cancer-associated and tissue-specific genes. Still preferably, the amplification is performed by RT-PCR
using random sequence primers or gene-specific primers.
In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA
fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.
In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of the therapeutic treatment; and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms. Preferably, the amplification is performed by RT-PCR, and the change of the expression of the genes in the ESTs is monitored by sequencing the ESTs and comparing the resulting sequences at various time points; or by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the ESTs at various time points.
In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:
a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising:
a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s).
Preferably, the gene-specific primers are selected from the group consisting of insulin-specific primers, atrial natriuretic factor-specific primers, zinc finger protein gene-specific primers, beta-myosin heavy chain gene-specific primers, amyloid precurser protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers. Further preferably, the gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ II) Nos. 5 and 6. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.
In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.
Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

Construction of a cDNA library RNA extracted from human tissues (including fetal heart, adult heart, liver, brain, prostate gland and whole blood) were used to construct unidirectional cDNA libraries. The first mammalian heart cDNA library was constructed as early as 1982. Since then, the methodology has been revised and optimal conditions have been developed for construction of human heart and hematopoietic progenitor cDNA
libraries (Liew et al., 1984; Liew 1993, Claudio et al., 1998). Most of the novel genes which were identified by sequence annotation can now be obtained as full length transcripts.

Catalogue of blood cell ESTs Random partial sequencing of expressed sequence tags (ESTs) of cDNA clones from the blood cell library was carried out to establish an EST
database of blood. The known genes as derived from the ESTs were categorized into seven major cellular functions (Hwang, Dempsey et al., 1997).

Differential screening of cDNA library cDNA probes generated from transcripts of each tissue were used to hybridize the blood cell cDNA clones (Liew et al., 1997). The "positive"
signals which were hybridized with P-labelled cDNA probes were defined as genes which shared identity with blood and respective tissues. The "negative" spots which were not exposed to P-labelled cDNA probes were considered to be blood-cell-enriched or low frequency transcripts.

Reverse transcriptase-polymerase chain reaction (RT-PCR) assay RNA extracted from samples of human tissue was used for RT-PCR
analysis (Jin et al. 1990). Three pairs of forward and reverse primers were designed for human cardiac beta-myosin heavy chain gene (PMyHC), amyloid precurser protein (APP) gene and adenomatous polyposis-coli protein (APC) gene. The PCR
products were also subjected to automated DNA sequencing to verify the sequences as derived from the specific transcripts of blood.

Detection of tissue specific gene expression in human blood using RT-PCR
The beta-myosin heavy chain gene (pMyHC) transcript (inRNA) is known to be highly expressed in ventricles of the human heart. This sarcomeric protein is important for heart muscle contraction and its presence would not be expected in other non-muscle tissues and blood. In 1990, the gene for human cardiac 13MyHC was completely sequenced (Liew et al. 1990) and was comprised of 4 ;xons and 42 introns.
The method of reverse transcription polymerase chain reaction (RT-PCR) was used to determine whether this cardiac specific mRNA is also present in human blood. A pair of primers was designed; the forward primer (SEQ ID No. 3) was on the boundary of exons 21 and 22, and the reverse primer (SEQ ID No. 4) was on the boundary of exons 24 and 25. This region of mRNA is only present in i3MyHC
and is not found in the alpha-myosin heavy chain gene (aMyHC).
A blood sample was first treated with lysing buffer and then undergone centrifuge. The resulting pellets were further processed with RT-PCR. RT-PCR
was performed using the total blood cell RNA as a template. A nested PCR product was generated and used for sequencing. The sequencing results were subjected to BLAST
and the identity of exons 21 to 25 was confirmed to be from 13MyHC (Figure 1B).
Using the same method just described, two other tissue specific genes -amyloid precursor protein (APP, forward primer, SEQ ID No. 7; reverse primer, SEQ
ID No. 8) found in the brain and associated with Alzheimer's disease, and adenomatous polyposis coli protein (APC) found in the colon and rectum and associated with colorectal cancer (Groden et al. 1991; Santoro and Groden 1997) -were also detected in the RNA extracted from human blood (Figure 1A).

Multiple RT-PCR analysis on a drop of blood from a normal/diseased individual A drop of blood was extracted to obtain RNA to carry out quantitative RT-PCR analysis. Specific primers for the insulin gene were designed: forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3" , SEQ ID No. 2) of exons 1 and 2 of insulin gene. Such reverse primer was obtained by deleting the intron between the exons 1 and 2. Blood samples of 4 normal subjects were assayed. It was found that the insulin gene is expressed in the blood and the quantitative expression of the insulin gene in a drop of blood is influenced by fasting and non-fasting states of normal healthy subjects (Figure 2). This very low level of expression of the insulin gene reflects the phenotypic status of a person and strongly suggests that there is a physiological and pathological role for its expression, contrary to the basal or illegitimate theory of transcription suggested by Chelly et al. (1989) and Kimoto (1998).
Same quantitative RT-PCR analysis was performed using insulin specific primers on RNA samples extracted from a drop of blood from a normal healthy person, a person having late-onset diabetes (Type II) and a person having asymptomatic diabetes. It was found that the insulin gene is expressed differentially amongst subjects that are healthy, diagnosed as type II diabetic, and also in an asymptomatic preclinical patient (Figure 3).
Similarly, specific primers for the atrial natriuretic factor (ANF) gene were designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No. 6) and RT-PCR analysis was performed on a drop of blood. ANF is known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients.
However, atrial natriuretic factor was observed to be expressed in the blood and the expression of the atrial natriuretic factor gene is significantly higher in the blood of patients with heart failure as compared to the blood of a normal control patient.
Specific primers for the zinc finger protein gene (ZFP, forward primer, SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed and RT-PCR
analysis was performed on a drop of blood. ZFP is known to be high in heart tissue biopsies of cardiac hypertrophy and heart failure patients. In the present study, the expression of ZFP was observed in the blood as well as differential expression levels of ZFP amongst the normal, diabetic and asymptomatic preclinical subjects (Figure 4); although neither of the non-normal subjects has been specifically diagnosed as suffering from cardiac hypertrophy and/or heart failure, the higher expression levels of the ZFP gene in their blood may indicate that these subjects are headed in that general direction.
It was hypothesized that a housekeeping gene such as glyceraldehyde dehydrogenase (GADH) which is required and highly expressed in all cells would not be differentially expressed in the blood of normal vs. disease subjects. This hypothesis was confirmed by RT-PCR using GADH specific primers (Figure 4).
Thus, GADH is useful as an internal control.
Standardized levels of insulin gene or ZFP gene expressed in a drop of blood were estimated using a housekeeping gene as an internal control relative to insulin or ZFP expressed (Figures 5A & 5B). The levels of insulin gene expressed in each fractionated cell from whole blood were also standardized and shown in Figure 5C.

Human blood cell cDNA library In order to further substantiate the present invention, differential screening of the human blood cell cDNA library was conducted. cDNA probes derived from human blood, adult heart or brain were respectively hybridized to the human blood cDNA library clones. As shown in Figure 7, more than 95% of the "positively" identified clones are identical between the blood and other tissue samples.
DNA sequencing of randomly selected clones from the human whole blood cell cDNA library was also performed. This allowed information regarding the cellular function of blood to be obtained concurrently with gene identification. More than 20,000 expressed sequence tags (ESTs) have been generated and characterized to date, 17.6% of which did not result in a statistically significant match to entries in the GenBank databases and thus were designated as "Novel" ESTs. These results are summarized in Figure 7 together with the seven cellular functions related to percent distribution of known genes in blood and in the fetal heart.
From 20,000 ESTs, 1,800 have been identified as known genes which may not all appear in the hemapoietic system. For example, the insulin gene and the atrial natriuretic factor gene have not been detected in these 20,000 ESTs but their transcripts were detected in a drop of blood, strongly suggesting that all transcripts of the human genome can be detected by performing RT-PCR analysis on a drop of blood.
In addition, approximately 400 novel genes have been identified from the 20,000 ESTs characterized to date, and these will be subjected to full length sequencing and open reading frame alignment to reduce the actual number of novel ESTs prior to screening for disease markers.
Analysis of the approximately 6,283 ESTs which have known matches in the GenBank databases revealed that this dataset represents over 1,800 unique genes. These genes have been catalogued into seven cellular functions.
Comparisons of this set of unique genes with ESTs derived from human brain, heart, lung and kidney demonstrated a greater than 50% overlap in expression (Table 1).

Overlap of Genes Expressed in Blood *
Tissues ESTs** Overlap in Blood brain 134,000 60%
heart 65,000 59%
lung 60,200 58%
kidney 32,300 54%

* Estimated from limited known genes of about 1,800 as derived from the database of 6,297 ESTs from human blood cell library.
** Obtained from the National Centre of Biotechnology Information (NCBI), U.S.A.

Blood cell ESTs The results from the differential screening clearly indicate that the transcripts expressed in the whole blood are reflective of genes expressed in all cells and tissues of the body. More than 95% of detectable spots were identical from two different tissues. The remaining 5% of spots may represent cell- or tissue-specific transcripts; however, results obtained from partial sequencing to generate ESTs of these clones revealed most of them not to be cell- or tissue-specific transcripts.
Therefore, the negative spots are postulated to be reflective of low abundance transcripts in the tissue from which the cDNA probes were derived.
An alternative approach that was employed to identify transcripts expressed at low levels is the large-scale generation of expressed sequence tags (ESTs). There is substantial evidence regarding the efficiency of this technology to detect previously characterized (known) and uncharacterized (unknown or novel) genes expressed in the cardiovascular system (Hwang & Dempsey et al.. 1997).
In the present invention, 20,000 ESTs have been produced from a human blood cell cDNA library and resulted in the identification of approximately 1,800 unique known genes (Table 2) In the most recent GenBanIc release, analysis of more than 300,000 ESTs in the database (dbESTs) generated more than 48,000 gene clusters which are thought to represent approximately 50% of the genes in the human genome. Only 4,800 of the dbESTs are blood-derived. In the present invention, 20,000 ESTs have been obtained to date from a human blood cDNA library, which provides the world's most informative database with respect to blood cell transcripts. From the limited amount of information generated so far (i.e. 1,800 unique genes), it has already been determined that more than 50% of the transcripts are found in other cells or tissues of the human body (Table 2). Thus, it is expected that by increasing the number of ESTs generated, more genes will be identified that have an overlap in expression between the blood and other tissues. Furthermore, the transcripts for several genes which are known to have tissue-restricted patterns of expression (i.e. r3MyHC, APP, APC, ANF, ZFP) have also been demonstrated to be present in blood.
Most recently, a cDNA library of human hematopoietic progenitor stem cells has also been constructed. From the limited set of 1,000 ESTs, there are at least 200 known genes that are shared with other tissue related genes (Claudio et al.
1998).
Table 2 demonstrates the expression of known genes of specific tissues in blood cells. Previously, only the presence of "housekeeping" genes would have been expected. Additionally, the presence of at least 25 of the currently known 500 genes corresponding to molecular drug targets was detected. These molecular drug targets are used in the treatment of a variety of diseases which involve inflammation, renal and cardiovascular function, neoplastic disease, immunomodulation and viral infection (Drews & Ryser, 1997). It is expected that additional novel ESTs will represent future molecular drug targets.

Comparison of 1,800 Unique Genes Identified in the Blood Cell cDNA Library to Genes Previously Identified in Specific Tissues No. of Accession -Gene Identification ESTs No. Tissue Distribution Br Br - F-1 K Li Lu 100 kDa coactivator 2 U22055 ' + ' +
10kD protein (BC10) 2 AF053470 . + + - + +
_ 14-3-3 epsilon 2 ' U54778 - + _+ +
14-3-3 protein ' 11 028964 -+ - -+ +
_ 15-kDa selenoprotein T AF051894 ' + + +
(SEP15) . .
1-phosphatidylinosito1-4- 1 578798 -phosphate 5-kinase isoforrn C
23 klrhighly basic protein - 21 ' X56932 + + + + + +
2-5A-dependent lillase 1 L10381 2'-5'oligoadenylate 4 M87284 B
synthetase 2 (OAS2) . .
36-k0a phosphothyrosine 2 - AJ223280 T +
protein .
3-7 gene product (non- 1 064159 -exact 86%aa) 3-phosphoglycerate ' 1 AF006043 T + + ' + -dehydrogenase (PGAD) 3-pnme-phosphoadenosine . 2 U53447 + + + + ' +
5-prime-phosphosulfate synthase 1 (PAPSS1) 46kd mannose 6- 1 X56257 phosphate receptor (MPR46) (low match) '5-aminoimidazore-4- 1 089976 carboxamide ribonucieotide transformylase 5'-nucleotidase 3 ' D38524 ' T
_ ..
6-phosphofructo-2- T 049818 +
kinase/fructose-2,6-biphosphatase 4 (PFKFB4) 6-phosphotructo-2- 1 - AI-041829 = kinase/fructose-2,6-bisphosphatase (PF2K) . . , (1 kd heat shock cognate 23 Y00371 --protein hsc70 76 kDa membrane protein Z U81-006 + + - + + +
(P76) 8-oxoguanine DNA 1 096710 ' 5 gtycosyiase (OGG1) a disintegrin and - 1 AF0096T5 T ' ' + ' metalloprotease domain 10 (ADAM10) a disintegnn and 1 ' 025579 13 - + ' metalloprotease domain 8 (ADAM8) A kinase anchor protein 95 ' 2 Y1T997 ' B, T + ' +
(AKAP95) activated A kinase anchor protein, 2 - X97335 + + " + ^ +
149kD (AKAP149) A4 differentiation- 1 U93305 dependent protein (A4), triple UM domain protein (LM06), and synaptophysin (SYP);
calcium channel alpha-1 subunit (CACNA1F) _ . .
'Aliil.. and putative M8604 1 - U07561 -Met protein Absent in melanoma 1 1 U83115 ' + + ¨ +
(AIM1) "
accessory proteins ' 2 Z31696 ' + - +

(DXS1357E) acetyl-Coenzyme A -2 X12966 " + " + + + + - +
acyltransferase (peroxisomal 3-oxoacyl-Coenzyme A thiolase) (ACM) acetyl-Coenzyme A 1 1 D88152 T lymphoma' + + ' transporter (ACATN) , acidic 82 kDa protein 4 U15552 acidic protein rich in 1 Y07969 5 " + + ' + ' + "
leucines (SSP29) Acomtase 2, mitochondria! 1 U80040 +
+ + + +
(ACO2) .
. .
actin binding protein 1 AF059569 MAYVEN .
actin, beta (AU (B) 158 X04098 1, B + ' +
+
actin, beta (AC B) (non- 1 M10277 exact, low match 73%) .
actin, gamma (low score) 1 - K00791 actin, gamma f (AC1G1) 4 X04098 +
- + ' + + " + ' + -high in many libraries actin-binding LIM protein 4 D31883 + ¨ + + ¨ +
(ABLIM) .
Actinfn, alpha 1 (AC íN1) - 8 M95178 ' + + + +
actinin, alpha 4 (ACTN4) ' 1 D89980 ' + ' + ' ' +
activated p21cdc42fis ' 1 L13738 ' B " + ' +
kinase (ACK) .
activated RNA polymerase 1 X79805 ' + + + + +
iltranscription cofactor 4 (PC4) . .
activating transcription 1 X55544 +
factor 1 (ATF1) , i _.
activating transcription 1 X15875- + + +
factor 2 (ATF2) , . _ ' _ activating transcription 2 M86842- .4. +
factor 4 (tax-responsive enhancer element 867) (ATF4) -active BCR-related gene 1 U01147 ' + + + + +
(ABR) :
¨ . .
'acyl-CoA oxidase (ACM) 1 U03254 ' acyl-Coenzyme A ' 2 M16827 dehydrogenase, C-4 to C-12 straight chain (ACADM) acyl-Coenzyme A ' 3 043682 - + + -- + + + +
dehydrogenase, very long chain (ACADVL) 'acyloxyacyl hydrolase 3 M62840 - T .1. ' + 4.
(neutrophil) (AOAH) - --adaptin, delta (ADM) 2 U91930 + + +
adaptin, delta (AD (D) 1 -- AC005328 (non-exact 59%) .
'adaptin, gamma (ADTG) 1 - Y12226 + + +
+ .
adapror complex sigma38 - 2 X99459 + - + +
(AP3S3) acfaptor protein p150- -- 1 Y08991 , adducin 1 pha) (ADD1) 2 - L07261 ' + +
+ J

adducin 1 (a)pha) (add1) 3 ' L29296 + + + + +
, adducin 3 (gamma) (A01.)3) 3 U37122 B, NA1 + + + +
adenine nucleotide 2 ' M57424 . + + +
translocator 2 (fibroblast) (ANT2) adenine nucleotide 1 J02683 translocator 2 (fibroblast) (ANT2) (non-exact 81%) adenine nucleotide 1 J02883 translocator 2 (fibroblast) (ANT2) (non-exact, 79%) .
. , adenine nucleotide 1 42883 translocator 2 (fibroblast) (ANT2) (non-exact, 86%) , adenine nucleotide ' 3 J03592 + + + +
translocator 3 (liver) (ANT3) adenosine deaminase, ' 6 U18121 ' + ' + +
RNA-specific (ADAR) adenylate cyclase 3 2 - Al-033861 + ' + + " + + ' ,(ADCY3) adenylate cyclase 7 I ' 025538 (ADCY7) , adenylate kinase 2 (A1(2) 2 U39945 + - + ' ' + +
, ________________________________________________________________________ adenylate kinase 3 (AK3) 1 X60673 (non-exact, 67%) adenyiyi cyclase- 28 M98474 T " + - +
associated protein (CAP) , adipose differentiation- 1 X97324 . + + +
related protein; adipophilin (ADFP) ADP-nbosylation factor 1 13 ' M84326 _ + + ' + ' + "
(ARF1) ADP-nbosylition factor 3 2 M33384 + - + ' +
(ARF3) . , ADP-nbosylation factor 4" 1 M36341 T lymphoma + + +
(ARF4) ADP-nbosylation factor 5 1 M57567 - + + +
+ -(ARF5) __________________________________________________________________ ADP-nbosylatton factor 1 L04510 ' +
domain protein 1, 64kD
(ARFD1) _ ADP-ribosyltransferase 4 ' M32721 + _ + + + + +
(NAD+; poly (ADP-ribose) polymerase) (ADPRT) adrenergic, beta, receptor 2 X61157 a " + " +
kinase 1 (ADRBK1) _______________________________________________________ adrenoleukaystrophy-like ' 1 AJ000327 1 (ALDL1) , - ¨
AL-binding protein 1 1 ' 086479 (AEBP1) (non-exact, 62%) -._ , ________________________________________________________________________ .. .
A-gamma-globin 1 V00514 _ ________________________________________________________________________ _ A"-gamma-giobin 1 J00176 (chromosome 11 allele - -'agammaglobulinaemia 1 U78027 , tyrosine kinase (ATI9 AHNAK nucleoprotein 4 M80899 + + + + +
(desmoyokin) (AHNAK) alanyi (membrane) 1 X13276 + - +
aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal .
aminopeptidase, CD13, =
p150) (ANPEP) -_ alcohol dehydrogenase 5 1 ' m2gb /2 (class III), chi polypeptide (ADH5) - ___________ 1 aldehyde dehydrogenase ' 1 AF003341 + + +
1, soluble (ALDH1) 1 k .

aldehyde dehydrogenase 2 ' U75286 ' (fatty aldehyde dehydrogenase) (ALDH10) aldehyde reductase i (low - 3 J04795 - B + + ' + - + -Km aldose reductase) (ALDR1) aldo-keto reductase family - 2 J04794 B + - + ' ' + ' 1, member A1 (aldehyde reductase) (AKR1A1) , -aldo-keto reductase family 1 .
017793 + + _ + +
1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3) alcto-keto reducttse family - 1 Y16675 + + + - +
"
7, member A2 (aflatoxin aldehyde reductase) ,(AKR7A2) aldolase A, fructose- ' 7 ' X12447 + + + -bisphosphate (ALDOA) aldolase C, fructose- 2 -X05196 + + +
bisphosphate (ALDOC) alkaline phosphatase, 1 4502062-liver/bone/kidney (ALPL) ALL-1 (r-Ll54/31;L04284 4 Z69780 .
HRX) alpha mannosidase II 1 055649 + ' +
isozyme -alpha thalassemia/mental 3 U75653 + + + + +
retardation syndrome X-linked (ATRX) alpha-2 macroglobulin 1 Z11711 , alpha-2-globin 2 V00516 , ______________ alpha-Zmacroglobuhn 1 - 006985 receptor/lipoprotein receptor protein (A2MR/LRP) alpha-polypeptide of N- 1 M13520 acetyl-alpha-glucosaminIdase (HEXA2 alpha-spectnn 1 X86901 .. _______________________ alpha-subunit of Gaa 1 X07854 -(GTP-binding signal transduction protein) 'aminin receptor 1 (67-10); 2 J03799 T + + , + +
Ribosomal protein SA
(LAMR1) , ammolevuti-hate, delta-, 1 , X64467 , + ......_ dehydratase (ALAD) , L H
amino--lerminal enhancer of' 2 X73358 + + + + +
split (AES) _ __________________ 'amino-terminal enhancer of ' 3 ¨ U04241 B + + + +
split (AES) , ____________________ AMP deaminase isoform L 8 ' M91029 ' + +
.(AMPD2) amphiphysin (Stitt-Mann 1 U07616 Er ' + - +
syndrome with breast cancer 128kD autoantigen) (AMPH) , amptuphysin (Stitt-Mann 1 U07616 syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%2_ , amphiphysin (Stitt-Wiann 1 U07616 .-1-syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%) .
amphiphysin II ' 4 U87558 + + +
, ____________________ amphiphysin If (67% a 1 AF068915 amphiphysin?) amphiphysin II (non-exact - 1 AF001383 , 69% aa) amphiphysin-like (AMPHL) 1 _______________ U68485 4. 4.
amphiphysin-like (AMPHL) '- I Al-068918 _ (low match) _ AMY-1 1 ' 050692 B, T - +
amyloid beta (A4) - 1 L77864+ ... .
+ + +
precursor protein-binding, family B, member 1 (Fe65) (APBB1) -amyloid beta (A4) - 6 L27631 1 lymphoma + + + +
precursor-like protein 2 (APLP2) .
ankyrin 3, node of Ranvier 1 U43965 (ankyrin G) (ANK) (non-exact, 50%) annexin 1 (lipocortin 1) 1 X05908 ' + + ' + -+ ' (ANX1) annexin 11 1 028364 -annexin 11 (lipocortin 11; 7 000017 + + - + - + - + + high in many libraries calpactin I, heavy polypeptide) (ANX2) annexin IV (placental ' 1 M19383 + + + + ' +
anticoagulant protein 11) (ANX4) annexin V (endonexin 11) 2 M21731 + + + ' +
(ANX5) annexin V (endonexin 11) 1 M19384 + + + +
(ANXV) ¨
-annexin VI (p68) (ANX6) 6 Y00097 + + + +
-annexin VII (synexin) 1 J04543 ' + + + ' +
(ANX7) antigen identified-by -2 11AT62/9 _____ + ' + + +
monoclonal antibodies 12E7, F21 and 013 (MIC2) antigen identified by 3 J02939 + + + + +
monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1) .
antigen TQ1 1 anti-oxidant protein 2 (non- 1 - 014662----' + " + ' + ' + +
selenium g(utathione peroxidase, acidic calcium-independent phospholipase A2) (KIAA0106) APEX-nuclease 5 X66133 + - + + +
(multifunctional DNA repair enzyme) (APEX) .
Apapoprotein L (APOL) 1 Z82215 ' (59%aa) .
apoptosis inhibitor 1-(APF1) - 1 L49431 + + + + +
apoptosis inhibitor 4 - 1 U75285 B, W + + + -(survivin) (API4) .
apoptosis inhibitor 5 (API5) 1 083857 1 lymphoma + "a +
, osis specific protein 1 ' Y11-588 B + + +
in 124 apoptofic protease ' 1 AF013263 6 4. + + ' activatin9 factor (APAF1) , aquaponn 3 (AQP3) 1 AE3001325 T ' ' +
aquaponn 9 (AQP9) - 7 A60087/b i activated +
arachid-ohate 12- 1 M58704 T + +
lipoxy9enase (ALOX12) . - .
arachidonate 5- ' 3 - X52195 + + + +
lipoxygenase-activating protein (ALOX5AP) .
ariadne homolog (ARI) 1 AJ009771 + + + + +
anadne-2(D. ' 1 - AF099149 + + + - +
+
melanogaster) homolog (all-trans retinoic acid inducible RING finger) (AR12) ARP1 (actin-related protein 1 X82206 + +
1, yeast) homolog A
(centractin alpha) (ACTR1A) ARP2 (achn-related protein 9 AI-006082 - + + + +
2, yeast) homolog (ACTR2) ARP2/3 protein compex 5 ' Al- 006085 T activated, +
+ +
subunit 34 (ARC34) W
Arp2J3-protein compex 6 AF006084- monocyte + + +
subunit p41 (ARC411 stimulated Arp2/3 protein compex 1 ' AF006084 subunit p41 (ARC41)) (low match) Arp2/3 protein complex 20 AF01780T - + + ' + +
subunit p16 VtIRC16) _ Arp2/3 protein comfflex 2 AFOO6U87 + + ' P + +
subunit p20 (ARC20) Arp2/3 protein complex 3 Al-905086 W + +
subunit p21(ARC21) .. , ARP3 (actin-related protein 11 - Al-UtRi083' W + + +
3, yeast) homolog (ACTR3) arrestin, beta 2 (ARM:52) 1 AF106841 B, T, W + - + +
arsA (bacterial) arsenite 1 AF047469 13, T + - +
transporter, ATP-binding, homolog 1 (ASNA1) _ aryl hydrocarbon receptor - 2 AF044288 B + + + ' nuclear translocator-like (ARNTL) .
aryl hydrocarbon receptor- 1 U31913 + + ' + + ' + ' interacting protein (AIP
aryisultatase A (ARSA) 1 X52151 T activated + +
, asialoglycoprotein receptor - 1 __ 1411025 + +
2 (ASGR2) .
asparaginyi-tRNA 3 084273 ' + + + ' synthetase (NARS) ._ ... - . .
.
aspartyl-tRNA synthetase 1 J05032 a + + +
(DARS) _ .. _ ataxia tAnglectesia 1 U52828 ' B, T + +
mutated (includes complementation groups A, C and D) (ATM) ataxin-2-like protein A2LP 1 AF034373 B, T + ' + - +
(A2LG) activated -1 _ AI F6 " 1 F00587 ' + - +
. . .
AM binding cassette 1 U88667 transporter (ABCR) (non-exact 80%) .
ATirsrilhase (F1-A1 Prise) 1 X59066 alpha subunit, mitochondria!
ATP synthase beta subunit ' 1 M19482 "
gene _ A IP synthase, H+ ' 1 X60221 + + + ' + ' +
transporting, mitochondrial FO complex, subunit b, isoform 1 (ATP5F1) -Al P synthase, H+ 1 X69907 T activated + + ' + ' + ' transporting, mitochondria!
FO complex, subunit c (subunit 9), isoform 1 (ATP5G1) -A i P synthase, H+ ' 3 014710 transporting, mitochondria!
F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) A I F' synthase, H+ ' 1 1314710 transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) (low match) -Al P synthase, H+ 2 M27132 1 ________________________ transporting, mitochondria' F1 complex, beta polypeptide (ATP5B) ATP synthase, H+ 1 ' D16563 W - + + + +
transporting, mitochondria' F1 complex, gamma polypeptide 1 (ATP5C1) A1 P synthase, hi+ " 1 ' AF092124 + + + + + +
transporting, mitochondrial FIFO, subunit g (ATP5JG) 'Al P/G1 P-binding protein 2 ' U73524 - + + + + +
(HEAB) ATPase, Ca++ - 5 - L69881 ' +
transporting, ubiquitous (ATP2A3) ATPase, H+ transporting, 2 D89052 + + + + - +
lysosomal (vacuolar proton pumpj 21k0 (ATP6F) _ ATPase, H+ transporting, 1 X762a ' + + ' + + ' lysosomal (vacuolar proton pump) 31kD (ATP8E) ATPase, 11+ transporting, 5 X69151.
+ + + - + .
lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D) A I Pase, H+ transporting, 3 109235 + ' +
lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoforrn 1 (ATP6A1) Al Pase, H+ Vansporting, 6 ' X62949 + + ' + + ¨ + ' lysosomal (vacuolar proton pump), beta polypeptide, 56/581(D, isoform 2 (ATP882) ,.
Al Pase, H+ transporting, 2 ' AF038g54 - + " + ' + + +
high in testis lysosomal (vacuolar proton pump), member .1 (ATP6J) ATPase, H+ transporting, ' 1 ' 016469 + ' + + +
lysosomal (vacuolar proton = ump), subunit 1 (ATP6S1) Al P-binding cassette 50 1 ' 0027302 + + - + - + ' +
(INF-alpha stimulated) (ABC50) Ai P-binding cassette ' 1 AF047690 protein M-ABC1 (mitochondria') A I P-dependent RNA 1 ' AJ010840 ? lymphoma + ' +
helicase , 'autoantigen (Hs.75528) 2 - L05426 r activated - " + . -autoantigen (Hs.75528) 1 ' L05425 = = -=
(non-exact 84%) I. .
autoantigen (Hs.75682) 1 - U . , 17474 ' 8 + +
autoantigen La/S-13 1 - 435121"
axin (AXINI) 1 - AF009674- 4- T ' + - -axonemal dynein heavy 1 " AJ000522 +
chain (DNAH17) 8R1-associated protein 3 1 A8017111 (BAIAP3) (non-exact 54%) 1 basement membrane- 1 " AF044896 . 1 induced gene (1CB1) basic Ieuane zipper " 2 ' U79751 nuclear factor 1 (JEM-1) =
(BLZ.F1) basic transcription factor 3 ' 5 - X RUN + + + + + +
(BTF3) . _ basigin (BSG) " 1" ' L10240 ' + - - --- +
1 - AF042384 ' B + -+ +
... ______________________________________________________________________ 13-cell CLL./lymphoma 6 1 U00115 + +
(zinc finger protein 51) (BCL6) .
B-cell translocation gene 1,. 1 X61123 + +
anti-proliferative (BTG) 13CL2/adenovirus L113 1 U15173 - B + ' ' 4. 4.
19kD-interacting protein 2 (BNIP2) _ BCL.2/adenovirus E1B - 2 F067396 + + + +
19kD-interacting protein 3-like (BNIP3L) bechn 1 (coiled-coil, 1 ' AF077301 B + + + ' myosin-like BCL2-interacting protein) (BECN1) beta-1,2icr- 2 U15128 acetylglucosaminyitransfer ase II (MGA'T2) beta-2-microglobulin (B2M) 63 682297 + + + + - + + high in invasive prostate tumor beta-Fexosaminidase alpha 1 M16411 ' chain (HEXA) beta-tubulin 7 V0059 g- + + + + +
+ high in many libranes beta-tubulin (non-exact, 1 AF070561 76%) . . .
beta-tubulin, pseudogene 1 J00315 . .

biotinidase (BTD) (non-eact 1 U03274 62%) biotinidase (61D) (non- 1 U03274 exact 70%) biotinidase (B1D) (non- 1 . 1703274- -exact, 56%) PRECURSOR
biphenyl hydrolase-like 1 - X81372 + ' ¨ +
(serine hydrolase) (BPHL) bone marrow stromal cell 1 D21878 ' +
antigen 1 (BST1) .
box-dependent myc- 1 AF043900 interacting protein isoform BIN1-10 (BIN1) box-dependent myc- ' 1 F043900 interacting protein isoforrn BIN1-10 (BIN1) (non-exact, 64%) ., brain my047 protein 1 Al-063505 T + + +
õ ________________________________________________________________________ branched chain keto acid 3 Z14093 T + + +
dehydro9enase El, alpha polypephde (maple syrup urine disease) (BCKDHA) _________________________________________________ BRCA1 associated protein- - 1 D87462 + + + +
1 (ubiquitin carboxy-terminal hydrolase) (BAP1) ______________________________________________ BRCA1, Rho7 and yeti 1 L78833 genes, and 1pf35 ________________________________________________________ breakpoint cfuster region ' 2 ' AI-044773 + +
protein, uterine leiomyoma, 1; baMer to autointegration factor (BCRP1) . . .
breakpoint cluster region 2 AF044774 + + + +
protein, uterine leiomyoma, 2 (BCRP2) breast cancer anti-estrogen' 1 U92715 resistance 3 (BCAR3) (non-exact 73%) _________________________________________________________ Bromodomain-containing 2 M91585 ' +
protein, 140kD (peregriri) (BR140) 13Mton's 1 U13424 agammaglobutinemia tyrosine kinase (Btk) Bruton's tyrosine kinase 1 U78027 (BTK) -Bruton's tyrosine kinase 1 U (W2 ( ' (BTK), alpha-D-galactosidase A (GLA), L44-like ribosomal protein (L44L) and FTP3 (FTP3) 'b i L42 (Bi Ci2) 6 Y09943 + - + ' + + +
BTK region cfone ftp ' 1 -1J78027 + + + + +
BTK region c.lone ftp-3 ' 1 001923 __ - _____________ +
+ + .
BUB3 (budding uninhibited 4 ' AT-053304 + + + + +
by benzimidazoles 3, yeast) homolog (8U83) , .
butyrate response factor 1 4 X79067 + " += ¨ + + -+ ' EGF-response factor 1) BRF1) utyrophilin (BTF I) ' 7 ' [J93 - I- ..,-+ + +
butyrophilin like receptor - 1 ____ AB020625.I - -CAG repeat containing - 2 ' U80744 - += +
(CTG4A) CAGI-132 2 U80743 + + +
. .
calcium channel, voltage- 1 M83566 dependent, L type, alpha 1D subunit (CACNA1D) (low match) .
calcium/calmodulin- 1 ÄF069765 ' + + ' + ' +
dependent protein kinase (CaM kinase)11 gamma (CAMK2G) _ calcium/calmodulin- " 1 ' F101264 B - + + + ' dependent protein kinase kinase (KIAA0787) _ calmodulin (=MI9311) " 7 045887 calmodulin 1 6 M27319 B " + + + +
(phosphorylase kinase, delta) cCALM1) ..
rcalnexin (CANX) 3 M94859 T " + ' " + +
- ______________________________________________________________________ calpain, large polypeptide 5 X04366 ' += +
+ + _ LI (CAPNI) calpain, large polypeptide 5 - M23254 4. +
L2 (CANP2) , calpain, small polypeptide 1 " X04I05 ' + - +
+--- +
(CAPN4) ..
'' calpastatin (CAS F) 3 016217 - +
Calponin 2 2 - 1383735 + ' + +
4 _ _____________________ -calponin 2 (CNN2) 1 083735 B, T ' + +
.. _ .
calponin 2 (CNN2) (low 1 D83735 score) calumenin (CALU) - 3 AF013759 B ' + ' + " + ______ -, _________________________________________________________________________ _ CAMP response element- - 4 - L05912 --' binding protein CRE-Bpa (ti_GS185L15.1) cAMP-dependent protein -4 1 M90380 kinase type 11 (Ht31) , .. .
canicufar multispecific 1 AF009670 - + +
+
organic anion transporter (CMOAT2) ________________________________________________________________ capping protein (actin - a (Jb663 r B, T ' + ' +
filament) muscle Z-line, alpha 1 (CAPZA1) capping protein (actin - -2 003269 B + +
filament) muscle Z-line, alpha 2 (CAPZA2) Capping protein (actin 1 - U03271 + + + + +
filament) muscle Z-line, beta (CAPZB) capping protein (actin 8 M94345 + + I + ___ +
filament), gelsolin-like (CAPG) _ carbamoyl-phosphate 1 078586-- + + ' + + +
synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) baffionic anhydrase V, 1 L19297 ' ' + +
mitochondria' (CA5) carboxypeptidase D (CPD) ' 3 - U65090 ' B - + +
-camitineTacylcamitine 1 YT0319 + + +
translocase (CACT) Cas-Br-M (munne) ¨ 2 X57110 õ
+ .
ecotropic retroviral transforming sequence (cbl) 'casein Wiese 1, alpha 1 " 1 ' L37042 ' + ' + +
+ ' + ' (CSNK1A1) 'casein kinase 2, alpha 1 2 M55265 ' 8 + ' + - +
polypeptide (CSNIK2A1) casein kinase I gamma 3L ' 1 ' AF049090.1 (CSNK1 G3L) casein kinase 71 alp-ha 1 - X69951 subunit(S72393) CASP8 and FADDAke - 4 AF015450- _ + + + + + -. .
apoptosis regulator (CFLAR) ¨ _ caspase 1, apoptbsis- 7 U13697 + +
related cysteine protease (interleukin 1, beta, convertase) (CASP1) caspase 10, apoptosis- 1 U60519 - 5, T actiated, T +
related cysteine proteas lymphoma (CASP10) ..
caspase T apoptosis- - 3 U13'737 - B, T - + + + ¨ +
related cysteine protease (CASP3) caspase 4, apoptosis- 6 U25804 + + -- + + + -related cysteine protease (CASP4) caspase 5, apoptosis- ' 1 U28015 ' ' +
related cysteine protease (CASP5) caspase 8, apoptosis- ' 2 X98173 ' + --+ - +-related cysteine protease (CASP8) caspase 0, apoptosis- 1 U56390 13-- + + . .
related cysteine protease (CASP9) .
catalase (CAT) - 5 ' X04076 ' B + + - ¨ + -catechoi-O- 1 M65213 ' + + ' + ' methyltransferase (COMT) , -catenin (cadherin- 6 014î'O + + l--associated protein), alpha 1 (102kD) (CTNNA1) catnelicidin antimicrobial 1 . X89655 - b peptide (CAMP) cattlepsin 5 (CTSB) 4- L1-8510 + + +
cathepsin C (CTSCy 3 - U1941b + + + + ' catkepsin D (lysosomal 4 M1123'3 - + ' + ¨ +
aspartylyrotease) (CTSD) -cathepsin (CTSL) 1 J05036 ¨ + ' -cathepsin-G (C I SG) 1 - M16117 ' T, W+
cathepsin S (CTSS) 34 M86553 B, Monocyfi stimuratec, T ' + +
lymphoma _ _ 'cathepsin VV (Iymphopain) - 4 ' AF013611 -+
(CTSVV) C8Frinieracting ' 1 AF098297 corepressor CIR (=U03644 recepin) CCAAT/enhancer binding " 3 X87248 + _________ + +
+ , protein (C/EBP), alpha (CEBPA) _ CCAATfenhancer binding 1 S63168 + + +
protein (C/EBP), delta (CEBPB) GCAAT-box-binding 2 M37197 T lymphoma" - + + -transcription factor (CBF2) . .
CCR5 receptor (CCR5) 1 AF011504 (non-exact?) CD14 antigen (C014) 11 M86511 + - + + + +
CD18 (7=M95293) 4 - X64071 _ .
CD1C antigen, c 2 M28827 ' ' +
polypeptide (CD1C) .
CD2 antigen (cytoplasmic 1 AF104222 tail)-binding protein 2 (CD28P2) õ
CD2 antigen (p50), sheep 4 M14362 + + + ' ' +
red blood cell receptor (CD2) CO2 cytoplasmic tail- 2 AF038602-- ¨ ' +
bindinsprotein 1 (CD2BP1) CD2-iigen (CD20) 1 X12530 = . .
, CO20 receptor (57) 1 X0(103 -CDarlt igen (CO22) 1 U62631 ¨B
CD24 signal transducer 1 M58664 . , CD33 antigen (gp67) 1 M23197 + ' (CD33) CD33 antigen-like 2; 08 1 ._ U71383 . . .
binding protein-2 (CD33L2) (non-exact, 68%) .
CD33L2 (61% aa) 1 ' D86359 _ _ .
CDS antigen (collagen 7 M98398 T lymphoma + + +
typel receptor, thrombosportdin receptor) (CD36) CD3Tanbgen (CD37) 5 - X14046 + + ' + +
¨ , CD38 aR 1 ' D84277 C039 antigen (CD39) __ 1 U87967 B - + + +
. . . .
CD3D antigen, delta 1 - X03934 + + +
polypeptide (TiT3 complex) (CD3D) CD3E antigen, epsilon - 1 X03884 + - . + . .
polypeptide (TiT3 complex) (CD3E) CO3G antigen, gamma 2 ' "X06026 W +
polypeptide (TiT3 complex) CD3Z antigen, zeta 2 J04132 + +
polypeptide (TiT3 comp(ex) (CD3Z) CDS:zeta (clone pBS NK1) ' 1 " X55510 C04 (low match) 1 S68043 CD4 antigen (p55) (CD4) ' 4 m12807 - + + +
CD44 antigen (homing " 6 X56794 W
function and Indian blood group system (CD44) CD48 antigen (8-cell 3 '' X06341 + + ' + + ' +
membrane protein) (CD48) CD53 anbgen (CD53) 10 - L11670 - + ' + ¨ + +
CD53 antigen ((A)WO-ow 1 ' = 08 (1 =
match) . .
CD63 antigen (melanoma 1' 3 M59907 antigen) (CD63) C068 antigen (CD68) . 2 Sb72'..* 4. 4. 4. 4.

CD74 arftigen (invanant 72 K01144 + + + + + + high in many libranes polypeptide of major histocompatibility complex, class 11 antigen-associated) (CD74) CD79A antigen 2 M80462 +
(immunoglobulin-associated alpha) (C079A) , CD79B antigen 2 M89957 +
(immunoglobulin-associated beta) (C079B) _ CD8 antigen, alpha 2 M27161 + + +
polypeptide (p32) (CD8A) . .
CD8 antigen, beta 1 X 1 3 4 4 5 W
polypeptide 1 (p37) (CD8B1) CD81 antigen (target of - 1 M33680 + + +
antiproliferative antibody 1 (CD81) CD83 antigen (activated B 1 Q01151 B ' + + ' +
lymphocytes, mmunoglobulin superfamily) (CD83) .
CD84 antigen (leukocyte 1 U82988 + + +
antigen) (CD84) CD86 antigen 1 L25259 +
CO9 antigen (p24) (CD9) 2 M38690 + + +
CD97 antigen (CD97) ' 12 X84 __ /UU + + ' +
C097 antigen (CD97) 1 P48960 (noin-exact 59%) CD97 antigen (CD97) (non- 1 ' X94630 + + +
exact 62%) CDC23 (cell division cycle 1 AI-053977 + __ + +
23, yeast, homolog) (CDC23) C0C37 homolog 1 U63131 B + + + +
Cdc42 effector protein 3 2 Al-104857 El + + +
(CEP3) CDC-like kinase (CLK) 1 L29219 + + + +
CDC-likii-kinase 2 (CLK2) 1 AF023268 B + +
CDW52 antigen 13 X15183 T activated + + ' + -(CAMPATH-1 antigen) (CDW52) cell cycle progression 1 AF011794 , I
restoration 8 protein(CPR8) cell division cycle 10 4 S72008 + + + + +
(homologous to CDC10 of S. cerevisiae) (CDC10) . .
cell division cycle 20, - 1 U05340 + + +
S.cerevisiae homolog (CDC20) cell division cycle 25B 6 Z68092 + + + + +
(CDC25B) .
cell division cycle 2-like 1 1 AF06 /514 (PITSLRE proteins) (CDC2L1) (non-exact 42%) cell division cycle 42 (GTP- 5 M35543 + + - + + +
binding protein, 25kD) (CDC42) .
cell division protein (non- 1 Af-063015 ' exact 68%) _ -(S/G2 NUCLEAR
ANTIGEN) centromere protein B 1 X55039 + +
(80kD) (CENPB) cep250 centrosome 3 AF U22655 B + +
associated protein ceroid-lipofusanosis, 7 AR:117456 + + + + +
+ high in bone =
neuronal 2, late infantile (Jansky-Bielschowsky disease) (CLN2) c-fgr (4463877 6 ' X52206 nonreceptor protein-tyrosine kinase (fgr)) .
CG1-19 protein 3 AF132953.1 chaperonin containing 1 X74801 + + - +
TCP1, subunit 3 (gamma) (CCT3) chaperonin containing 1 Ai-026291 + + ' + ' + ¨
TCP1, subunit 4 (delta) (CCT4) chaperonin containing 4 L.277o6" ' B + +
TCP1, subunit 6A (zeta 1) (CCT6A) chaperonin containing 4 - AF026292 a + +
TCP1, subunit 7 (eta) (CCT7) :
Chediak-Higashi syndrome 1 U67615 B, T + ' + +
1 (CHS1)_ lymphoma .
Lhediak-Higashi syndrome 1 U67615 1 (CHS9 (low score) chemokine (C-C motif) 4 U03905 1 receptor 2 (CCR2) ________________________________________ , chemokine (C-C motif) 1 X85740 receptor 4 (CCR4) (low match) (may contain repeat) , -chemokine (C-C motif) 6 L31581 receptor 7 (CCR7) . . .
chemokine (C-X3-C) 5 U20350 +
receptor 1 (CX3CR1) .
chemogine (C-X-C motif), 5 M99293 + + + + +
receptor 4 (fusin) (CXCR4) .
chitinase 3-like 1 (cartilage 2 ' M80927 - + +
+
glycoprotein-39) (CHI3L1) thitinase 3-like 2 (CH13L2) ' 2 U49835 + ' + +
chloride channel 1 , 1 G18280 _ skeletal muscle (CLCN1) .
_ chionde channel 6 1 D28475 + +
(CLCN6) , Chlonde intracellular ' 1 U93205 + + + + + ' channel 1 (CLIC1) .
chondroitm sulfate 5 X15998 +
proteoglycan 2 (versican) (CSPG2) chondroitin sulfate 2 ' J02814 + +
proteoglycan core protein -chromatin assembly factor 1 Q09028 1 p48 subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48) (retinoblastoma-binding protein 4) (MSI1 protein homolog) chromodomain helicase 2 AI-006513 =
DNA binding protein 1 (CHD1) , chromodomain helicase 1 AF054177 DNA binding protein 1-like (CHD1L) chromodomain helicase 1 AF006514 5 + + +
DNA binding protein 2 (CHD2) ...
chromodomain helicase - 1 ' AF006515 DNA binding protein 3 (CHD3) .
_ chromomain helicase ' 5 X86691 + + + + +
DNA binding protein 4 (CHD4) chromosome 1 open 1 - AF054176- ¨
reading frame 7 (C1ORF7) , chromosome 1 specific 1 - AB007962 transcript KIAA0493 .
chromosome 17 open 1 . AJ008112 T +
reading frame 1B
(C170RF113) .
chromosome 4 open 1 - AF006621 . .4. 4. 4. +
reading frame 1 (C4ORF1) 4._ chromosome condensation 2 AF060219 + - + + +
1-like (CHC1L) chromosome X open 1 715T64 B + + - + _ reading frame 5 (CXORF5) chromosome-associated 2 AF092564 B + + + +
,polypeptide C(CAP-C) .
c1g42 1 AF026944 .. _..
ag5 3 - AF026941 citrate synthase (CS) 2 - AF047042 - + " + +
+ -=
class I major ' 2 ' U31.1/2 histocompatibility antigen (HLA-Cw3) _ class i major 1 - U3T372 histocompatibility antigen (HLA-Cw3) (low match) clathrin assembly protein 3 - U45976 ' B ' + - + +
lymphoid myeloid leukemia (CALM) . .
clathrin heavy chain " 1 X55878 _ , .
clathnn, heavy polypeptide- 1 D21260 like 2 (CLTCL2) , clathnn, light polypeptide 1 M20472 (Lca) (CLTA) (low match) clathnn- ' 3 A 066475 + " + + + +
associated/assembly/adapt or protein, medium 1 (CLAPM1) , ¨
cleavage stimulation factor,' 1 - M85085 3' pre-RNA, subunit 2 64kD
(CSTF2) (non-exact 82%) , , cleavage stimulation factor,' 1 ' U15782 B + + +
3' pre-RNA, subunit 3, 77kD (CSTF3) , cla ' 1 U9220 ' B +' 4. ' clone 23815 (Hs.82845) ' 1 U90916 ' + . + + 1 clone 24592 mRNA ' 1 ' 088378 + - + + - + ' + -sequence tlq/MBI3SPA receptor - 1 A 1J94333 C1qR(p) 0 I .
.
dusterin (complement Iysis 1 M64722 + + + + + +
inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) (CLU) , 'CMI4-sialic acid transporter 1 087969 ' B ' + " +
(CMPST) .
CMRF35 ' 3 X66171 c-myc oncogene containing. . 1 X54629 coxIll coagulation factor If ' 1 M62424 ' + + +
(thrombin) receptor (F2R) .
, coagulation factor V ' 1 M14335 ' + + +
(proaccelerin, labile factor) (F5) .
-coagulgion factor XIII a - 3 M219138 subunit coagulation factor XIII, A1 ' 6 M14354+ ' . õ.
+ + +
pdypeptide (F13A1) -coated vesicle membrane T X92098 + + + + + +
protein (RNP24) coatomer protein complex, 5 - U24105 T _____________ - +
+ .
subunit alpha (COPA . - .. .
Goblin 1 (non-muscle) - 13 - X954O4 - + ' + + + + +
high in fetal brain (CFL1) . , . .
cold inducible RNA-binding 7 D/8134 + + +
protein (CIRBP) cold shock domain protein 3 - X95325 ' + +
A (CSDA) collagen, type IX, al-pha 2 3 - AF019406 -1:3 -(COL9A2) colony stimulating factor 1 3 X03663 - + + +
receptor, formerly McDonough feline sarcoma viral (v-frns) oncogene homolog (CSF1R) . . ._ -colony stimulating factor 2 5 M59941-receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) colony stimulating factor 2 1 ' M59941 -receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) (low match) colony sfimulating factor 3 16 ' X55720 receptor (granulocyte) (CSF3R) complement component5 1 M62505 L
receptor 1 (C5a ligand) (C5R1) conserved gene amplified -- 2 AF000152 4. + + + -in osteosarcoma (054) -Cr01219 (constffutive 2 AF031647 + + +
photomorphogenic, Arabidopsis, homolog) subunit 3 (COPS3) COPla homolog (HCIDP9) 2 - U51205 g -- + ' + - +
+ +
COM protein, homolog of 4 - X97064- - + + -s. cerevisiae SEC23p (SEC23A) ____________ copine 1 (CPRE,1)-- -2 - U83246- -El + + .
+
bowel (CPNtl) (low ' 1 U83245 score) c,oproporphynnogen ' 1 D16611- + ' + +
oxidase (coproporphyria, harderoporphyria) (CPO) _ bore-binding factor, beta ' 1 E20298 +
subunit (CBFB) -carom - 22 - X89109 T, W + + +
._ .
-carom (low match) ' 1 ' U34690' coronin (non-exact, 7-1%) - 1- X89109 ' cot (cancer Osaka thyroid) 1 D1449T + + + + +
pncogene (COT) _ .. .
wyptochrome 1 - 1 D8465T + + +
(Ootolyase-like) (CRY1) D (carboxy=Terminal 1 AF081287 + + + +
domain, RNA polymerase 11, polypeptide A) phosphatase, subunit 1 (CTDP1) .
C-terminal binding protein - 1 1737408 g + + + -1 (CTBP1) _ C-temunai-binding protein - 2 F016507 + + +
2 (CTBP2) CUG tnpiet repeat, RNA- - 3 U63289 + + + + -binding protein 1 (CUGBP1) .
cullin 1 (CUL1) - 3 1J58087- + 4. + +
cullin 3 (CUL3) 2 ' U58089 . + + + ' +
. .
cut TDrosophda)-like 1- - 1- M74099 B +
(CCAAT displacement protein) (CUTL1) 'cyclin 02 (=NM) ' -2- - 013639 -,- + + + i +
cyan 03 (CCND3) 5 - M92287 5, T - + ' + ' lymphoma cyclin Gf(CNNG1) 1 078341 - B - + - + - +
cyclin l ' 3 D50310 '- B ' + +
- .
cyclin Tr(CNNT1) 1 -- AF048732 5, T 5 _ lymphoma - t _ cyclin-dependent kinase 2 ' 1 X62071 (CDK2) .
Fyclin-dependerif kinase 1 S76986 _ inhibitor (p27Kip1) cyan-dependent kinase 2 - 567388 - + + ' + ' + + ' + A
inhibitor 1A (p21, Cip1) (CDKN1A) CYP2D7-CYP2116 1 , X90926 _ , h intergenic region (partial) -cyttatin 13 (stefin B) (CSTB) 1 L0.*08 + + 4.
. - -cysteme and glyarte-nch 5 1 L54057 - + r-protein 3 (cardiac LIM
protein) (CSRP31 cybdine deaminase (CDA) 2 - L27943 - -+
' cytochrome b 1 ' AF042b00 cytocfirome b (CYTB) 1 AF042518 (isolate Au85) cytoffirome b(-245) beta 2 X05895 chain N-terminal region (X-linked granulomatous disease gene) , cytochrome b-245, beta 2 X04011 + + +
polypeptide (chronic granulomatous disease) (CYBB) cytochrome G 1 - P00001 _ .
cytochrome c oxidase 1 U90915 T + + + +
subunit IV (COX4) cytocfirome c oxidase r 2 M59250 - . .
+
subunit Vb (COX5B) -cytochrome c oxidase 6 AB007618 + + + + õ
+
subunit VII-related protein (COX7RP) , cytokine suppressive anti- 1 L35263 iymphocyle - + - + ' + ' inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1) õ
Cytoplasmic 1 - 569272 A ' ' 4.
antiproteinase=38 kda intracellular serine proteinase inhibitor cykdoxic granule- 1 1 S70114 associated RNA-binding protein p40-TIA-1 1-t)1231D123) ' 1 014878 + , '1"
+ , , 1 X74802 _ . ,...
damage-specific DNA ' 2 AJUU2Vb5- + ' + - + + ' + - + "
binding protein 1 (127kD) (DDB1) DGFir (low match y ' 1 ' AFU1/835 ZEAI)H (Asp-Glu-Ala- 1 ' U it3524 + + + + +
Asp/His) box binding protein 1 (DDXBP1) DEAD7H (Asp-Glu-Ala- 2 1./59321 T + ,- + ' + -' +
Asp) box polypeptide (72KD) (P72) 1 _ .
DEAD/H (Asp-G1u-Na- 1 1 " X70649 + + + 1' Asp/His) box polypeptide 1 (DDX1) i_ _ I

DEAD/H (Asp-(31u-Ala- 2 - AB001636 Asp/His) box polypeptide 15 (DDX15) DEAD/H (Asp-(31u-Ala- 2 ' A5f51-11-49 - + + + ' + -+ -Asp/His) box polypeptide 16 (DDX16) .
DEAD/H (Asp-Giu-Ala- 3 1J50553 - + + + - + - +
Asp/His) box polypeptide 3 (DDX3) DEAD/H (Asp-Glu-Ala- 3T X15729 ' + + + ¨ + ¨ - + ' Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5) ¨ ¨
DEAD/H (Asp-Glu-Ala- 1 ' AF-015812 Asp/His) box polypeptide 5 (RNA helicase, 68k0) (DDX5) (low match) DEAD/H (Asp-(3lu-Ala- 2 D17532 - + +
Asp/His) box polypeptide 6 (RNA helicase, 54kD) (DDX6) IDEAD/1-1(Asp-Glu-Ala- " 1 050487 + + + _______ +
Asp/His) box polypeptide 8 (RNA helicase, 54kD) (DDX8) , DEA17R (Asp-Glu-Ala- 3 L13848 + + + + +
Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase 11;
leukophysin) (DDX9) DEAD7R (Asp-Glu-Ala- 1 Ai-000985 + + ' + ' Asp/His) box polypeptide, Y chromosome (DBY) _ _ _ Death associated protein 3 2 ' X83544 + + + + + +
(DAP3) death effector domain- ' 1 AF083236 + + + +
containing protein (DEDD) .
death-associated protein 6 2 - AT-039136 + + ' +
' +
(DAXX) dedicator of cyto-kinesis 2 4 086964 ' + + ' *-+ " +
(DOCK2) defender against cell death 1 ' 015057 . + + +
1 (DAD1) Defensin, alpha 1, myeloid- 4 ' LT2690- - ¨
+ +
related segyence (DEFA1) DEK gene-01065231E) 1 ' X64229 5 .. -delta sTeep inducing 4 Z50781 + + + + +
peptide, immunoreactor (DSIPI) -crendritic cell protein 3 F064603 + + + + +
(GA17) deoxycybdine kinase 1 - M60527 (DCK) deoxyribonuclease ff, -3 ABOD4574 lysosomal (DNASE2) .
DGI 2 L77566 +
. .
diacylacerol iunase 3 - 016440 diacylgircerol kinase alpha 3 AF0647n " +
(DAGK ) (clone 24) _ diacylglycerol kinase alpha 1 AF0647T1 (DAGK1) (clone 24) (low match) . .
diaphanous (Drosophila, 1 AF051782 a, monocyte` + +
- + +
hornolog) 1 (DIAPH1) stimulated diaphorase (NADH) ' 1 Y09501 + + + + + - + -(cytochrome b-5 reductase) (DIA1) -differentiated Embryo 1 AB004066 + + +
Chondrocyte expressed gene 1 (DEC1) differentiated Embryo 1 AF3004066¨
Chondrocyte expressed gene 1 (DEC1) (low match) differentiation antigen 1 L23415 131-George syndrome critical 1 ' X84076 + + +
region gene 2 (DGCR2) dihydrolipoamide 2 J03520 + + +
dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD) _ dihydroiipoamide S- 1 Y00978 B ' + +
acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT) dihydropynmidinase=Re 2 1 D/8013 + + + +
(DRYSL2) .
dinG gene 1 Y10571 dipthena toxin resistance 3 Al-Ob . -13 + + + +
protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2) _ _ disintegnn-protease Oon- 1 Y13323 -exact 72%) DJ-1 protein 2 ¨ AF021819 + + + + +
Dmx-like 1-(DMXL1) ' 1 AJ005821 + + ' +
I- =
DNA (cytosine-)- 3 X63692 T activated, + + +
methyltransferase 1 lymphoma (DNMT1) . =
DNA fragmentation factor, 1 AF064019 40 kD, beta subunit (DFFB) DNA fragmentation factor, 2 ' U9T985¨ - T ' + + +
45 kD, alpha subunit (DFFA) .
, DNA mismatch repair I - U17840 protein (hMLH1) DNA-segment on ' 3 M64241 + + + + + + high in many libraries chromosome X (unique) 648 expressed sequence , DNA segment, single copy 3 ' M73547 1 p=--+ + + +
probe LNS-CAULNS-CAll (deleted in polyposis (D5S346) .
UNA-damage-inducible 1 L24498 transcript 1 (DDIT1) (low match) DnaJ protein - 1 AJOUT309 bnaJ protein 1 AJ001309 _ docking protein 2,-56R0 1 AF034970 _ (DOK2) dolichyl- 1 D89060 + + + + + + activated T cell diphosphooligosaccharide-protein glycosyltransferase (DDOST) dolichyl-phosphate 1 086198 T activated + + - +
mannosyltransferase polypeptide 1, catalytic subunit (DPM1) down-regulatedby - 1 AJ223183 +
activation (immunoglobulin superfamily) (DORA) .
down-regulated in 1 ' P40879 adenoma DRA (low match) D-type cyclin-interacting 1 AF082569 13 _ + +
protein 1 (DIP1) dual specifiaty 4 X68277 + + + + + +
phosphatase 1 (DUSP1) dual specificity 1 AF023917 + + + + +
phosphatase 11 (RNA/RNP
complex 1-interacting) (dusp11) dual specificity 1 L051-47 + + + +
phosphatase 3 (vaccinia virus phosphatase VH1-related) (DUSP3) dual specificity 6 X93920 + + + + + +
phosphatase 6 (DUSP6) . .
dynactin 1 (p150, Glued 3 X98801 (Drosophila) homolog) (DYTN1) dynactin 1 (p150, Glued " 1 X98801 B + +
(Drosophila) homolog) (DYTN1) (low match) dynamin 2 (DNM2) 1 L36983 .
. ..
dynamitin (dynactin 1 U50733 complex 50 kD subunit) (DCTN-50) (non-exact 88%) dynein, axonemal, heavy 1 X99947 polypeptide 17-like (non-exact, 57%aa) dynein, cytoplasmic, light 1 AF035812 B " + + ' +
intermediate polypeptide 2 (DNCLI2) . .
dynein, cytoplasmic, light 1 AF035812 intermediate polypeptide 2 (DNCLI2) (non-exact, 69%) dyskeratosis congenita 1, 1 U59151 s + ' + ' +
dyskerin (DKC1) dystonia 1, torsion 1 AF007871 + + + .
+
(autosomal dominant) (DYT1) dystrobrevin, beta (DTNB) 1 AF022728 +
dystrophia myotonica- 1 L19267 + + .I. .4.
containing WD repeat motif (DMWD) dystrophia myotonica- 1 L08835 + + + +
protein kinase (DMPK) dystrophin (muscular 1 X14298 dystrophy, Duchenne and Becker types) (DMD) (low match, 59%aa) .
E1B-55kDa-associated 1 AJ007509 W + + + +
protein h2F transcription factor 3 2 D38550 + ' + + + +
(E2F3) _ E2F transcription factor 4, 1 X86096 B + - +
p107/p130-binding (E2F4) .
E2F transcnption factor 5, 2 U15642 + + + +
p130-binding (E2F5) E74-like factor 1 (ets 1 M82882 ' 8 . + + +
domain transcription factor) (ELF1) EtaPike factor 4 (ets 3 1J32645 + + +
domain transcription factor) (ELF4) .
E74-like factor 4-(-ets 1 U32645 domain transcription factor) (ELF4) (non-exact, 71%) early development 4 U89278 + + + + +
regulator 2 (homolog of polyhomeotic 2) (EDR2) .
EBV induced G-protein 1 - L08177 W ' coupled receptor (EBI2) ecotropic viral integration 3 M60830 + +
site 2B (EVI2B) ectin, galactoside-binding, 1 - J04456 +
soluble, 1 (galectin 1) (LGALS1) EGF-Tike-domain, multiple ' 1 A6011541 4 (EGFI.4) elF-2-associated- p67 ' 3 - U13261 El + õ + .
homolog J..
elastin (supravalvular aortic 1 M24762 + +
stenosis, Williams-Beuren syndrome) (ELN) (low match) õ
elav-type RNA-binding 3 U69546 protein (ETR-3) electron-transfer- ' 2 ' J04058 ' +
flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA) .
ELK 37 El S-domain protein ' 2- Z36715 " - + ' ' +
(SRF accessory protein 2) (ELK3) elongation factor 1-beta - 1 L.2(5404 elongation factor Ts ' I ' AF110399 (mitochondrial protein) , elongation factor Tu- ' 1 X84694 nuclear encoded mitochondria! õ
eMDC Irprotein ' 1 AJ242015.1 . ________________________________________________________________________ ems1 sequence (mammary 1 M98343 ' + + + - +
tumor and squamous cell carcinoma-associated (p80185 src substrate) (EMS1) . .
endogenous retroviral 1 Z70664 element HC2 .
endosulfine alpha (ENSA) 1 ' X99906 T ' +
_ ______________ endofheilal differentiation, - 2 ' M3121-0 + + +
+
sphingolipid G-protein-coupled receptor, 1 (EDG1) .
endothelial differentiation, - 1 M31210 "
sphingolipid G-protein-coupled receptor, 1 (EDG1) (low match 66%) , endothelial monocyte- - 1 U1011-7 + + - + - + +
activating polypeptide (EMAPII) .
enoiase 1, (alpha) (ENOT) - 12 M14328 + + + + + + ' enoiase 2, (gamma, - 1 X51956 - +
neuronal) (EN02) .
enolase-alpha ' 1 D28437 , , ______________ enoyl Coenzyme A - 2 U16660 -hydratase 1, peroxisomal (ECH1) -1 ____________________________________ enoy1Coenzyme A - 1 -D13900 + + + - + + +
hydratase, short chain, 1, mitochondrial (ECHS1) ___________________________________________________ ENOYL-COA - 1 -P30084 ' HYDRATASE, MITOCHONDRIAL
PRECURSOR (SHORT
CHAIN ENOYL-COA
HYDRATASE) (SCEH) (ENOYL-COA
HYDRATASE 1) (low match, non-exact 56%) , _ epidermal growth facfor ¨ 2 _ 1U07707 ' + + + -receptor pathway substrate 15 (EPS15) , EP1DIDYMAL 2 - Q15668' -SECRETORY PROTEIN
El PRECURSOR (EPI-1) (HE1) (EPIDIDYMAL
SECRETORY PROTEIN
14.6) (ESP14.6) epithelial membrane 1 - U87947 + + + + +
protein 3 (EM(P3) _ Epoxide hydrolase 1, 1 ' L29765 +
only microsomal (xenobiotic) (EPHX1) ENCL2 (=L47234) - 1- ' X52221 ERF-2 3 U07802 - + + ' + " + + - high in gall bladder ERp28 protein " 1 ' X94910' + + + + +
erythrocyte membrane 2 - M&1635 ' protein , erythroleukemic cells K562 -2 L25343 -_ . ..
EST (Hs.I139509) 2 U24I66 estrogen receptor-related 1 - L38487 protein (hERRal) ESTs, Highly similar to ''' 1 X66503 '' 13, T + +
ADENYLOSUCCINATE
SYNTHETASE
ESTs, Moderately similar to 1 U28811 + ' + + + +
cysteine-rich fibroblast growth factor receptor .
'ET-binding ffictor 1 (StiFl) ' 1 U93181 + + +
ets domain protein ERI- 1 U15655 + ' + ' + - +
' +
eukaryotic translation 326 ' X03556 ' T + ' + +
elongation factor 1 alpha 1 (EEF1A1) eukaryohc translation 1 " X03558 ' elongation factor 1 alpha 1 (EEF1A1) (low match) eukaryotic translation 1 '' X03558 elongation factor 1 alpha 1 (EEF1A1) (low match) eukaryotic translation 5 X60489 + + + + +
elongation factor 1 beta 2 (EEF182) eukaryotic translation 1 Z21507 + + ' + + ' + ' + -elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D) eukaryotic translation 31 1T1531 elongation factor 1 gamma (EEFIG) eukaryotic trantlation ' 2 X51466 - + .4.
elongation factor 2 (EEF2) _ _ eukaryotic translation ' 1 - J02645 initiation factor 2, subunit 1 (alpha, 35kD ) (EIF2S1) eukaryobe trantiation ' 1 M29536 initiation factor 2, subunit 2 (beta, 38kD ) (EIF2S2) ..
eukaryottc translation 3 L19161 ' ' + +
initiation factor 2, subunit 3 (gamma, 52kD) (EIF2S3) .. _ .
eukaryotic translation ' 2 U78311 initiation factor 3, subunit (theta, 150/170kD) (EIF3S10) .
eukaryotic translation ' 3 U36764 - + + + + + + NO
in white blood initiation factor 3, subunit 2 cells (beta, 36kD) (EIF3S2) eukaryotic translation 6 U54559 + - + ' + - +
+ 'high in spleen initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3) eukaryotic translation ' 9 ' A1-020833 + + +
+
initiation factor 3, subunit 4 (delta, 44kD) (EIF3S4) eukaryotic translation 4 - U94175 + + + - + +
high in bladder initiation factor 3, subunit 6 (48kD) (EIF3S6) eukaryotic Yanslation 1 - U82962 - + ' + - + ' + Highly represented initiation factor 3, subunit 6 (1.4833 pct) in library (EIF3S6) 36 human gall bladder eukaryotic translation 3 *- U54558 + + + + +
initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7) .._ .
eukaryobc translation 5 046025 + + - + - + + + ' high in testis initiation factor 3, subunit 8, 110KD (EIF3S8) eukaryotic ilansfation 1 AF012088 initiation factor 4 gamma, 1 (EIF4G) eukaryotic translation - 1 AF012088 initiation factor 4 gamma, 1 , (EIF4G) (low match) eukaryotic translation 2 - 012685 initiation factor 4 gamma, 1 (E1F4G1) -, 'eukaryotic translation 6 ' U73824 ' + + - + - + + +
initiation factor 4 gamma, 2 (EIF4G2) -eukaryotic Eansiation ' 2 ¨ U76111 + _ + + + + +
initiation factor 4 gamma, 2 (EIFG2) eukaryotic translation - 29 013748 initiation factor 4A, isoform 1 (E1F4A1) , eukaryotic translation - 11 1330655 + + + + + +
initiation factor 4A, isoform 2 (EIF4A2) _ eukaryotic translation 18 X55733 + + + + +
initiation factor 4B .E1F4B) eukaryotic translation 1 P06730 initiation factor 4E (EIF4E) Elikaiyotic translation ' 3 L36056 T, 6 - + - - ' + -' + -initiation factor 4E binding protein 2 (EIF4EBP2) eukaryotic translation 2 ' Q15058 -initiation factor 4H (EIF4H) i_ -4 eukaryotic translation 2 - U49436 + + + + - + +
initiation factor 5 (EIF5) eukaryotic transiabon ' 2 U90176 + + + + +
termination factor 1 (ETF1) .
EV12-protein 1 M55266 +
Ewing sarcoma breakpoint 1 1 _ X66899 + + + + +
region 1 (EWSR1) EVVS/FLI1 activated 2 Al-020264 transcript 2 homolog (EAT-2) EVVS-E1A-F chimeric ' 1 U35622 protein excision repair cross- 1 M28650 + + ' + + +
complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) (ERCC1) excision repair cross- 1 X89978 - + + + +
complementing rodent repair deficiency, complementation group 5 (xeroderrna pigmentosum, complementation group G
(Cockayne syndrome)) (ERCC5) exostoses (multiple)-like 3 1 AF001690- - + + + +
(EXTL3) F11 ' 1 ¨ X77744 ' +
- ¨

F1-ATFrase beta subunit ' 2- ' X03559 - r ______________ T
r (F-1 beta) ranconi anaemia group A - -2 ' Z83095 ' -1 _ Fanconi anemia, 1 ' X99226 + + + + -1 complementation group A
(FANCA) _ far upstream element ' 2 U05040 + + +
(FUSE) binding protein 1 (FUBPI) farnesyf diphosphate - 1 - J05262 + + + + +
synthase (famesyl pyrophosphate synthetase,dimethylallyltra nstransferase, geranyltranstransferase) (FDPS) , farnesyl-diphosphate - 2 - X69141 + + + + + +
famesyltransferase 1 (FDFT1) famesyltransferase, CAAX - 2 1.00635- ' + +
box, beta (FNTB) Fas ligand (gene and - 1 ' A1-044583 -promoter region) ¨
Fas-ligand associated - 1 - U70667 factor 1 fatty-acid-Coenzyme A 4 ' 010040 + + + + + +
ligase, long-chain 1 (FACLI) Fc flagment of IgA, ' 1 ' X54150"
receptor for (FCAR) _ _ I-c Fagment of IgE, high 1 M33195 + ' + + + +
affinity I, receptor for;
gamma polypeptide FCER1G) . -Fc fragment of IgE, low 2 X04772 + +
affinity II, receptor for (CD23A) (FCER2) _ Fc fragment a IgG, low 6 M31932 + + + ' + + + ' affinity Ila, receptor for (CD32) Fc fragment of IgG, low 1 X62b/2 + + + ' + -1 + ' +
affinity Ila, receptor for (CD32) (FCGR2A) , Fc fragment of IgG', low - 34 - X07934 + + + - + - +
affinity Illa, receptor for (CD16) (FCGR3A) Fc fragment orIgG, 3 U12255 f + + ' + + +-high in many libranes receptor, transporter, alpha (FCGRT) , Tc-fgr ' 1 ' ZT3983 ' Fc-gamma-receptor11113- ' 2 ' M90746 - -(FCGR3B) feline sarcoma (Snyder- - 3 X06292 Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fps) oncogene homolog(FES) c-fes/fps) female sterile homeotic- ' 2 X96670- + ' + --P- + - +
' + ' related gene 1 (mouse homolog) (FSRGI) ferritin L-Chaib 9 ' Y09188 femlin, heavy polypeptide T 4 M1TI46 + + ' + - + + +
fertifin alpha pseudogene ' 1 " Y09232 -fetal Alzheimer antigen 2 U05237 . . _ +
(FALZ) fetal Ig heavy chain - 1 ' M34024 variable region .._, fibrillarin (FBL) 1 X55597 + " + - + - + ' + +
_ fibrinogen-iike protein 2 3 Z36531 ' - ' - +
(T49) ¨

fibroblast growth factor 1 M35718 + + + + + +
receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome) syndrome, Pfeiffer syndrome, Jackson-Weiss) (FGFR2) ficolin (collagen/fibnnogen 19 ' D83920 + +
domain-containing) 1 (FCN1) ._ .
gamin A, alpha (actin- 2 ' X5341-6 binding protein-280) (FLNA) Mann 6,-beta (aam- 1 AF043045 + ' + -- - + ' binding protein-278) (FLNB) Finkel-Biskis:Reilly murihe - 2 X65923 " +
+ + ' + 1 + ' + Highly represented in sarcoma virus (FBR-MuSV) intraepithelial ubiquitously expressed (fox neoplasia and derived); ribosomal protein invasive prostate S30 (FAL9 tumor FR-506 binding protein 1 M80199 + - + - + "+ ¨
+
FK5O8kiinding protein 1A 2 M34531 (12kD) (FKBP1A) ._ -. _ FK5Of3-binding protein 18 1 M92423 + + +
(12.6 kD) (FKBP1B) .
1-K506-binding protein 5 4 U71321 _ ¨
+ + + +
(FKBP5) .
Fligfilless 1 (Drosophila) - 3 U80184 ' +
homolog (FLO) Flightless I (Drosophila) - 1 ' U60184 homolog (FIJI) (low match) FLN29 (FLN29) 2 AB007447 + ' + - +
.
Hotillin 2 (FLOT2) 5 M60922 + + + + + +
toiate receptor 2 (fital) 1 AF000380 ' + + ---+ " +
(FOLR2) forkhead (Drosophila j- 1 AI-032886 ' + + ' + + ' homolog (rhabdomyosarcoma) like 1 (FKHRL1) , Formica-peptide receptor 1 - 9 ' M50627 + + - + - + ' ' + -(FPR1) formyl peplide receptor-like' 1 M84562 __ ,- ---Hf-ound only in 1 (FPRL1) libraries from placenta .
formy1 peptide receptor-like' 1 M84562 1 (FPRL1) (low score) I_ L
fragile X mental retardation _ 1 L29074 + + + +
1 (FMR1) , fragile Tmental 1 025165 + ' + - + + ¨
retardation, autosomal homolog 1 (FXR1) I- --, , Friend leukemia virus - 3 M93255- + +
integration 1 (FL11) -fructose-bisphosphatase 1 1 - 026054 + - +
(FBP1) FSHD-assOaated repeat 1 U85056 -DNA, proximal region fucose-1-phosphate " 1 ' AFO17445 + + + - .
guanylyltransferase (FPGT) fullTangth insert cDNA 1 ' AF086122 clone ZA78A09 fulaingth insert cDNA " 1 - AF075061 fumarate hydratase (FH) 1 U59309 + - + + ' + ' õ .
Flow match) ' 1 . X99006 . _ FYN-binding protein (FY13- = 16 U93049 + +
120/130) (FYB) _ G alpha interacting protein 1 X91809- - - -=
(GAIP) (low score) G protein beta subunif-like 2 - D25398 protein 12.3 .
1.,i protein-coupled receptor 1 . X81892 +
64 (HE6) (non-exact 59%) G protein-coupled receptor 2 ' L16862 ' + + - + +
kinase 6 (GPRK6) G1 to S phase transition 1 2 X17644 ' + ¨ +
' + + ' +
(GSPT1) GA-binding protein 1 " D13316- ' + + + + + -transcription factor, beta subunit 2 (47kD) (GABPB2) -4 galactose-1-phosphate 2 M60091 uridylyltransferase (GALT) galactosidase,beta 1 3 ' -M27508 ' + 4. 4.
(GLB1) galactosyltransferase 1 ' M13701 (=X13223 N-acetylglucosamide-(beta 1-4)-galactosyltransferase) galectin-9 isoform 1 AB006782 - + ' + +
, gamma2-adaptin (G2AD) 1 ' AF068706 - + + ' + +
_ gamma-actin 2 ' M37130 gamma-aminobutync acid 2 ' AJ012187 ' = + ' + +
(GABA) B receptor 1 (GABBR1) .
.
GA IA-binding protein 2 '1 ' M68891 + +
(GATA2) GA I A-binding protein 3 1 M69106 ' + ' + ' +
(GATA3) GCN5 (general control of 3 D64007 - + + + + +
amino-acid synthesis, yeast, homolog)-like 1 (GCN5L1) _ GDP dissociation inhibitor 1 , D45021 + +
+ - + ' ' + high in adult brain 1 (GDI1) .
., 'GOP dissociation inhibitor 4 Y13286 2 (GCI2) GD-related protein ' 4 U68142 + + + + + ' (HKE1.5) ¨
gelsolin (amyloidosis, 3 X04412 + + + + +
Finnish type) (GSN) general transcription factor 4 Y14946 + + + + + +
II, I (GTF2I) general transcription factor 1 AP-038968 + +
+ + + + high in fetal brain II , i. pseudogene 1 (GTF2IP1) .
general transcription factor 4 X64037 + _ + + + +
IIF, polypeptide 1 (74kD
subunit) (GTF2F1) general transcription factor 2 - Z30093 B, T
IIH, polypeptide 3 (34kD
subunit) (GTF2H3) general transcription factor 3 Y07595 + ' + +
IIH, polypeptide 4 (52kD
subunit) (GTF2H4) general transcription factor 1 ' U14134 ' + + + +
IIIA (GTF3A) _ general transcription factor 1 U026T9- ' + +
IIIC, polypeptide 1 (alpha subunit, 220kID) (GTF3C1) general transcnption factor 3 - D13636- - + ' + + +
+ +
IIIC, polypeptide 2 (beta subunit, 110kD) (GTF3C2) ... .
germline immunoglobulin 1 L06612 heavy chain (ICHM) ¨
germline immunoglobulin 1 X92236 heavy chain, variabl region , germline immunoglobuiin 1 X92343 heavy chain, variable region, (21-2) GLE1 (yeast homolog)-like, 1 AF058922 + +
RNA export mediator (GLE1L) glia maturation factor, beta 1 ' A13001106 + + ' + ' +
(GMFB) glioma-associated ' 1 ' X07384 oncogene homolog (zinc finger protein) (GLI) gibma-associated ' 1 ' X07384 ' oncogene homolog (zinc finger protein) (GLI) (low score) ... , . .
globin, alpha 2 1 - V0U516 _ glucocorticoid receptor 1 ' M32284 (=M69104) .
glucocortica _ d receptor 2 080947 = + + + + +
(GRL) glucos phosphate 1 4. 109105 ' isomerase (CONTAINS
LARGE REPEAT) -glucosamine (N-acefy1)-6- 1 Z12173 +
sulfatase (Sanfilippo disease IIID) (GNS) glucosamine (N-acetyl)-6- 1 Lí2173 ' sulfatase (Sanfilippo disease IIID) (GNS) (non-exact 56%) .
glucose fransporter-like " 1 - M20681 + +
+ + +
protein-III (GLUT3) glucose transporter-like ' 1 M20681 protein-III (GLUT3) (low match) glucosidase, alpha; acid ' 1 ¨ YOUB39 + + + 6 +
(Pompe disease, glycogen storage disease type II) (GAA) .
Mucosidase, beta; aad 1 - K02920 + + + + +
(includes glucosylceramidase) (GBA) 1 . . .
glutamate dehydrogenase 1 P.' M20867 + + + + +
1 (GLUD1) .
glutamate-ammonialigase - 12 X59834 + + + + ` +
(glutamine synthase) (GLUL) glutamate-ammonia ligase 1 -- Y0038T
(glutamine synthase) (GLUL) (low score) glutamate-cysteine Nese 1 ' M90656 ' +
(gamma-Mutamylcysteine synthetase), catalytic (72.80) (GLCLC) glutamine cyclotransferase 1 " X71125 ' + +
glutamine-tructose-6- 1 - 190516 + - '-- + -phosphate transaminase 1 (GFPT1) giutammyl-tRNA 1 ' X72396 synthetase glutaminifT-tRNA 6 ' X'7601-3 + + - + ' + ' +
synthetase (OARS) glutamyl-proliff-IRNA ' 1 X54328 synthetase (EPRS) .
glutathione peroxidase 1 2 - M211304 + + + + + +
(GPX1) .
glutathione peroxidase 4 1 X71973 + + + + +
(phospholipid hydroperoxidase) (GPX4) .
glutathione S-transferase pi ' 1 U30897 + + + + -+ "
(GSTP1) glutathione S-transferase 1 - AF070657-subunit 13 homobg glyceraldehyde-3- ' IZ J02642 - ' ' + ' phosphate dehydrogenase (GAPD) , =

glycogenin ((3YG) 1 1J31525 + + i + ' + ' . , glycophonn C (Gerbich 1 XT2496 + - + + +
blood group) (GYPC)_ glycoprotein M6B (GPM6B) ' 1 U45955 + +
RitckrZiNA synthetase 1 - U09587 - + ' += + +
glyoxalase I (lactoyt i L07837 + " + -- += + ' +
glutathione lyase) (GLYI) _______________________________________________ golgi autoantigen, golgin 1 1J51587 + + -subfamily a, 1 (GOLGA1) _________________________________________________ golgi autoantigen, golgin 1 L06147 subfamily a, 2 (GOLGA2) (non-exact, 70%) ________________________________________________________ golgi aufbantigen, goigin 1 ' U31906 subfamily a, 4 (GOLGA4) golgi autoantigen, golgin 1 ' X75304 - + ' + ' +
+
subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1) _ ' gp2512 protein " 4 ' X90872 grancalcin 8 ' M81637 + - += " +
granulin (GRN) 16 " X62320 + + + + + -- ________________________________________________________________________ granulin (GRN) (low match) 1 X62320 ' Granulysin (NKG5) 5 ' M85276 + ' + ' granzyme A (granzyme 1, 1 M18737 + + + + +
cytotoxic T-Iymphocyte-associated serine esterase 3) (GZMA) . .
GR82-related adaptor 1 U52518 ' T only protein (GRAP) Grb2--relaled adaptor - 1 AF090456 T + ' protein 2 (GRAP2) GRO1 oncogene 1 X54489 - + - +
(melanoma growth stimulating activity, alpha) SGRO1) growth arrest and DNA- ' 1 S40706 damage-inducible gene (GADD153) growth arrest-specific7 4 ' AB007854 - ' + +
(GAS7) __________________________________________________________________ growth factor receptor- ' 1 X62852 B + ' + +
bound protein 2 (GRB2) GS1 (protein of unknown ' 1 ' M86934 - + + +
function) GS3955 4 - D87119 ' + + + +
GTP-biriding protein 1- 1 ' U87964 + + + "
(GTPBP1) .
GIP binding, protein similar - 1 U87791 + + + +
to S. cerevisme HBS1 (HBS1) GlPase activating protein- 1 ' AB011110 + - + ' + ' - + -high fetal brain like (GAPL) _____________________________________________________________ -GTP-binding protein (low 1 ' Z49068 ' match) __________________________________________________________________ -GTP-binding protein G(K), ' 1 - P08754 alpha subunit (=G(I) ALPHA-3)(=GTP-bInding regulatory protein Gi alpha-3 chain) _ _ _______________ Gu protein (GURDB) - 2 - U41387 + + + +
. - .. . .
guanine nucleotide binding 1 -protein guanine nucleotide binding- 4 - J03004 + + + - + ' +
protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2) _ guanine nucleotide binding - 7 M20597 + + + +
-+ =
protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3) guanine nucleotide binding 2 -1 X04409 5, T + . + +
protein (G protein), alpha stimulating activity polypeptide 1 (GNAS1) guanine nucleotide binding 1 - Z18859 ._ protein (G protein), alpha transducing activity polypeptide 2 (GNAT2) A
guanine nucleotide binding 2 AF0176bb + = + = + " + ' protein (G protein), beta 5 (GNB5) guanine nucleotide-binding 5 M36430 + + + + + +
protein (G protein), beta polypeptide 1 (GNB1) guanine nucleotide binding ' 2 ' AP011496 + + +
protein (G protein), q polypeptide (GNAQ) _ guanine nucleotide binding f ¨ L25665 + + + + - +
protein-like 1 (GNL1) _ guanine nucleotide . _ 1 - L1385T + + + +
exchange factor - -guanine nucleotide 1 X15610 + + + + +
regulatory factor (LFP40) guanine nucleotide 1 ' U72206 ' + + + + +
regulatory factor (LFP40) GUANINE NOCLEOTIDE- 1 P25388 _ BINDING PROTEIN BETA
SUBUNIT-LIKE PROTEIN
12.3 (P205) (RECEPTOR
OF ACTIVATED PROTEIN
KINASE C 1) (RACK1) GUANINE- 1 U10860 +
MONOPHOSPHATE
SYNTHETASE (GMPS) guanosine monophosphate- 1 M24470 reductase (GMPR) (non-exact, 72%) 9uanosine-diphosph4tase 1 AF0-16032 like protein guanylate binding protein r 2 M55542 + + + + +
1, interferon-inducible, 67kD (GBP1) . _. _ ...
guanylate binding protein ' 6 M55543 + + + + +
2, interferon-inducible (GBP2) .1-12x histone family, ' 1 183742 ' member C (H2AFC) .
FITAlusfone family, ' 2 AP041483 1 + ' + + +
+
member Y (H2A
H2Bilistone family, ' 2 180783 - + + ' + + + + high in adrenal gland ' member L (H2BFL)tumor 112-calponin ' 1 ' D88059 .
_ H-2K binding factor-2 ' T ' L-)8904 1- + + - + -+ ' 'H3 histone family, member 1 K (H3FK) H3 histone, family 3A 7 M11353 + + + + + 'high in ovary (H3F3A) _ H3 histone, family . -3B ' 15 ' 148950 - + + + +
=+ high in endothelial (H3.36) (H3F3B) cells hbc647 - 1 - U68494 - + + + +
heat shock 27kD protein 1 1 U12404 ' + + + +
(HSPB1) heat shock 4010-protein 1 ' 4 - D85429 ' + = - + -- + - + + +
high in testis (HSPF1) . .
heat shock 601(0-protein 1 3 M22382 + . _ + + + + +
(chaperonin) (HSPD1) _ heat shock 70kD protein 1 7 M59828 + ' + - + + + + high in activated V
(HSPA1A) cells 'heat shock 70k13-pro-tein 5 13 - X87949 + +
+ .
(glucose-regulated protein, 78kD) (HSPA5) heat shock 70k1D protein 6 - 4 X51757 + + +
(HSP7061) (HSPA6) heat shock 7010 protein 2 L15189 + + + + +
9B (mortalin-2) (HSPA9B) _ HEAT SHOCK COGNATE ' 1 P11142 71 KD PROTEIN . -heat shock factor binding 2 ' AF068754 protein 1 (HSBP1) heat shock protein 90 13 M27024 + + + + +
' + high in many libraries heat shock protein, DNAJ- T D13388- + + - + +
like 2 (HSJ2) , Hect (homologous to the 1 U50078 ' + ' + ' +
' E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 (HERC1) hect domain and RLD 2 1 A5062391 + + + + +
(HERC2) helicase-like protein (HLP) 1 X98378 + + - + +
_ , helix-loop-helix protein 1 ' M65214 +
HE47 (E2A) hematopoietic cell-specific 18 X16663 + + + +
Lyn substrate 1 (HCLS1) heme oxygenase 1 ' X06985 + + + +
(decycling) 1 (HMOX1) HEMOGLOBIN ALPHA 1 ' P19015 CHAIN
hemoglobin beta (beta ' 5 - AF1 17710 globin) _ _ ._ hemoglobin, alpha 1 ' 301 V00491 + 1- +
(HBA1) . .
hemoglobin, alpha 1 1 V00491-(HBA1) (low match) hemoglobin, alpha 1 (low . 1 - V00493 match) _ , hemoglobin, alpha 1 (non- 1 J00153 ' exact, 76%) . .
hemoglobin, alpha 1 (non- 1 V00493 exact, 82%) hemoglobin, beta (HBB) ' 129 V00497 + - + - + + + + high in many libraries' hemoglobin, beta-(HBB) 1 V00497 (low match) hemoglobin, beta (F1BB) - 1 - 148220 -(low match) hemoTune (C-X-C motif), 1 - 1:11-0924 - + - + --' + .
. + +
receptor 4 (fusin) (CXCR4) hemopoietic cell kinase 5 M16591 + +
(HCK) hepatitis C-associated ' 2 . 028908 microtubular aggregate iprotein p44 -hepatoma-denved growth ' 1 ' 1316431 ' + + + + +
factor . .
Hermansky-Pudlak 2 U65676 syndrome (HPS) .. . .
HERV-E integrase (non- 1 A1-028246 exact 76%aa) ¨
heterogeneous nuclear 2 663912 + + + +
protein similar to rat helix destabilizing protein (FBRNP) ..
heterogeneous nuclear 4 M16342 ribonucleoprotein (C1/C2) (HNRPC) .
heterogeneous nuclear 1 M65028 ' + + - + + + +
ribonucleoprotein A/8 (HNRPAB) _ ..._ heterogeneous nuclear 20' - X12671 + + - + + + + High in alveolar , ribonucleoprotein A1 rhabdomyosarcoma (HNRPA1) heterogeneous nuclear 3 ' M29064 + + + + + + High in activated T
ribonucleoprotein A2/B1 cell, fetal brain (HNRPA2B1) 'heterogeneous nuclear 2 ' D55673 ' + + + + + +
ribonucleoprotein D
(hnRNP D) heterogeneous nuclear 5 D89092 + + + + + +
ribonucleoprotein D-like (HNRPDL) .
heterogeneous nuclear 1 L28010- ' + - + + + +
ribonucleoprotein F
(HNRPF) _ heterogeneous nuclear 1 L28010 ribonucleoprotein F
(HNRPF) (83%) ..
heterogeneous nuclear 2 ' Z23064 + + + +
ribonudeoprotein G
(HNRPG) heterogeneous nuclear 3 P55795 ribonucleoprotein H
(HNRPH) (FTP-3) heterogeneous nuclear 1 ' P31943 ribonucleoprotein H
(HNRPH) (low match) heterogeneous nuclear 2 L22009 + + + + ' + ' ribonucleoprotein H1 (H) (HNRPH1) heterogeneous nuclear 21 S74678 + + + + + +
ribonudeoprotein K
(HNRPK) heterogeneous nucFear 1 ' AF000364 + + + ' + " +
ribonucleoprotein R
(HNRPR) heterogeneous nuclear 3 X65488 + + + + + +
ribonucleoprotein U
(scaffold attachment factor A) (HNRPU) .
hexokinase 1 (HK1) 2 X66957 + + + +
hexokinase 2 (HK2) ' 3 Z46376 + + - + + .
+
hexokinase 3 (HK3) 2 U51333 _._ . .
hexosaminidase A (alpha 1 1 S62047 polypeptide) (HEXA
HGMP071 gene for 2 U76377 olfactory receptor High density lipoprotein - 2 M64098 + _ + + +
+ +
binding protein (HDLBP) .
high-mobility group 5 ' X12597 + + + + + +
(nonhistone chromosomal) protein 1 (HMG1) .
high-mobility group 1 ' D63874 (nonhistone chromosomal) protein 1 (HMG1) (non-exact 60%) . _ _ High-mobility group 2 - MT2623 + + + + +
(nonhistone chromosomal) protein 17 (HMG17) high-mobility group 2 M83665 + + + + + +
(nonhistone chromosomal) protein 2 (HMG2) , high--mo-bility group 2 L17131 + + + + +
(nonhistone chromosomal) protein isoforms I and Y
high-nsk humanpapillbma - 1 AF090990.1 viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histicline ammonia-lyase I D16626 - +, only _ (HAL) hisE-dyl-tRNA synthetase 2 - Z11518 ' +
+ + + + +
(HARS) , histocompatibilify antigen T _________ - U313/2 (HLA-Cw3), class I
histone diace44ase 1 4 ' U50074 + + + + +
(HDAD) . .
hisfone deacetyfase 1- - 2 050405 + + + + +
(HDAC1) histone deacetylase E (NY- 1 A)-096U1---+ +
CO-9) 1-IK2 gene for hexokinase 11 1 Z46362 ._ 1-10 . -monocyte inhibitory 2 U91928 +
receptor precursor HLA class i heavy chain 1 .
(HLA-Cw*1701) , HLA class I locus C heavy 1 X58536 chain -.
HCA class 116E3-4-beta ' 1 X03022-chain .
HLA class III region - 1 U89335 + ' + + + +
containing NOTCH49ene HIJVA ' 1 Z72423 . .
HLA-A 2 ' AJ006020 HLA-'74O2 1 ' AJ223060 , _ . . -FILA-B i X8340T
, 1-11.A-13 1 X78426 _ HLA-8 associated ' T - Z...i /1613 + + + A + + +
transcript-1 (D6S81E) HLA-B associated- 2 M33509 " + - + ' + +
transcript-2 (D6S51E) .
HLA-B'1529 4 D44501-- _ HLA-6w72 antigen 119 L09736 + + + + + + high in many libranes ,-HLA-C gene (HLA- 1 D83957 Cvt0701 alWM) J
r HCA-Cw*0701 9 ' Z46810 , HLA-Cw`0801 1 - D64151 _ -HLA-Cw*1203 1 064146 -HLA-DC classll 2 - X00370 histocompatibility antigens alpha-chain (=K01160) HLA-DR alpha-chain - 17 M60333 + ' + ' + + " + + high in spleen HLA-F (leukocyte antigen 1 3 X17093 + + ' +
F) , HMG box containing ' 3 4 AF019214 ' protein 1 . .
SHAH f (=U83845) - 1 - A13017806.1 - , Hinob33 3- ' Y14155 HMTIIhnRNP 2 -C18021-3 + + + + --+
methyltransferase, S.
cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 ' 2 - 028382 . . _ 'homeobox (=X58250 1 Mb0721 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis) homeobox protein (HLX1) 4 1 - U14326 (=M60721) homeocromain-interacting ' 1 ' AF004849 ' + + + - +
protein kinase 3 (HIPK3) . .
, hornofo-g ofdrosophila past ' 2 AF001434 + + + + +
(PAST) 'homqbg of-yeast (B. - 3 D5091-6 " + + + +
cerevisiae) ufd2 (UFD2) HPV16 El protein binding 1 096131 + + ' +
protein HR1HFB2157 ' 1 A801-5344 _ . ... ..
+ + +
HRX-Iike protein 1 Y08836 (=AF010403 ALR) , hsc70 gene for 71 kd heat 3 ' Y00371-shock cognate protein . .
HSPC012 1 ' AF077036.1 HSPCO21 1 AF077207.1 HsPex13p 1 ' U71-374 htra2-beta-2 1 U87836 + + + + +
Hl.)-K4 1 U60644 .
huncl8b2 1 ' -1J63533 ' + ' + + ' ' + ' HUNK! 1- Y12059 ' + ' + ' + + +
huntingtin-interacting T ' F04952 -protein HYPA/FBP11 (HYPA) hVps41p (HVPS41) ' 1 U87309 , hydroxyacyl-Coenzyme A 1 U04627 - + + . .
+
dehydrogenase/3-ketoacyl-Coenzyme A
thiolase/enoyl-Coenzyme A
hydratase (trifunctional protein), alpha subunit (HADHA) hydroxyacyl-Crdenzyme A 1 01 481 + + + ' + - ' +
dehydrogenase/3-ketoacyl-Coenzyme A
thiolase/enoyl-Coenzyme A
hydratase (trifunctional protein), beta subunit (HADHB) hydiaxysteroid (17-beta) ' 1 U34879 . .
+ r--+ ¨
dehydrogenase 1 (HSD1781) ' hypothetical protein 1- -. . .
, hypothetical protein 1 (AL008729) (dJ257A7.2) 1 . ' hypothetical protein '- 1 U96629 '' (CIT987SK_2A8_1 chromosome 8) .
hypothetical protein (clone ' 1 Al-(5b5004 24640) .
hypothetical protein (clone - 1 ' Z70222 ICRFp507G2490).
hypothetical protein - 1- L022238 - -- 1 (dJ1042K10.4) (non-exact 76%) hypothetical protein ' 2 L031432 -(dJ465N24.1 similar to predicted yeast and worm proteins) , hypothetical protein 2 ' AL008730 _ (dJ487J7.1.1) hypothetical protein - 2 AL023653 ' ,... . .
.
(dJ753P9.2) .
hypothetical protein ' 1 AL0501-31.1 (DKFZp5861111) .
, hypothetical protein 1 ' AL008729 (J257A7.2) . .
hypothetical protein - 1 ABDO /900 (KIAA0440) (=AF026504 =
R.norvegicus SPA-1 like protein) ' ,.. . , hypothetical protein (LIFI r 1 region) 'hypothetical protein (5164) 1 P49755 , J ' hypothetical protein (similar 1 AF109907 to thrombospondin) (non-exact 56%) hypothetical protein 3 1 . .
hypothetical protein B 1 U47926 (HSU47926) (non-exact, 56%) hypothetical protein from 3 U50532 + ' + ' + + +
BCRA2 region (CG005) hypoxia-inducible factor 1, 1 AF050115 alpha subunit (basic helix-loop-helix transcription factor) (HIF1A) la-associatedinvanant 1 - M13555 gamma-chain (clones lambda-y (1,2,3)) iduronate 2-sulfatase 2 M58342 + + + + +
(Hunter syndrome) (IDS) , Ig heavy chain V region 1 L20779 -(=D11016) . . .
Ig heavy chain variable 2 M34024 region Ig heavy chain variable 1 L75378 region (VH4DJ) (clone T14.4) Ig heavy chain variable 1 Z75392 -region (VH4DJ) (clone T22.18) , Ig J chain 1 - M12378 ..
Ig kappa ' 1 ' 549007 _ . ' IG kappa light chain ' 1 ' X63398 -variable region A20 ' Ig kappa light chain, V- and- 1 - 1D90158 J-region (=X59315) Ig lambda light chain 1 L8-5052 -variable region (26-341TIIIF120) ' Ig mu-chain VDJ4-region 1 M16949 . -Ig rearranged anti-myelin T M29469 .
kappa-chain (V-J4-region, hybridoma AE6-5) ..
Ig rearranged H-chain 2 M97920 mRNA V-region .
ig rearranged light-chain V 1 M74020 region (=D90158) .
IGF-11mRNA-bindi-ng 1 U97188 + + +
protein 3 (KOC1) (non-exact, 75%) , lgG Fc binding protein 1- - 0if4239 ' + + + +
(FC(GAMMA)BP) IgG heavy chain variable _ 1- M83136 region (vH26) IgM heavy chain (C mu, 1 X14939 .
membrane exons) , IL-1 receptor type 11 1 U14177 t-(ITK) . .
immediate early protein 1 M62831 + + + +
(ETR101) , Immunoglobulin (CD79A) - 1 - Y08915 B, T ' + + + ' binding protein 1 (1GBP1) , (=K02878) immunoglobulin G Fc 1- Z46223 receptor 1119 immunoglobulin gamma 3 3 Y14737- + + ' + 'high in many libraries' (Gm marker) (IGHG3) _ immunoglobulin gamma 1 L66542 _______ -T
heavy chain variable region (=X61011) _ _ immunoglobulin heavy 1 X62109 -chain (VI-3B) .
immunoglobulin heavy 1 - X86356 chain J region .
immunoglobulin heavy 2 - X86355 chain J region, B1 haplotype .
immunoglobulin heavy 1 AF062126 chain variable region (IGH) (clone 21u-48) immunoglobulin heavy 1 A1-062212 chain variable region (IGH) (clone 23u-1) immunoglobulin heavy " 2 M99641 chain variable region V1-18 (IGHVQ) (=X60503) .
immunoglobulin heavy 2 M99672 chain variable region V3-43 (IGHVO) , immunoglobulin heavy 3 M99649 chain variable region V3-7 (IGHVC_O) ImmunOlobulin IgH heavy 1- U07986 chain Fd fragment immunoglobulin kappa Eight ' 1 X68081-chain . .
immunoglobulin kappa fight 1 X12686 chain V-segment A27 .
immunoglobulin light chain 1 - 086990 immunoglo5Ulin light &am - 1 D86996 - - -i (low match) _ . .
immunoglobulin light chain 1- L29167 variable region (lambda IIlb subgroup) from IgM
rheumatoid factor ' immunoglobulin M heavy - 1 ___ S50 Aft chain V region=anti-lipid A
antibody immunoglobulin mu (IGFIM) 9 X7086 + + + + -immunoglobulin mu binding 1 ' L24544 T ' + +
protein 2 (IGHMBP2) immunoglobulin - 1 Z33642 superfamily, member 2 (IGSF2) .._.
Immunogiobulin VH mkNA 1 X61013 -(487 bp) (=M99652 immunoglobulin heavy chain variable region V3-11 (IGHVG))) .
imogen '38 ((MOGEN38) 1 ' Z68T47 + - + + +
. .
IMP (inosine 1 J05272 + + + +
monophosphate) dehy&ogenase 1 (IMPDH1) IMP (inosine 2 L39210 + + + + +
monophosphate) dehydrogenase 2 (IMPDH2) inc finger protein 151 (PKI- 1 Ya9723 + + - + + +
67) (ZNF151) .
inc finger protein, t;"21-12, 1 Al-011573 + +
rapidly tumed over (ZNF20) inducible poiy(A)-binding 1 U33818 ++ . ,.
+ + +
protein (IPABP) _ inducible poly(A)-binding 1 U33818 protein (IPABP) (low match) induable protein 2 L47738 + + + + + .
(Hs.80313) in-hator of DNA binding 2, 4 M97796 - + + + + + -+
dominant negative helix-loop-helix protein (1D2) .
inhibitor of kappa lighf 2 AF044196 polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP) inositol 1,3,4-trisphosphate 1 U51336 + + + ' + + +
5/6-kinase .
. . _ .
inositol-1,4,5 trisphosphate - 1 U23850 + + +
receptor type 1 (ITPR1) .
inositol 1,4,5-trisphosphate 2 X57206 B - + .- + +
3-kinase B (ITPKB) .
inositol monophOsphatase ' 1 -538980 _ inositol-polyphosphate-5- 2 U84400 + + + + +
phosphatase, 145kD
(INPP5D) .
I ns(1,3,4,5)P4-binding 1 X89399 ' + ' -' +
protein .
insulin-like growth factor 2 5 Y00285 + + + + +
receptor (IGF2R) . _. .
_ , integral membrane protein 1 L38961 + + +
1 (ITM1) integral membrane protein 1 - AF038953 T ' + + _ +
2C (ITM2C) .
integral membrane protein ' 3 U61734 + ' + + ' +" + ' +
Tmp21-1(p23) .
integnn beta 4-binding - 2 AF047433 . .. .
.._ + +
protein (ITGB4BP) integnn, alpha 2b (platelet 3 - M34480 ' - + .
.
+
glycoprotein Ilb of Ilb/Illa complex, antigen CD416) (ITGA2B) integrin, alpha 5 4 X06256 + - + + + +
(fibronectin receptor, alpha polypeptide) (ITGA5) .
integnn, alpha L (antigen 6 Y00796 CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) .
(ITGAL1 .
integnn, alpha M - 1- IV11-8044 (complement componentreceptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM) integnn, alpha X (antigen 1 - M81695 + + +
CD11C (p150), alpha polypeptide) (ITGAX) .
integnn, beta 1 (fibronectin - 2 X07979 receptor, beta polypeptide, antigen CD29 includes MDF2 MSK12) (ITGB1) õ
integnn, beta 2 (antigen 32 M15395 + +
CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) (ITGB2) . .
integrin, beta 7 (I fG137) - 1 M58892 + .
Integnn-linked kinase (ILK) 1 ' U40282 + + + + +
'intercellular adhesion 1 J03132 + + + +
molecule 1 (CD54), human rhinovirus receptor (ICAM1) .
intercellular adhesion 1 - X1-5606 + + + + +
molecule 2 (ICAM2) ¨ - -. intercellular adhesion - 6 Xli98T9 - +
+
molecule 3 (ICAM3) , _ intercellular adhesion - 1 L27670 ' +
molecule 4. Landsteiner-Wiener blood group (ICAM4) , interferon consensus 1 M91196 W,1- lymphoma sequence binding protein 1 (ICSBP1) Interferon consensus -1 M91196 -sequence binding protein 1 (1CSBP1) (low match) , interferon regulatory factor 4 ' X15949 + + + +
2 (IRF2) 'interferon regulatory 4 L05072 - + + + + - +
factorl (IRF1) _ _ 'interferon regulatory ' 1 '- U51-127 - + + +
factor5 (1RF5) Interferon, gamma- -2 M63838 ' + - + + + +
inducible protein 16 (1F116) . .
interferon, gamma- 9 ' J03909 + + + +
inducible protein 30 (IF130) GUANYLATE-BINDING
PROTEIN 1 (GUANINE

PROTEIN 1) (non-exact 62%) interferon-Induced protein 3- - X54958 + + + +
17 (IF117) interferon-induced protein 5 - M14660 ' 54 (IF154) -interferon-inducible-(1-8D) ' 5 X57351 - T + + +
interferon-inducible (1-8U) ' 1 X57352 - + + - + ' interferon-related 5 ''' -Y10313 - + + +
developmental regulator 1 (IFRO1) _ inierreron-siimulated- 2 ' M87503 + + +
transcription factor 3, gamma (48kD) (ISGF3G) .
interleulon 1 receptor, type 1 U64094 +
II (IL1R2) Interleukin 10 receptor, 1 ' U08988 T activated + +
beta (1.10RB) 'infirleukin 12 receptor, 2 U03187 + - -, ,only found in T cell beta 1 (IL12RB1) , interleukin 13 receptor, -- 2 Y09328 + + + + +
alpha 1 (IL13RA1) _.
' interleukin 16 (lymphocyte 6 ' 1J82972 +
chemoattractant factor) fiL16) interleukin T8 receptor 1 1 1- U43672 ' SIL18R1) interteukin Z receptor, beta - 9 M26UB2 (11.2RB) .
interteukin 2 receptor, 6 D11086 + + +
gamma (severe combined immunodeficiency) (II.2RG) interl-eulan 4 receptor a - X52425 ' + - + - + ' +
(IL4R) ,_ .. i .
intedeulan 6 receptor ' 5 h X12830 + +
-(IL6R) interieukin 6 signal 1 - M57230 transducer (gp130, oncostatin M receptor) .
(IL6ST) 1nterleu-kin 7 receptor 14 ' M29696 + - - - +
(1L7R) _ ' interieukin 7 receptor ' 1 - Ai-043123 --4 (IL7R) (low match) interieukin 8 (11.8).
8 Y00787 + + +
High in activated,' -,cells, bone and pancreatic Islets --interleukin 8 receptor alpha 11 - 1_18591 - u (IL8RA) , _ interieukin 8 receptor, beta 14 " M94582 (IL8RB) interieukin enhancer a UT0323 ' + ' + + + ' + + high in uterus binding factor 2, 45kD
' (ILF2) interleukin enhancer 2 U10324 binding factor 3, 90kD
(ILF3) u.
inteiretikin-1 receptor- - 2 L76191 - + r + +
+
associated kinase 1 (IRAK1) .
inteileukin-1 receptor- 1 U52112"
associated kinase 1 (low match) .
interleukin-10 receptor, 5 1 U00672 + r + - + ---+
alpha (IL1ORA) .
Interleukin-T1 receptor, 7 ' Z313-102- -alpha (MIRA) 'IN i ERLEUKIN-14 1 ' P40222 _ PRECURSOR (IL-14) (HIGH MOLECULAR
WEIGHT B-CELL
GROWTH FACTOR) (HMW-BCGF) (non-exact 46%) intestinal carboxyiesterase; ' 1 ' 060553 - + ' + .
Wer carboxylesterase-2 (ICE) inversin protein (non-exact 1 ' AF084367 52%) IQ motif containing 6- 1.33075 GTPase activating protein 1 (IQGAP1) fa mobt containing 1 - U51903-1--:--.. + -GTPase activating protein 2 (IQGAP2) .
isocitlate dehydrogenase r 1 ' AF020038 + + " + - + - +
+ -(NADP+), soluble (IDH1) -I
isoc.itiate dehydrogenase 2 Z ' X69433 ' +
' + " + ' + - + +
(NADP+), mitochondrial (IDH2) isocitrate dehydrogenase 3 2 U07681 +
(NAD+) alpha (IDH3A) .
isocitrate dehydrogenase 3 1 Z68907 + + + + +
(NAD+) gamma (IDH3G) isolate Aus3 cytochrome b 1 ' ÄF042516 (CYTB) , isolate "fz.-CCR5-179 CCR5 t - AF011524 r -receptor (CCR5) isopentenyl-diphosphaTe ' 5 X1 r025 + + + + ' +
delta isomerase (1011) .
Janus kinase 1- (-a protein - 4 - M64174 + + - + ' + + ' tyrosine kinase) (JAK1) Janus kinase 2 la protein - 1 - AF005216 tyrosine kinase) (JAK2) 11... 1.
Jk-recomblnation signal 2 L07876 binding protein (RBPJK) JM1 protein ' 1 ' AJ005890 + - +
jumoriii (mouse) homolog 1 U57592 __ + + + +
(JMJ) jun D proto-oncogene 1 - X51346 + - + ' + + ' ' +
(JUND) Jun dimerization protein 1 Al-111167 --only found in germ junction plakoglobin (J(JP) 1 ' M23410 - + ' + +
+
. =

kangai 1 (styvression of 1 U20770 + + + + + +
tumorigenicity 6, prostate;
CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody 1A4)) (KAI1) karyopherin (importin) beta 2 L39793 + ' + ' + 6 + ' + +
1 (KPNB1) karyophenn (importin) beta T '' U72395 ' + " + + - + ' 2 (KPNB2) karyophenn alpha 1 ' 1 - 575295 + ' + ' + +
' (importin aipha 5) (KPNA1) karyophenn alpha 2 (RAG ' 1 U09559 cohort 1, importin alpha 1) (DPNA2) karyophenn alpha a 1 089618 + +
(importin alpha 4) (KPNA3) ' karyopherin alpha 4 1 M17887 ' + +
(KPNA4) Katanin (80 WA) (KAT) 1 ' AF052432 + ' + ' + 4 RE03 protein 2 AF064604 Kelch-like tCH-associated 1 D50922 protein 1 (KIAA0132) (66%aa) Keratin 8 (KRT8) 1 " -X74929- + + + + +
ketohexokinase ' 1 X78678 " + ' + +
(fructokinase) (KHK) KIAA01)01 (KIAA0001) 1 015391 (72% aa) KIAA0001 (KIAA0001) 1 Q15391 (76% aa) "
KiAAVD1 (K1AA0001) 1 Q15391 .
(non-exact 72%) KIAA'0002-(KIAA0002) 5 D13627- + + + +
KIAA0005 (KIAA0005) ' 4 ' 1)13630 ' + + - + +
RIAA0010 (K1AA0010) 1 013635 ' ' + ' 4 +
KIAA0016 (K1AA0016) 1 D13641 . + .
+ + + +
KIAA0017 (K1AA0017) 2 087686 ' MA00221KIAA0022) 2 ' 014664¨ - + "- + +
KIAA0023 (KIAA0023) 'I ' 014689 +
KIAA)o24 (KIAA0024 ' 1 014594 + .
+ 4 + + ' +
KIAA0025 (KIAA0025) 1 D14695 ' + + + + = +
RIAA0026 (KIAA0026) -' 2 D14812 + + + +
KIAA0027 1 025217 +
KIRA0'2JKIAA0032) 2 025215 " + + +
KIAA0040 MA0(J40) - 1 025539 + - + ' + * + +
KIAA0050 (KIAA0050) 4 - 1)26069 KIAA0053 (KIAA0053) 17 029642 + + +
RIAA00b7 (K1AA0057) 1 D31762 + 4' + +
+ + high in fetal lung "
K1AA0058 (KIAA0058) 11 D31767 + -A--4. ' + : + +
KIAA0063 (KIAAM63) 3 . D31884 + - + + + ' +
KIAA0064 (KIAADU64) 1 031764 ' + + - + ' + ' 4 + ' KIAA0066 1 031886 + _ + + + +
' lcIAAU068 1 038549 + ' + 4 + " + +
KIAA0073 3 D38552 " + ' + + ' +
KIAA0081 2 042039 + ' + " +
'Iumoom 2 042043 + . . .
+ + + +
R1AA0085 26 U30498 + + ' + + ' + ' +
KIAA0088 3 042041 + + + ' + - + + ' RRAOtigo 2 042044 + ..
+ + _+ + +
RIAA0092 (KIAA0092y 1 042054 . . .
+ + + + ' - .

KIAA0094 3 042084 + +
K AA0095 KIM' 195) 1 1J s ; 5 KIAA0096 1 li ' 3.3. + + + + +
KTAA009 ' =T' 00971 T X9 = = T + + +
RTAA0099 (K AA0099) 3 - = 134 = 51 + + + + + +
K AA0102 (K AA01-02) 2 014658 + + ' + +
KIAA0105 1 014661 5 + + +

KIAA0120 (non-exact, - 1 ' "183106 65%) KIAA0121 (K AA0 2 ) 1 1D 091-1 + + + ' + +
K AA0123- 1 P21064 + - += + +
_________________________________________________________________________ , KIAA0128 1 ' 0519 8 + + + + +
KIAA0129 (KIAA0129 1 13549 9 + + ' + +
KIAA0130 (KIAA0131) ' 1 ' 1 5995 + + +
. .
KIAA0136 2 1050!2.
KIAA0137 (K AA01 7) 1 .8-004;85 + + + +
KIAA0140 (KIAA0140) 1 1350930 + + + +
_ ________________________ KIAA0141 (KIAA0141) ' 3 050931 KIAA0144 (KIAA0144 3 0634 ; + + ' += + +
_ KIARYI 44 (K AA0144) (Fow 1 0634 8 match) KIAA0144 (non-exact = ' o) 1 QT. 187 __________________ _ KIAA0144 (non-exact OTT, 1 QI T5T
Muka146 2 063480 + + + r +
1<IAA0148 (K AA014;) 1 1363482 + +
KIAAI3154 2 063876 + + + + +
KIAA01136 1 9 = 3879 + + + +
K AA0160 2 Ma:
KTAA-0161 (K AA0161) 1 079983 + + +
, _________________ KIAA1T164 (KIRA. 64) 3 979'85 KIAA0167 ' AA I -57) 1 979989 +
KIAAOT68 K AA01 = :) 3 - 9 9990 + + 4- " +
KIAA0169 3 D-7999f _ _________________ KIAA0171 (K AA0 7 ) 3 ' 1)79993 + " += + +
K1.A01741K AAO 7. ) 7 9 9-96 + + + + +
KIAA0179 2 D:MOT + + + +
KIAAOT81 1 -1 11;0003 + + + ' +
KIAA-0T83 4- e:ser5 + + + + + +
- _ KIAAM1T4 1 e:04.6 + + + + +
KIAA0191 (72% aa) 1 1783//6 KIAA0191 (non-exa 77wo '- 1 ________________________ _ -KIAA0193 (KM. !3 1 ' =; 777 - + + + + +
K1' A0200 (KIAA0200) 1 usif _ :5 - + + + +
KIAA0210 ' = = t TO) 3 "' D-86965 _ _________________ KIAA0217 2 D ; 6971 + + + + +
KIAA0219 2 077 00 + ' + + +
KIAA0222 (KIAA 1222 1 B869 5 -_ KIAA0223 2 1J869 5 - . .
KIAA0229 1 98698Z + + ' KIAA0232 (K " 1232) 1 D869:5 + + + + ____________ KIAA0233 (KIAA02 1 ' TJ87P 1 ¨ ______________ KIAA0235 -2 -D871 8 + + ' + +
KIAA0.239 1 ' 987076 + + _ _________________ KIAA0239 (non-exact ; 6 i ) 1 D: 076 I
' olr= I 1 IP : I
KIAA0242 4 D:7684+ + ____________ 4 KIAA024.8 2 D87435 4.
K AA-0241a (KIAA0249) 3 D:7436 + +++ ++
' IAAZ 5 D87442 +
KIAA-02.54 K AA0254) 1 D87443 KIAA0255(KIAA0255) 4 087444 .4. + + +
KIAA0262 (KIAA0262) 3 087451 + + 4. + +
KIAA0263 (MA0263) 1 D8745 + + + + +
KIAA0254 3 1087453 _________ + + + +
RIAA0268 1 D87742 + + + +
' 4.1)269 1 Q92658 ' =v= 0275(K AA0275) 3 D874.5 + + + +
KIAA0304 (KIAA0304) 2 AB002302 + + + + + +
KIAA0308. 2 A13002366 + + +
KIAA0310 (KIAAI 310) 1 . :ye I: + + + +
' PT 0314 (=U96635 3 A8002312 M.mUsCUIus ubiquitin protein ligase Nedd-4) ' AA0315 (K AA-03 5 4 AB002313 + + + + +
' .V, i = 6: . 2 A8002323 R.norvegicus cytoplasmic dynein heavy chain (MAP
1C)) KIAA0329 tic AA0329) 1 A=002327 + + + +
KIAA0330 1 AB002328 + + + +
KIAA0332" 1 A6002330 + + + +
KIAA0313 = = = I 331 + + + + +
KmAccat KIAA0 ;) 3 A8002334 + + + + +
KIRA 36 (kIAA0336 ( ow 1 A=00 334 match) ' 'T` AZ (KIAA0342) 1 AB002340 + +
+
K AA0344 KIAA0344 . : r I 342 + ____ +
MA6354 (KIAA0354) 1 b002352 + + + + _______ +
KIAA0365 (KIAA/ 365) 1111=1. ' : I i SZe + + + + + +
' .V= I II = =:11 =:
AA0372 (RIAA03 2 A8002370 iii- 10111+11111 ____________ KIAA0375 RIAA03 5 A8002373 + +
' .11, t ' ,V, I AB002375 + + +
KIAA1379 AB0023 7 +
KIAA03 9 (non-exact, B0623 T
65%) KIAA0380 (K1AA0380) AB '02378 + + + +
KIAA038(J ' A 0380) AB, I 8 (60%aa) K AA63132 K1AA0382 ARTR)2380 + + + +
K AA(1383 A:01:12381 KIAA6386 AA-03:6) AB002384 KlAA03=2 AB002390 KTAA 8 9 ' AA0387) . = : = ir : + + ______ + + +
KIAA0403 A5007:63 KIAA0404 1 AB007864 + +
K AACP1 I = = = . .7869 + +
KIAA0:421 ¨:.= ::=1 + + + +
KIAA0424 (non-exact :Zoo) 1 AB007884 K1AA0428 (K1AA0428) - 9 Y1-3829 KIAA0429 (KIAA0429) - 2 AWL/ /889 + + + + +
KIAA0430 (KIAAU430) 2 AI:WU/Firm -only in ovary KIAA0432 (KIAA0432) 2 U86753 I + +
KIAA0435 (KIAA043b) 1 AB007895 KIAA0438 (KIAA0438)--- 1 A8007898 , + + + +
KIAA0447 (KIAA0447) - 3 A8007916 + + + + +
-KIAA0449 ' 1 AB007918 + +

1 A8007925 + + + +
KIAA0458 (KIAA0458) ' 1 A1300 42 /
KIAA0462 _ 1 A13007931 + + + + +
KIAA0465 1 A13001934 + + + + +
KIAA04 /6 (KIAA0476) 1 A1300794b + + +
KIAA0489 .

KIAA0494 (KIAA0494) 1 A1300/983 + + ' + + +
KIAA0515 " 1 A8U11087 + + - + + +

3 AB011093 + + + -KIAA0b2b - 1 A13011097 + - +
- -KIAA0530 1 ' AB011102 + + +
KIAA0532 1 AI3011104 + + + + +
_ KIAAti537 (KIAA0537) 1 AE3011109 KIAA054t) 1 AB011112 + . -+ + + +

+ + +

+ + + +
KIAA0b49 2 A8011121_ + + + +
K1AA0b51 2 A8011123 + - +
KIAA0554 8 A13011126 + + + + ' KIAA0b61 1 A8011133 + +
KIAA0562 (KIAA0562) 1 ' AB011134 KIAA0b63 (KIAA0563) 1 AB011135 KIAA0b69 (KIAA0569) 2 AB011141 + + + ' +
.
KIAA0571 (KIAA0571y 2 AB011143 + + +
, KIAAUb /3 ' 1 AB011145 ' + + +

RT/Wb /6 1 AB011148 .

KIAA0584 1 AB011156 +
KIAA0592 3 AB011164 + + + + +
KIAA0596 ' 1 AB011168 + +
KIAA0598 (KIAA0598) 1 AB011170 + + +
..
KIAA0608 1 AB011180 + + ' KIAAU614 2 AB014514 + + + + +
- -KIAA0615 (KIAA0615) ' 1 AB014515 KIAA0621 1 AB014521 + + +
KIAA0648 1 A8014648 + + + + ' KIAA0652 (KIAA0652) 1 A131/14552 + + + + +
' XIAA0671 (KIAA0671) 1 AB0145/1 + + +
KIAA06 /5 (K IAA0875) 1 A130145 /5--- + + +
, KIAA06 /13 1 AB014576 ' + + + +
WAA0677 (KIAA0677) 2 AB014577 + ' + + + +
, XIAA0618 1 AB014578 + + + + +
XIAA0679 6 A13014579 + + + +
- ____________________________________________________ , KIAA0680 (KIAA0680) 1 A5014580 _ KIAA0692 1 ' B014592 + + + + +
KIAA0697 " 1 A13014597 KIAA0699 1 A5014599 + + + + +
KIAAO7D0 ' 1 ' A5014600 - + + + ' +
KIAA0737 (KIAA0737) ' 3 ' AF014837 + + " + + +
KlAA0748 (KIAA0/413) ' 2 ' AB015291 +
KIAA0763 (KIAA0763) 2 - A5018306 + + + + +
KIAAOrbEi (KIAA0769) 2 B018312 + ' + + +
KIAA6/62 - 1 A5018325 + + ' + high in BPH
stroma KIAA0796 1 ' AB018339 + + + + ' KIAA0798 (K1AA0798) 1 ' AB018341 _ KI/M823 1 AB020630 , , KIAA0854 ._ 1 A5020661 + .. .
+ + + +
, KIAA0856 1 A13020663 " + ' + + + ' KIAA0860 _ 1 A5020667 + + -, KIAA0862 1 AF054828 + + +
"
KIAA0871 (non-exact 88%) - 1 ' A8020678 ¨
KIAA0873 _ 1 A5020680 ' + + ' + " + -A
KIAA0892 1 A6020699 + - +
' + " + A " + _ KIAA0908 - 1 A13020713 + + + + .
+
KIAA0991 , 1 A5023208.1 .I.
' killer celflectin-like 1 U11276 ' + + +
_ receptor subfamily B, member 1 (KLRB1) , . , ..
Killer cell lectin-like 1 U96846 receptor subfamily C, member 4 (KLRC4) _ kinectin 1 (kinesin receptor) 1 - 013629 (KTN1) .
kinesin family member 58 2 X65873 - + + A + "
(KIF5B) .. .
kinesin-like DNA binding " 1 - A5017430 + + + + +
protein _ L _ Krueppel-related DNA- " 1 1k,461869 binding protein (176) (low match) Kruppel related gene - 1 M20675 (clone pHKR1RS) Kruppel-like zinc finger ' 3 U51869 + - + + ' + + + ' protein 2f9 Kruppel-like zinc finger 1 U44975 + + + + "
protein Zfa (non-exact =
76%) 1 ... _ kruppel-type zinc finger 1 AB011414.1 protein, ZK1 L apofemtin 3 -X03742 _ 'lactate dehydrogenase A ' 3 X02152 " + ' + " + + +
(LDHA) _ õ
lactate dehydrogenase A 1 - X02152 -(LDHA) non-exact, 81%) _ lactate dehydrogenase B 5 X13794 + ' + + + + + high in fetal lung (LDHB)fibrablast . . , lactotransfenin (LTF) 1 U07543 + + + high in bone marrow laminin binding protein (low 1 - 028372 score) laminin receptor 1 (67k0); 20 X15005 + + A
+ + " + + 'high in many Iibranes Ribosomal protein SA
(LAMR1) - = õ
laminin receptor homoTog 1 ¨ S35960 g re9ion) , laminin, gamma 1 (formerly ' 2 ,J032U2 + + + +
LAMB2) (LAMC1) l ,._.

latent transforming growth 2 M34'- + 4. + +
' factor beta binding protein 1 (LTBP1) . .
LAZ3/BCE6 1 Z79581 ' (=Z79582;1328522/4) wit - 2 Z34975 ' + + ' + - + +
lecithin-choiesteror 1 M17959 ' acyltransferase (LCAT) (non-exact, 66%) _ lectin, galactoside-binding, 1 M87842 ' +
soluble, 2 (gaiectin 2) (LGALS2) .
lectin, galactoside-binding, 1 L13210 + + + ' + +
soluble, 3 binding protein (galectin 6 binding protein) (LGALS3BP) leucine nch repeat (in i-Lli) 5 AJ223075 " + + + + +
+
interacting protein 1 leucocyte Teucocyte immunoglobulin- 2 AF072099 ' +
ike receptor-5 (LIR-5) .
eucocyte immunoglobulin- 7 AF025530 -ike receptor-6a (LIR-6) eucocyte immunoglobulin- 2 U82275 + only found in UNS
ike receptor-7 (LIR-7) .
euicemia virus receptor 1 1 L20859 " + - + ¨ + - + ' +
(GLVR1) _ leukocyte adhesion pro-tein 1 ' M29484 ' p150,95 alpha subunit leukocyte antigen, HLA-A2 3 Y13267 ,.._ leukocyte immunoglobulin- ' 3 - AF025528 +
like receptor (MIR-10) leukocyte tyrosine kmase - 1" ' A60702 ' +
found only in blood (LTK) .
leukocyte-associated Ig- -3 - AF013249 +
like receptor 1 (LIAR1) Ieultotnene A4 hydrolase 6 J03459 + + + + + +
(LTA4H) !woman (LDPL) 2 - AF062075 + + +
ligase I, DNA, ATP- T ' M36067 B, T -+ + + +
dependent (LIG1) LIM and SH3 protein 1 2 X82456 + + + + + +
(LASP1) MA-domain kinase 2 . 2' AG002073 ' + + ¨ + + +
(LIMK2) ime-1 protein 1 Line-1 repeat mRNA with 2 1 U93566 + + + + + +
open reading frames -Line-1 repeat with 2 open 1' M22332 + ' + ' + + + + hi0 in gastric tumor reading frames .
LINE-1 REVERSE 1 P08547 ' TRANSCRIPTASE
HOMOLOG
lipase A, lysosomaraacr, 4 X764813 + + + + - +
cholesterol esterase (Wolman disease) (LIPA) . _ . .
lipase, hormone-sensitive 1 L11706 + + +
(LIPE) _ _ .
LMP7 l' " L11045 Lon protease-like proteinZ . .
X74215 + + + ' + ' +
(LONP) _ low density lipoprotein- 2 AF058414 + only in liver related protein 1 (alpha-2-macroglobulin receptor) (LRP1) . .
low density lipoprotein- 1 - M63959 = + + + + -related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1) low density lipoprotein- 1 M63959 related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1) (non-exact, 75%) low-affinity Fc-gamma 1 L08107 receptor IIA
LPS-induced TNI--alpha 9 AF010312 + + ' + + + +
. factor (PIG7) Lst-1 ' 1 U00921 + ' + + + +
L-type amino acid 1 A1-1-04032 transporter subunit LAT1 lung resistance-related 1 X79882 + + ' + + +
protein (LRP) Lymphocyte antigen 75 1 ' AI-011333 B
(LY75) lymphocyte antigen 9 (LY9) 2 L42621 , lymphocyte antigen I-ILA- 2 L42345 B*4402 and HLA-B*5101 lymphocyte cytosolic 42 J02923 protein 1 (L-plastin) (LCP1) lymphocyte cytosolic 4 U20158 T lymphoma, ractivated protein 2 (SH2 domain-containing leukocyte protein of 76kD) (LCP2) lymphocyte glycoprotein 2 X04391 ' + +
T1/Leu-1 lymphocyte-specific protein 16 M33552 + ' + + + +
1 (LSP1) lymphocyte-specific protein 7 M36881 + +
tyrosine kinase (LCK) lymphoid phosphatase 1 AI-001847 LyP1 Iymphoid-restricted 4 U10485 - + _ + +
membrane protein (LRMP) . .
lymphoid-specific SP100 ' 1 A -U36500 +
homolog (LYSP100-A) lymphoma proprotein 2 U33849 + 4. .1. + +
convertase (LPC) LYSOSOMAL 1 P10619 ¨
PROTECTIVE PROTEIN
PRECURSOR
(CATHEPSIN A) (CARBOXYPEPTIDASE C) lysosomal-associated 1 J04182 + + + + -- + +
membrane protein 1 (LAMP1) Lysosomal-associated 1 J04183 ' + + + + +
membrane protein 2 (LAMP2) lysozyme (renal 39 M19045 + + + + +
amyloidosis) (LYZ) lysyl-tRNA synthetase 2 D32053 + + + + +
(KARS) .
M phase phosphoprotein 1 X98494 (U3 small nucleolar ribonucleoprotein) (MPP-

10) .
M1-type and M2-type ' 2 X56494 -pyruvate kinase m6A methyltransferase 7 AF014837 + ' + + ¨
(MT-A70) mab-21 (C. elegans)-like 1- 1 . U38810 + + + +
(MAB21L1) MacMarcks 1 X70326 + _ + + + + +
macrophage-associated 1 Z22968 + + + +
antigen (MM130) MADS box transcription 1 - U49020 ____ + + + +
enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2A) MADS box transcription 1 - L08895 ' ' + ' + + ' +
enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C) .. .
major cytoplasmic tRNA- 1 X17516 Val(lAC) (reM33940) . .
major histocompatibility1 'M95531 complex class I beta chain (HLA-B) -major histocompatibility 41 Z93949 -' + ' + - + - + -' + high in vinous complex, class I, A (HLA-A)adenoma .. -major histocompatibility 1- - Z72422 complex, class I, A (HLA-A) (low match) major histocompatibility 82 ' M24097 ' + + + " + ' + ' +
complex, class l, C (HAL-C) .
major histocompatibility 77 M20022 ++ , --+ + +
complex, class I, E (FILA-E) major histocompatibifity 2 U-15085 + ' + + - += ' +
complex, class II, DM
BETA (HLA-DMB) major histocompatibility 10 M5T466 '-µ + + + + +
complex, class II, DP beta 1 (HLA-DPB1) major histocompatibility 9 V00522 - + + + - + + ' complex, class II, DR beta 1 (HLA-DRB1) Major histocompatibility 2 M24070 .-' 4 + + ¨ + +
complex, class II, Y box-binding protein I; DNA-binding protein B (YB1) .
malate dehydrogenase 1, 1 055654 ., + + + ' += " + +
NAD (soluble) (mdh1) .
melee dehydrogenase 1, 3 D55654 + + + ' +
NAD (soluble) (MDH1) ' `malonyl-CoA 2 AF 04/83'z decarboxyiase precursor ' maltase-glucoamylase 1 AF016833 ' - +
(mg) _ manic fnnge (D-rosophila) 1 U94352 - + + + + +
homolog (MFNG) mannose phosphate 1 X76057 + + + +
isomerase (MPI) .
mannose phosphate - 2 -X76057 + + + +
isomerase (mpi) ' mannose-S-phosphate 3 X56253 + + + +
receptor (cation dependent) (M6PR) mannose-P-doilchoi 1 - AF038961 + + + ' +
utilitzation defect 1 (MPDU1) mannosidase, alpha B, 1 U60885 + ' + + " + -lysosomal (MANB) mannosyl (alpha-1,3-)- - 1 NI55621 - + + + + + +
glycoprotein beta-1,2-N-acetylglucosaminyltransfer ase (MGAT1) _ map 4q35 repeat region - 1 AI-064849 MAP kinase-interacting 2 A8000409 _ + + + + +
serine/threonine kinase 1 (MKNK1) _ MAP/ERK kinase kinase 3 5 - -U78876 +
(MEKK3) MAP/ERK kinase kinase 5 1 ' D84476 " + + +
(MEKK5) MAP/trucrotubuie affinity- 4 M80359 + + + ' regulating kinase 3 (MARK3) Marenostrfn protein - 1 Y14441 - 1---.
MASL1 1 7\-13016816 _____ - -_ . ________________________________________________________________________ 'MAX dimenzatfon protein ' 3 L06895 __ +
(MAD) _ MaxiK potassium channel 1 AFOS5M6 beta subunit MBP-2 for MHC binding 1 " X65644 * + ' + + " + "
protein 2 Meis (mouse) homolog 3 1 U68385 + + + +
(MEIS3) J , melanoma-associated " 1 M12154 antigen p97 (melanotransferrin) _..k . _____________________ .
membrane cofactor protein -- 4 X59405 + + + +
(CD46, trophoblast-lymphocyte cross-reactive antigen) (MCP) membrane component, 4 014696 + + " + + +
chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125) (M17S2) 'membrane metallo- 2 J03, /9 8 ' + + + +
endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) (MME) , *membrane protein, ' 2 M54925 + - + + ' + ' + "
palmitoylated 1 (55kD) (MPP1) Meningioma expressed 1 -U94780 +
antiRen (MGEA) , meningioma-expressed 1 U73682 + ' + + +
antigen 11 (MEA11) _, _________________________________________________ Menkes Disease (ATP (A) 1 LO6T33 +
putative Cu++-transporting P'-type ATPase . .
*meLaflothionein 2A (MT2A) - 1 ¨ V00594 + ' + I + + +
Thetaxin 1 (MTX1) 1 1U46920 H + ' + '4" +
_ inethionine L 2 X68836 + + + + +
adenosyltransferase II, alpha (MAT2A) methyl-CpG binding 1 " Y10(48 domain protein 1 (MBD1) (non-exact 59%aa) . + + + + H
+ i methylene tetrahydrofolate - 2 X16396 +
dehydrogenase (NAD+
dependent), , methenyltetrahydrofolate cydohydrolase (MTHED2) methylenetetrahydroforate 1 - J04031 + + + - + + "
dehydrogenase (NADP+
dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahrrofolate synthetase MTHED1) ______________________________________________________ -methyltrans erase, ()illative- '2 AJ224442 MHC antigen (HLA-B) 1 U14943 (=142024) ¨ -MC class 1 region 2 ' AF055066 MIC-class I antigen (HLA- 1 - U70863 A2) _____________________________________________________________________ MC class l antigen (HLA- 1 U19736 A33) , ... .
MHC class I antigen (HLA- ' 1 U38915 C) MHO class I antigen 1 U52813 B*5801 (HLA-B) MHC class I antigen HLA-A ' 2 F01593 (HLA-A) .
MHC class i an-bgen HLA-A 1 U361i87 (HLA-A-2402 allele) .
MHC class I antigen HLA- - 2 X13112 .

MHC class I antigen HLA-B - 1 - U67331 -(B*0801 variant) (=AF028596) . . -. .
MHC class lantigen HLA-B i U67330 ' (8*0801 variant) (=U88254) _ MHC Class I antigen FILA-B 1 AI-01,328 (B*48 allele) MHC crass i antigen HLA-E3 1 AF014770 (HLA-B*1502 allele) MHC class 1 antigen HLA-B 1 U58543 (HLA-B*40MD) WIC class I antigen FICA-B 1 - AF028596 (HLA-B*4103 allele) .
-MHC class I antigen HLA-B 1 AF035648 . .
-gene (HLA-B*4402 variant allele) .
MHC class I antigen HLA-B 1 U52175 GN00110-B*3910 MHC class I antigen HLA- . 1 083030 Cw*04011 õ
MHC class !antigen 1 U56434 R69772 HLA-A (A*0302) MHC classl antigen 1 ' U58469 SHCHA (HLA-B*4403 variant) .
MHC Gass I 1 U06697 -i histocompatibility antigen (HLA-B) (clone C21/14) -MHC class I FILA 571 ' 2 ' L07950-- _ _________________________________________________________________________ A
MHC class IHIA-A ' 1 Flp (Aw33.1) .
ÚMHC class I FILA-B ' 1 ' U18660 _ , , MHC class I HLA-B (M . A- 1 U18661 B-07ZEL allele) (=X86704) .
, MHC class I FILA-B (MA- - 1 U28759 _ B-08NR allele) , , , MHC class I HLA-B*3512 1 - L76094 ..
' MHC class I HLA-&41 3 U17572 variant (=U17572) . , MHC class 1 HLA-B442 - 1 ' M24038 chain .
MI-1C class FFILA-B51- ' 1 L41086 ' cd3.3 ___________________________________________________________________ WIFIC Gass I HLA-C allele 2 _______________________________________ Z33459 ..
MHC class IHLA-Cww03G4 1 064150 (=M84172; M99389) ' MHC class THLA-CW1)533" 3 ' z15144 .4 - i-M1-IC thss 1 ILA-Gwel- ' 1- M28206 _ ________________________________________________________________________ MHC class 1 MA-J anfigen 1 156139 ' õ ________________________________________________________________________ MHC class I lymphocyte - 1 M19670 ..
antigen A2 (A2.1) variant DK1 _____________________________________________________________________ 'MHC class I rtiro-13 antigen ' T ' X91625 . _______________________ MHC class-I polypeptide- ' 1- L14848 - +
related sequence A (MICA) ' IVING class I protein HLA-C- 1 U61274 heavy chain (C*0701new allele) (=AF017331) - - _ ________________ MHC arass 11DNA 1 L18885 Sequence (clone A37G7-1C11) _ MI4Cr-class 11 dt)-alpha 1 M16995 + + + +
associated with DRwti, DOw1 protein MHC class 0 0Q-beta 2- - M17564 - + - + ' +
associated with DR2, Daw1 protein 171-16 cress 11 FEAL-DC)- f ' M33842 LTR5 (DO,w8) DNA
fragment, long terminal repeat region MHC class II hla-dr alpha- - 1 J00195 chain (=J00197;M60334;K01117 1;J00194;M60333;X00274) .. , TAM class 11 FILA-DRB1 1 AF007883 ' MHC class 11 HLA-DRw11- ' f M21965 - -beta-I chain (DRw11.3) MI-1C class 11 lymphocyte 1 ' M23907 - - - - -antigen (DPw4-beta-1) MHO CLASS 11 1 P33075 = ' ' TRANSACTIVATOR CIITA
(non-exact 57%) .
MHC Hl-E2.1 (=X87679) I 1µ.132507 _ MHC HLA-E2.1 (alpha-2 ' 1 M32507 -domain) (low match) Mi-2 autoantigen 240 klla ' 1 U083/9 protein (non-exact 84%) ..
microsomal stress 70 1 U04735 protein ATPase core (stch) -microtubule-associated 1 - U19727 + + + + +
protein 4 (MAP4) - ' microtubule-associated 1 X73882 ' protein 7 (MAP7) mineralocorticoid receptor 2 M16801 ' + ' ' + +
(aldosterone receptor) (MLR) minIchromosome 1 X62153 '- + + + ' ' +
maintenance deficient (S.
cerevisiae) 3 (MCM31) minichromosome ' 1 A8011144 + - + + ' +
maintenance deficient (S.
cerevisiae) 3-associated protein (MCM3AP) minichromosome 2 X74795 + + + + + + r maintenance deficient (S.
cerevisiae) 5 (cell division cycle 46) (MCM5 mitochondiral cytochrome b 1 AF042517 - -(CYTB) 'rnitochondnal 165 rRNA- 11 L70759 . .
'mitochondria! ATP 2 X59066 synthase (F1-ATPase) alpha subunit mitochondria! ATP 1 X897:17 synthase c subunit (P1 form) mitochondrial cytochrome b 6 AF042508 (CYTB) mitochondnal cytochrome b 1 AB006202 small subunit of complex II , mitochondnaF 1 -P00395 ' CYTOCHROME C
OXIDASE POLYPEPTIDE I . . .
mitochondrial 1 P00403 CYTOCHROME C .
OXIDASE POLYPEPTIDE
II
mitochondrial cytochrome 2 P00403 C oxidase subunit 11 _ =

mdochondnal cytochrome 5 U12691 oxidase subunit II (COW
(=U12692 Hsa4 mitochondrion cytochrome oxidase subunit II) -mitochondnat DNA loop - 1 X89763 ' attachment sequences (clone LAS34) .
mitochondnal DNA ' 1 - U94703 + .
polymerase accessory subunit precursor (MtPolB) nuclear gene encoding mitochondria! protein, mitochondrial DNA, ' 1 ' X93334 complete genome .
mitochondrial genes for 8 V00710 -several tRNAs (Phe, Val, Leu) and 125 and 16S
ribosomal RNAs.
'mitochondrial genes for - 3 V00660 tRNA (Phe) and 12S rRNA
(fragment) _ mitochorkinal inner 1 AF106622 membrane preprotein translocase Thr17a mitochonanal isorate Afr7 1 ' AF042503--cytochrome b(CYTB) mitochondnal loop - 1 X89843 attachment sequence (clone LAS88) 'mitochondrial NADH ' 14 AF014893 . . _ .
dehydrogenase subunit 2 (ND2) , mitochoriarial translational 1 134600 + + + ' " +
initiation factor 2 (MTIF2) 'mitothondrion cyrocnrome ' i U09500 =
b _ 'mitogen inducible gene - 1 ' Z24725 + ' + +
' ' +
mig-2 mitogen inducible gene 1 Z24725 mig-2 (non-exact, 71%) mitogen-activated protein 2 U43784 + + -- + +
kinase-activated protein kinase 3 (MAPKAPK3) lanai 2 ' X80199 + + + + + .
IvILNET4 (=o38255 CAB1) ' 1 -X801-98 + + + +
moesin ticAV).- ' 14 M69066 + + + + +
monocytic leukaemia zinc 2 1747742 ' + + + ' +
finger protein (MOZ) MOP1 0 - 2 ' U29155 motor protein (Hs.75504) ' 2 021094 - + + ' + ' +
+
mouse double minute 2, 1 039736 + +
human homolog of; p53-binding protein (MDM2) , , M-phase phosphoprotein 6 - 1 X98263 + + + +
(MFP-6) mpp11 1viPS1- 1 U2031-4 , Mr 11-0,000 antigen - 2 ' 064134 .
' ++ . . .
+ +
MRC O3t-2, V-like region 1 X06324 -(=M17227) mu-adaffin-related protein- 1 - Y08387 -2: mu subunit of AP-4 (MU-ARP2) multifunctional polypeptide -- 1 . X53793 + - + + +
+
similar to SAICAR
synthetase and AIR
carboxylase (ADE2H1) - -_ "munne leukemia viral (bmi- 1 L13689 - + + + ' 1) oncogene homolog (BMI1) mutant (Daudi) beta2 - 44 =-= X07621 microglobulin mutated in colorectal 1 M62397 + + +
cancers (MCC) , myeloid cell leukemia 9 L08246 + + + + + --sequence 1 (BCL2-related) (MCL1) .
myeloid cell nuclear 11 . 181750 ' + +
differentiation antigeN
(MNDA) 'myeloid differentiation 4 U70451 + + ' + ' +
pnmary response gene (88) (MYD88) myeloid leukemia factor 2 3 U57342 + + +
(MLF2) .. , myeloid/lymphoid or mixed- ' 8 - U89867 4. + 4. +
lineage leukemia (trithorax (Drosophila) homolog);
transiocated to, 7 (MLLT7) MYR9 (cellular myosin 1 M81105 ' heavy chain) myomesin (M-protein) 2 1 X69089 (165kD) (MYOM2) myosin IE (MY01E) 11 X98411 + ' +
myosin light chain kinase 1 U48959 + - + + +
(MLCK) myosin phosphatase, 2 D87930 + + + +
ta et subunit 1 (MYPT1) myosin regulatory light 2 D5lY3 /2 chain (=1J26162) _ myosin VIla (low match 71) 1 U55208 ' myosin,-heavy polypeptide 3 M81105 + + + + +
9, non-muscle (MYH9) myosin, light polypeptide, 6 X54304 ' + + + + + +
regulatory, non-sarcomeric (20kD) (MLCB) myosin-1 beta 1 ' X98507 + + + + +
mynstoylated alanine-rich ¨ 1 - 010522 + +
protein kinase C substrate (MARCKS, 80K-L) (MACS) myrvirus (influenza) 1 M30817 + + + + +
resistance 1, homolog of murine (interferon-inducible protein p78) (MX1) , myxovirus (influenza) ' 3 ' M30818 +
resistance 2, homolog of murine (MX2) N-acelyigalactosamihidase; 2 ' M62783 + + + +
alpha- (NAGA) .
N-acetylglucosamine - 1 - L03532 + ' + + +
receptor 1 (thyroid) (NAGR1) , NACP/alpha-synuclein 2 U46896 N-acilaminoacyl-peptide 1 038441 ' ' + + + +
hydrolase (APEH) N-acylsphingosme 11 ' U47674 ' + + + + ' +
amidohydrolase (acid ceramidase) (ASAH) NAD+-specific isocitrate 1 tj49283 ' + ' + + + +
+
dehydrogenase beta subunit precursor (encoding mitochondria!
protein) NADH dehydrogenase 1 U53468.1 + + + + + +
(ubiquinone) 1 alpha subcomplex, 5 (13kD, B13) (NDUFA5) NAT3H dehydtogenase I AF0471-81 + + - + + + -(ubiquinone) 1 beta subcomplex, 5 (16kD, SGDH) (NDUFB5) _ NADH dehydrogenase 1 - AT05064B - + + + + +
(ubiquinone) Fe-S protein 2 (49kD) (NADH-coenzyme Q eductase) (NDUFS2) NADH dehydrogenase - 1 M22538 ' + + +
' +
(ubiquinone) flavoprotein 2 (2410) (NDUFV2) NADH:ubiquinone ' 2 AF053070 + ' + " + " + ' + +
dehydrogenase 51 kDa subunit (NDUFV1) NADH-GYTOCHROME 85 ' 1 - P00387 REDUCTASE (B5R) (50%aa) . . .
NADH-UBIQUINONE " 1 P03886 ' OXIDOREDUCTASE

Nardilysin (N-arginme 2 U64898 + + + + +
dibasic convertase) (NRD1) .
nascencpolypeptide- 5 X80909 + + 4. ' 4. , associated complex alpha polypeptide (NACA) - . .
natural killer cell group 7 8 ' S69115 + 4.
sequence (NKG7) natural killer cell transcript 19 M32011 + "
4 (NK4) natural killer-associated 1 ' U30274 + ¨ ' blood only transcript 3 (NKAT3) .. -natural killer-associated ' 1 ' AF02.20-45¨ +
' blood only transcript 5 (NKAT5) natural killer-tumor 1 ' 1.04288 8 + + +
recognition sequence (NKTR) N-deacetylase/N- " 2 - AF042084 + ' + - + " +
sulfotransferase (heparan glucosaminyl) 2 (NDST2) , Ndr protein kinase 3 Z35102 - +
Nedd-4-Tike ubiquitin- 1 U96113 protein ligase WWP1 , nel (chicken)-like 2 3 - D83018 ' + - +
(NELL2) _ N-ethylmaleimide-sensitive - 1 1J39412 ' + +
factor attachment protein, alpha (NAPA) ti-ethylmaleimide-sensitive ' 1' _________ U7810/ + 4. +
factor attachment protein, gamma (NAPG) , _ neural precursor cell ' 3 X92544 + + + + + high in testis expressed, developmentally down-regulated 5 (NEDD5) 'neural precursor cell 1 1723662 - + ' + + - + - + - +
"
expressed, developmentally down-regulated 8 (NEDD8) neuregulin f (NRG1) 1 U02330 + ' + + "
, neuroblastoma RAS viral ' 4 AB020692 + ' + - + +
+
(v-ras) oncogene homolog (RAS) . .
Neuroblestoma RAS viral" ' 1 =X68286 =
(v-ras) oncogene homolog (NRAS) (low match) _ Neurotibromin 2 (bilateral 1 -- 573853 + + -acoustic neuroma) (NF2) .
neuronal apoptosis 2 U19251 + + + +
inhibitory protein (NAIP) neuronal cell adhesion 1 AB002341 - + + + - +
molecule (NRCAM) - ¨

neuropathy target esterase 1 - AJ004832 - + + + + -(NT) ' neuropeptide Y3 receptor, 1 - D28433 ' 5'UTR (low score) neurotrophic tyrosine 1-4 X03541+ . _ + + + + +
kinase, receptor, type 1 (NTRK1) . . . .
_ neutrophil cytosolic factor ir Z ' U50720 (40kD) , 'N631 1 AI-129756 ..
. .
, NGAL (=X83006) 1 -X99133-nibnn - (NBS) 1 AF051334 . .
M , K ' 1 AB014587 - + + + +
. .
Ninjunn 1; nerve injury- 1 1I72661 ' + + + +
induced protein-1 nitrilase 1 (NITT) 1 AI-069987 (=AF069984) . . . .
NKG2-D (low match) (-non- - 1 ' -X54870 exact, 58%) Nmi 1 ' U32849 _ N-mynstoylkansferase 1 1 ' AF043324 - + + + + +
(NMT1) .
No arches-like (zebrafish) 1- 1 - U79569 + + + +
zinc finger protein (NAR) .
non-histone chromosome - 1 050420 + + + + + +
protein 2 (S. cerevisiae)-like 1 (NHP2L1) .
non-muscle (hbroblast) ' 1 tropomyosin .
non-muscle alpha-actinin ' f U48734 non-muscle myosin alkali ' 3 M22918 + - + - + + + - + High in fetal adrenal light chain (Hs.77385) gland and BPH
stroma non-neuronal enolase (EC 1 X16289 4.2.1.11) -õ
, non-receptor tyrosine 1 - M33689 phosphatase 1 ... , .
normal keratinocyte 3 + + + + +
+ 19 in many ibraries' substraction library mRNA, clone H22a , notch group protein (N) - 3 - M99437 novel protein 1 X99961 ---novel 1--cell activation 1- X94232 + õ + + +
protein N-ras protein NRU -1 - A60196 _. .
N-sulfoglucosamine - -1 ' U60111 + +
sulfohydrolase (sulfamidase) (SGSH) nsulin induced gene 1 1 -- 096876 + + + + + +
(INSIG1) ntegnn, alpha 4 (antigen -3- ' L12002 + ' ' +
GOOD, alpha 4 subunit of VIA-4 receptor) (ITGA14) nterferon, gamma-inducible 1 M63838 ' + + + + +
protein 16 (IF116) _ nterieukin 1, beta (BARB) 1- ' MI5330 , nuclear antigen H731-like Z U83908 ' ' + ' + + ¨ +
protein nuclear antigen-5p100 4- U36501 + ' ' + + +
(SP100) . ¨
Nuclear antigen SpT00 1 P23497 (SP100) (85%aa) .
-Nuclear antigen Sp100 1 P23497 (SP100) (89%aa) .
. .
_ nuclear autoantigenit 1 M97856 + +
sperm protein (histone-binding) (NASP) , nuclear corepressor KAP-1 1 U78773 (KAP-1) (=U95040; X97548 TIF1beta zinc finger protein) Nuclear domain 10 protein 4 U22897 + + + + + +
(NDP52) .
Nuclear factor (erythroid- 1 - S (4U1 ( + + + + +
derived 2)-like 2 (NFE2L2) .
Nuclear factor of kappa 2 - M58603 + + + " +
light polypaptide gene enhancer in B-cells 1 (p105) (NFKB1) nuclear factor of kappa 3 M69043 + + - + ' +
light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA) -nuclear factor related to - 1 - U08191 + + + +
kappa B binding protein (NFRKB) nuclear mitotic apparatus - 3 Z11583 ' + + + + + +
protein 1 (NUMA1) nuclear receptor 1 X97674 coactivator 2 (GRIP1) nuclear receptor 2 AF010277 + + + - +
coactivator 3 (AIB3) .
nuclear receptor 22 X77548 - + + + + +
coactivator 4 (ELE1) nuclear receptor interacting 1 X84373- ' + + +
protein 1 (NRIP1) -nuclear respiratory factor 1 1 U02683 B ' + +
(NRF1) _ nuclear RNA helicase, 4 U90426 + _ + + + - +
DECD variant of DEAD box family (DDXL) .
. .
nuclear transcription factor 1 X59711 s Y, alpha (NFYA) .
nuclear transcnption factor, 3 U15306 + ' + +
X-box binding 1 (NFX1) nuclear transport factor 2 - 1 X073T5 + + + + +
(placental protein 15) (PP15) _ nucleobindin (=M96824) 1 --1T31.336- -nucleaindin 1 (NUCB1) 2 M96824 + + + + +
_ .
, nucleolar phosphoprotein 1 234289 + ' +
p130 (P130) nuclear protein (KKE7D 1 Y12065 + ' + + + -+
repeat) (N0P56) , -nucleolar protein (MSP58) ' 1 AF015308 --t ' nucleolar protein 1 (120kD) 1 M32110 + +
(NOL1) -, nuckioTar protein p40 1 U86602- + + + - + +
nucleolin (NCL) - 2 - M60858----1 + + + + __ I +
nucleophosmin (nucleolar 14 -M28699 + ' + + + +
phosph7rotein B23, numatrin (NPM1) .
nucleop osmin-retinoic 1 U41742 acid receptor alpha fusion protein NPM-RAR long form _ nucleoponn (NUP368) 2 L41840 (=D42063 RanBP2 (Ran-binding protein 2)) )--nuc.leoporin 1531(13- 1 ' 225535 (NUP153) ________________________________________________________________ nucleoporin 98kD (NUP98) 1 U41815 nucteosome assembly 1 028430 protein nucleosome assembly 1 M8666/ + + + " +
protein 1-like 1 (NAP1L1) nucleosome assembly 2 U77456 + '-' + + + +
protein 1-like 4 (NAP1L4) _______________________________________________________________________ , 'nucleosome assembly - 1 D28430 protein, 5'UTR .
olfactory receptor (0R7- 1 U86281' 141) _ OLFACTORY RECEPTOR-' 1 P34962 (OR17-4) (non-exact 65%) oligodendrpcyte myelin 7 L05367 +
glycoprotein (OMG) .
0-linked-N- ' 1 U77413 + ' + + ' + +
ac.etylglucosamine (Gic.NAc) transferase (UDP-N-acetylglucosamine:polypep tide-N-acetylglucosaminyl transferase) (OG ¨ ____________________ , oncofetal tropholgast 1 A53531 glycoprotein 5T4 precursor (non-exact 55%) .
Oncogene TIM(TIM) (non- 1 (J02082 exact 84%) .
ORF (Hs.778683 1 ' M68864- + + ' + 4 4. + 4.
, ________________________________________________________________________ ORF1;191ER37 putative 1 U49973 A
transposase similar to pogo element Length =
454 .
ongin recognition complex, 2 - U27459 .
+ . , subunit 2 (yeast homolog)-like (ORC2L) ..
origin recognition complex, 1 AF022108 subunit 4 (yeast homolog)-like (ORC4L) (low match) omithine ammoiransterase 2 - M23204 + ' + ' +
(gyrate atrophy (OAT) _.
ornithine aecarboxylase ' 1 M20372 (ODC) omithine decarboxylase 11 078361 + + ' + ' + ' + + 'l-figh in pancreas, antizyme, ORF 1 and ORF and activated T
cells orphan receptor 2 U07132 + ' + + '+ +
(Hs.100221) US-9 precurosor 6 AB002806 ' + + ' + - + - + +
osteonectin (=X82259 BM- 1 U28381 40) vet centrosomal protein 1 AB008515 + + + +
RanBPM (RANBPM) , _____________________________________________________ over-expressed breast 1 L34839 1 .
tumor protein oviductal glycoprotein 1, 1 U09550 - - + + +
120kD (0V0P1) oxidase (cytochrome c) 1 X8Oblib + + + + +
assembly 1-like (OXAIL) oxoglutarate ' 4 1310523 T .
+ + + +
dehydrogenase (lipoamide) (OGDH) .
'oxysterol binding protein 1 M86917 + + _ +
(OSBP) OZt- 1 X70394 " + + + " " + ' 011- (non-exact zinc finger) 1 X70394 a1/CdcA2/Racf:activated 2 - U51120 + --r + + . .
kinase 1 (yeast Ste20-related) (PAK1) .
_ . .
P35-related protein (= 1 D63392 S80990 ficolin) _ $40 1 1J93569 ...
. _ p46phox (=U50720) 1 X77094 . -P47 LBC oncogerie " 4 ' U03634 _ p53-induced protein ' 1 ' AF010315 + _ + + + _ __________________________________________________________________ (PIG11) , panrb (low malch) 1 Y11287 _ ________________________ , ________________________________________________________________________ ' "
'p62 nucleoponn 1 ' X58521 ' _________________________________________________________________________ , p63571RNA/Or T X69910 + + ' + + + -transmembrane protein .
PAC clone 0J0701016 1 ' Q07108 from 7q33-q36 (non-exact 54%) 'palmitoyT-profein ' 10 U44772 + ' + + + ' thioesterase (ceroid-lipofuscinosis, neuronal 1, infantile; Haltia-Santavuori disease) (PPT) "papillary renal cell 1 - X99720 + ' + + + + +
carcinoma (translocation-associated) (PRCC) PAR prole!'" ' 1 - AF115850 " + +
_ .
partial EST (clone c-lgh04) h 1 1- Z43627 PAX3/forkhead- ' 1 U02368 transcription factor gene fusion L ________________________ paxillm (rixN) ' 4 086862 + + + +
IAIK1 protein 2 AJ007398- + + + + ' +
, PBS-ES1 (nz92e0i.s1 1 AA732534 NCI CGAP GCB1 clone IMAOE:130936) (low score) .
'F'DZ domain protein 1 AJ224747 r- + + +
(Drosophila inaD-like) (INALD) PLEN2ac Hunt domain 1 --t Z38108 encoding gene (=Z35728) .
"pepbdase D (PEPD) 1 J04605 `peptidylproly1 isomerase A 3 Y00052 - +
+ + " + ' + high in many libraries (cyclophilin A) (PPIA) peptklyIprolyl isomerase D 2 L11667 - T - + + + + -(cyclophilin D) (PPID) peptidyitiolylisomerase E 1 AF042386 _ + + + ' +
(cyclophilin E) (PPIE) PERB11.1 (=U56942 MAC " 1 L U69630 -class I chain-related protein A) .
...
perforin 1 (preforming 14 ' M28393 protein) (PRF1) peroxisomal acyl-CoA - 2 X86032 thioesterase (PTE1) Peroxisomai acyl- - 1 X71440 " + + + + - +
coenzyme A oxidase , j3eroxisomal famesylated 1 ' X75535 " + + + + +
protein (PXF) . .
_ phorbol-12-myristate-T3- - 1 - 090070 " 8, W
acetate-induced protein (PMAIP1 ) phosphate carrier 1 X77337 - - ¨
(mitochondriallene?) , Phosphate camer, 3 X60036 + + ' + - + - +
mitochondrial (PHC) phosphate 1 L28957 "' T + + ' cytidylyltransferase 1, choline, alpha isoform (PCYT1A) , PHOSPHAl IDATE " 1 092903 " ¨ ,-CYTIDYLYLTRANSFERAS
E (CDP-D1GLYCERIDE) phosphatidylinoiltol 3- 2 U57843 _ . , kinase delta catalytic subunit phosphatidylinositol 4- ' 3 ' A8005910 + + + +
+
kinase, catalytic, beta polypeptide (P1K4CB) ____________________________________________________ phosphafidylinositOlgtycan,- 1 L19783 ' + - + + - + +
class H (PIGH) -phosphatidylinositol 2 ' 030037 r ________________________ ¨
transfer protein (P1-7Pbeta) phosphatidylinositol 2 ' X98654 B, T +
transfer protein, lymphoma membrane-associated (PITPNM) _ , phosphatidylinositol 1 - X98654 transfer protein, membrane-associated (PITPNM) (non-exact 64%) i phosphatidylinosito1-4- 1 k U149o7 + + _ phosphate 5-kinase, type II, alpha (PIP5K2A) phosphatidylinosito1-4- 1 U85245+ ¨ , + + +
phosphate 5-kinase, type II, beta (PIP5K2B) phosphodiesterase 7A 1 ' L12052 B, W - + ' + + -(PDE7A) phosphodiesterase 18 1 ' U56976 - 0KCY
(PDES1B) phostishoglucomutase 1 2 ' M83088-I
+ + + +
(PGM1) phosphogluconate 1 U302bb ' + ' dehydrogenase (PGD) .
phosp-hoglycerate kinase 1 12 V00572 _ (PG1(1) phosphoglycerate mutase 3 J04173 + + - + ' + 1 + ' +
1 (brain) (PGAM1) phosiFoglycerate mutase 1 M55673 ' + + +
2 (muscle) (PGAM2) phosphoinositide-3-kinase, ' 1 1.29090 + + + ' catalytic, alpha polypeptide (PIK3CA) phosphomostbde-3-kinase, 4 U86450 + ' + ' + " --+
catalytic, delta polypeptide (PIK3CD) phosphomositide-Ainase, 1 ^ X83368 catalytic, gamma polypeptide (PIK3CG) phospholipase C ' 1 X14034 ¨ -:
phospholipase Crailta 1 2 . U09117 + + + +
(PLCD1) phospholipase C, gamma 1 1 - M34667- ' + - + + -- +
' 4- +
(formerly subtype 148) (PLCG1) phospN 1olipid scramblase ' 1 At-008445 ' -'phosphoribosyl - 1 = 061391 ' - + 4. +
pyrophosphate synthetase-associated protein 1 (PRPSAP1) phosphonbosylglyanamide ' 3 X54199--- + ' + + - + - +
formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimida zole synthetase (GART) .
phosphorylase tonne, 3 038616 ' ' + * + ' + + +
alpha 2 (liver), glycogen storage disease IX
(PH KA2) phosphorylase, glycogen; 1 U47025 ' + + +
- + - _ brain (PYGB) , phosphorylase, glycogen; 1 ' U47025 brain (PYGB) (low match, non-exact, 75%) pEosphorylase, glycogen; ' 1 Y15233 ' + + + + .
liver (Hers disease, lycogen storage disease type VI) (PYGL) , phosphorylabon regulatory ' 2 protein HP-10 .
. _ phosphotidylmositol 1 - 030036 ' + + .1. 4. +
transfer protein (PITPN) - .

'pigment epithehum-derived 1 U29953 + + - +
' + ' + + ' ' factor (PEDF) pim-1 oncogene (PIM1) 1 r M24779 + " + 1- +
pinin, desmosome 1 U77718 - 5 monOcyte, T Iympnoma associated protein (PNN) placenta (Dift33) 5 - U49188 + + + - - + 1 placenta (0iff33) (non- 1 - U49188 ' exact, 69%) _ placenta (D1ff48) 18 - U49187 +
b.. -placenta (D1ff48) (low 1 U49187 match) placenta(01ff48) (low 1 U49187 match) _ plasminogen activator, 1 X74039 + ' + - +
urokinase receptor (PLAUR) 2 platelet factor 4 (PF4) ' 1 M25897 - + +
platelet/endothelial-cell a M37780 + + + + ' +
adhesion molecule (CD31 ntigen) (PECAM1) pia elet-activating factor 4 U89386 ¨ + + + -acetylhydrolase 2 (40kD) (PAFAH2) _____________________________________ . . .
platelet-activating factor ' 1 ' U72342 + + + + +
+
acetylhydrolase, isoform lb, alpha subunit (45kD) (PAFAH1B1) platelet-activating factor 1 010202 t- + . 2. . ..
+
receptor (PTAFR) pleckstrin (PLEK) 10 X07743 ' + ' + +
pleckstrin (PLEK) (low 1 - X07743 t ________________________ match) . ___________ .
pleckstrin homology, Sec7 4 M85169 + + - + +
and coiled/coil domains 1(cytohesin 1) (PSCD1) pleckstnn homology,Sec7 4 L06633-- + ' +
and coiled/coil domains, binding protein (PSCDBP) pM5 protein 1 X57398 + . + 4 + + ¨ + ' _________________________________________________________________________ 2 poly (ADP-ribose) 1 X56140 polymerase (NAD (+) ADP-ribosyltransferase) (=X16674) poly(A) polymerase (PAP) - 1 . X76770 + ' + - + + --+
poly)-binding protein-like 19 Y00345 + - + 1" + ' +
+ +
1 (PABPL9 _ poly(rC)-binding protein 1 3 X7813T-- + - + " + + + +
SPCBP1) polyadenylate binding - 1 U75686 protein 4_ .
polycystic kidney disease 1 5 U24498 (autosomal dominant) (PKD1) polymerase (DNA - 1 OW __ 3 + + - +
directed), beta (POLB) polymerase (DNA 6 D84103 - , - . .
directed), gamma (POLG) polymerase (RNA) II (DNA -- 1 X63564 + + + + + +
directed) polypeptide A
(220kD) (POLR2A) polymyositisIscieroderma - 1 L01457 + ' + +
+ + ' + .
autoantigen 2 (100kD) (PMSCL2) _ _ polypyrimidine tract binding 1 A65372 ' + ' + ' + + + ' + 4 protein (heterogeneous nuclear ribonucleoprotein I) (PTB) _ , posiEve regukitor of- 3 - U13021 ¨ + -programmed cell death ICH-1L (Ich-1) , _ posimeiotic segregation 1 M16514 + -.
+ + + +
increased 2-like 12 (PMS2L1) postmeititic segregation 1 U38964 + - + + ' += .
+
increased 2-like 8 (PMS2L8) potassium inwardly- 1 - 08(291 rectifying channel, subfamily J, member 15 (KCNJ15) _ potassium voltage- . gated 1 AF051426 ' + + + ' ' +
channel, KQT-like subfamily, member 1 (KCNQ1) õ
POU domain, class 2-, ' 1 Z49194 _ +
associating factor 1 (POU2AF1) POU domain, class 2, ' 2 X13403 ' + + ' transcription factor 1 (POU2F1) _ PPAR binding protein 1 Y13467 + + + ' += " +
(PPARBP) PPAR gammaZ 1 ' D83233 pre-B-cell colony- 8 ' U02020 enhancing factor (PBEF) prefoldin 1 (PFDN-I) ' 1 - YI7392 + + ' + ' + - +
' +
pretoldin 5 (PRFLD5) __ 3 D89667 ----B ' + + ' +
, prefoldin subunit 3 1 ' YI7394 (--AU96759 von Hippel-Lindau binding protein (VBP-1)) .
pregnancy-associated 1 ' U28727 ' + - + high in placenta plasma protein A (PAPPA) pre-mRNA splicing factor 1 ' 1J08815 + + ' + - +=
- +
SF3a (60kD), similar to S.
cerevisiae PRP9 (spiiceosome-associated protein 61) (SF3A60) . .
pre-mRNA splicing factor 1 ' U08815 ' SF3a (60kD), similar to S.
cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60) (low score) .
pre-mRNA splicing factor 2 - 028423 - -SRp20, 5'UTR
preprotetnianslocase 3 ' X97544 + + + + " +
(TIM17) , pnon protein 1 -X82545 ..
prion protein (p27-30) ' 1 ¨ M13899 + + + +
(Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) (PRNP) _ ' pristanoyi-CoA oxfdase 1 Y1-1411 -(low match) pnstanoyi-CoA oxidase " 1 - 'Y11411 ' (low score) _ _ -procollagen-lysine, 2- 1 M98252 + , ' + + +
oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI) (PLOD) , procollagen-prohne, 2- 1 -- M24486+ . + + + + +
oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1 (P4HA1) =.
______________________________________________________________________________ procollagen-proline, 2- 4 - X051-30 + + + + +
+
oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55) T4HB) profilin 1 (PI-N1) ' 1 J03191 +
+ + + + +
_ progesterone receptor- - 2 - U28918 - " + - ' associated p48 protein (P48) prohibitin TPHB) ' 1 S85655 + ' + ' + +
+
proldelating cell nuclear ' 3 JU47T8 , + ' + ¨ + + " +
antigen (PCNA) , 1.
prolderation-associated 4 ' L19184 + ' + ¨
+ ' + + " +
gene A (natural iller-enhancing factor A) (PAGA) "proline-nch protein BstNI - 1 ' S62936 -subfamily 2 (PRB2) (non-exact, 43%aa) .
proline-senne-threonine 1 ' U94778 phosphatase interacting protein 1 (PSTPIP1) .
4. .
prolyiendopeptidase ' 2 - X74496 + + - + ' (PREP) , .
prolylcarboxypeptidase 5 L13977 + + + + +
(angiotensinase C) (PRCP) , _ promyelocytic leukemia 1 M80185- + + + + - +
(PML) properdin P factor, 4 X57748 +
___ complement (PFC) . _ pro-piatelel bast protein - 1 ' M54995 ' + + +
(includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP) pro-pfateiet basic protein 7 M54995 + + + ' (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP) , . .
. , proproTein convertase " 4 - U40623 subtillsin/kexin type 7 (PCSK7) .
prosaposin (vanant ' 89 D00422 + + + + + +
Gaucher disease and variant metachromatic leukodystrophy) (PSAP) .., prostaglandin- 1 ' U63846 B + ' + ' +
endoperoxide synthase 1 (prostaglandin G/H
synthase and cydooxygenase) (PTGS1) .
, .
prostaglandin- - 2 - L15326 "
endoperoxide synthase 2 (prostaglandin G/H
synthase and pyclooxygenase) (PTGS2) .
prostaglandin- - 1 - U64088 _ endoperoxide synthase-1 (=L08404; U84208) (all promoters) prostate carcinoma tumor ' 2 " L78132 ,antigen (pcta-1) protease inhibitor 1 (anti- 17 - K02212- + + + + +
high in many libr3nes elastase), alpha-1-antitrypsin (PI) protease inhibitor 2 (anti- 1 M93056 _ + ' +
elastase), monocyte/neutrophil (ELANH2) (low match) , proteasome (prosome, - 1 -1.02426 B ' + + +
macropain) 26S subunit, ATPase, 1 (PSMC1) proteasome (prosome, 1 M34079 + + + + ---+
macropain) 268 subunit, ATPase, 3 (PSMC3) _ proteasome (prosome, ' 2 - Al-020736 macropain) 26S subunit, ATPase, 4 (PSMC4) .
proteasome (prosome, 5 " 1.-38810 + ' + - + + + +
macropain) 26S subunit, ATPase, 5 (PSMC5) , proteasome (prosome, 2 078275 + + + + +
macropain) 26S subunit, ATPase, 6 (PMSC6) proteasome (prosome, 1 AF001212 T " + " " + "
macropain) 26S subunit, non-ATPase, 11 (PSMD11) J .
proteasome (prosome, 2 D/81b1 + __ + +
macropain) 26S subunit, non-ATPase, 2 (PSMD2) proteasome (prosome, 1 - 579862 T 4. + - - +
macropain) 26S subunit, non-ATPase, 5 (PSMD5) 4-prciteasome (prosome, 1 050063 + + + + high in many libraries macropain) 26S subunit, non-ATPase, 7 (Mov34 homolog) (PMSD7) proteasome (prosome, 1 ' AB003103 + + ' + +
macropain) 268 subunit, on-ATPase, 12 (PMSD12) proteasome (prosome, " J L0/633 + + + + +
macropain) activator subunit 1 (PA28 alpha) (PSME1) , proteasome (prosome, 2 000762 + + + ' + ' macropain) subunit, alpha type, 3 (PSMA3) , proteasome (prosome, 3 X61970 + + + + +
macropain) subunit, alpha type, 5 (PSMA5) i_ , proteasome (prosome, 3 AF054185 + ' + + + ' +
macropain) subunit, alpha type, 7 (PSMA7) proteasome (prosome, 1 ' AF022815 .
macropain) subunit, alpha type, 7 (PSMA7) (low match) protiasome(prosome, 1 D00761 ' + + + ' +-I + ' +
macropain) subunit, beta type, 1 (PSMB1) proteasome (prosome, - 1 - X7 T87-4---- + - + + - +
+
macropain) subunit, beta type, 10 (PSMB10) .
, proteasome (prosome, 1 D29012 - + + + +
macropain) subunit, beta type, 6 (PMSB6) , , proteasome (prosome, - 1 U17497 + ' + ' + + +
macropain) subunit, beta type, 8 (large multifunctional protease 7) (PSMB8) proteasome (prosome, 3 Z14977 + + +
macropain) subunit, beta type, 9 (large multifunctional protease 2) (PSMB9) -proteasome (prosome, 1 038048 - + + - + + + +
macropain) subunit, beta ype, 7 (PSMB7) .
protective protein for beta- ' 3 M22960 + + + + + +
galactosidase (galactosialidosis) (PPGB) .
protein A alternatively 1 U47925 + ' spliced form 2 (A-2) protein activator of the 1 AF072860 + + + +
high in testis interferon-induced protein kinase (PACT) .
protein disulfide isomerase- 2 049489 + + + + + +
related protein (P5) .
protein 1 ' L25441 + + +
geranylgeranyltransferase type I, beta subunit (PG GT1B) . . . . i protein-homologous to 20 M24194 + + + + + + high n many libraries chicken B complex protein, guanine nucleotide binding (H12.3) protein kinase A anchoring 1 AF037439 +
protein protein kinase C substrate 2 U50317 ' + - + + + ' +
80K-H (PRKCSH) . .
protein kinase C, beta 1 6 X063-1a + + + + +
(PRKCB1) _ protein kinase C, delta 1 ' 010495 + + + + +
(PRKCD) .
protein kinase C, eta 1 M55284 + - +
(PRKCH) protein kinasee, mu 1 X75756 (PRKCM) (non-exact 78%) Protein kinase C-like 1- 2 ' 026181 + ' + + + +
(PRKCL1) 'protein kinase, AMP- - 1 U42412 8, T + +
activated, gamma 1 non- lymphoma catalytic subunit (PRKAG1) protein kinase, CAMP- 4 - -M18468 + + + + +
dependent, regulatory, type l, alpha (tissue specific extinguisher 1) (PRKAR1A) .
-protein kinase, DNA- 1 - U4707T--" + + + +
activated, catalytic polypeptide (PRKDC) .
protein kinase, mitogen- 1 Z11695 ' B - + ' + -activated 1 (MAP kinase 1;
p40, p41) (PRKM1) protein kinase, mitogen- 1 L7/964 + + + +
activated 6 (extracellular signal-regulated kinase, p97) (PRKM6) protein kinase, mitogen- 1 U66839 + + + + +
activated, kinase 3 (MAP
kinase kinase 3) (PRKMK3) .
protein phosphalase 1, 5 M63960 - + + + + + ' +
catalytic subunit, alpha isoform (PPP1CA) protein phosphatase 1, -3 - Y1-3247 ' + + - + +
regulatory subunit 10 (PPPR10) protein phosphatase 1, - 2 150749 + + + + + +
regulatory subunit 7 .(PPP1R7) protein rihosphatase-2 1 X12656 + + + + + +
(formerly 2A), catalytic subunit. beta isoform (PPP2CB) -protein phosphatase 2 1 ' L07590 + + +
(formerly 2A), regulatory subunit El" (PR 72), alpha isoform and (PR 130), beta .
isoform (PPP2R3) _ protein phosphatase 2, 2 L42373 + + + + + ' regulatory subunit B (856), alpha isoform (PPP2R5A) protein phosphatase 2, 3 D78360 ' + + + + -regulatory subunit 8 (B56), delta isoform (PPP2R5D) .
protein phosphatase 2, 1 D26445 + + + + +
regulatory subunit 8 (B56), gamma isoform (PPP2R5C) protein phosphatase 2A 5 J02902 + + + + 4. 1 regulatory subunit alpha-isotype (alpha-PR65) _ protein phosphatase 4 2 Al-09!998 + + + + - +
(formerly X), catalytic subunit,PP4C) _ protein rosine kinase 2 4 L49207 + + +
beta (P K213) protein tyrosine 1 X54134 phosphatase epsilon protein 6frosine 2 L48723 + + + + +
phosphatase type IVA, member 2 (PTP4A2) protein tyrosine I - M31724 + - + + +
phosphatase, non-receptor type 1 (PTPN1) protein tyrosine ' 1 m93425- - + - + - + + high in testis phosphatase, non-receptor type 12 (PTPN12) protein tyrosine 1 ' M93425 phosphatase, non-receptor type 12 (PTPN12) (non-exact, 70%) prof-ern t rosine 2 M25393 - + ' + + ' +
phosphatase, non-receptor type 2 (PTPN2) ' protein tyrosine ' 1 ' M68941 + + ' r +
phosphatase, non-receptor tPTPN4)ype 4 (megakaryocyte) ( protein tyrosine 7 M74903 + + ' + + +
phosphatase, non-receptor type 6 (PTPN6) protein tyrosine 1 D1132T - + , + ,- +
phosphatase, non-receptor type 7 (PTPN7) protein tyrosine I M34668 + + + - + + ' phosphatase, receptor tPTPRA)ype, alpha polypeptide ( protein tyrosine 44 Y00638 + ' + ' + +
phosphatase, receptor type, c polypeptide (PTPRC) protein tyrosine 1 X58288 + + ' + " +
phosphatase, receptor type, M (PTPRM) protein Wosine 2 U81561 - + - + - +
phosphatase, receptor type, N polypeptide 2 (PTPRN2) , protein with polyglutamme 1 U94835 + + + + +
repeat (ERPROT213-21) protein-kinase, interferon- 1 U28424- + + ' + " + +
inducible double stranded RNA dependent inhibitor (PRKRI) .
'protein-L-isoaspartate (D- - 4 _ 013892 aspartate) 0-methyltransferase (PCMT1) .
'proteoglycan 1, secretory 7 J03223 ' + + ' +
granule (PRG1) prothymosin, alpha (gene 12 M14483 + + + + + +
sequence 28) (PTMA) _ ' prp28, U5 snRNP TM k T AF026402 + + + + +
protein (U5-100K) PRP4/S iK/VVIY . , splicing " 1 AF001687 + +
+ +
factor (HPRP4P) FM7 protein tyrosine 1 U40271 ' - + + + " - +
kinase 7 (PTK7) punnergic receptor P7X, 3 - AF000234 + ' + + +
ligand-gated ion channel, 4 (P2RX4) punnergic receptor P2X, T - 712851 +
macrophage only ligand-gated ion channel, 7 (P2RX7) puromycin-sensitive ' 1 Y07701 - 4. 4. - +
aminopeptidase (PSA) putative Al P(GTP)-binding 2 AJ010842 + + -protein .
' . , putative brain nucTearly- 1 A8018308 + + + - + +
targeted protein (KIAA0765) putative chemokine - 1 010923 +
receptor; GTP-binding protein (HM74) .
putative dienoyl-CoA ' 1 AF030249 isomerase (ECH1) .
putative G-binding protein 1 AR:165393 . , .
Putative human HLA class 1 U7347T e ' + - +

11 associated protein!
(PHAP1) Putative L.-type neutral - 1 A8007896 amino acid transporter (KIAA0436) putative mitochondria{ 1 AF050198 space protein 32.1 PROTEIN PRECURSOR
24 (MULTI-GLYCOSYLATED CORE
PROTEIN 24) (MGC-24) (MUC-24) .
putative nucleic acid 2 X/6302- + + + + ' +
binding protein J .
putative outer ' 1 ' U58970 + + + +
mitochondrial membrane 34 kDa translocase Htom34 . ...
putifive p150 (non-exact 1 U93568 88%) .
pufitive translation 1 L26247 + + + + + + High in moderately initiation factor (Still) differentiated colon adenocarcinoma putative tumor suppressor 1 --4 AR761836 - + + + +
protein (123F2) pyrroline 5-carboxylate T M77836 + + + + +

reductase pyruvate dehydiegenase ' 1 - D90084 + + + + +
(hpoamide) alpha 1 (PDHA1) .
.
pyruvate dehydrogenase 2 J03576 + + + + +
(hpoamide) beta (PDHB) = ruvate dehydrogenase - 3 - Y13145 + +
complex, lipoyl-containing component X; E3-binding protein (PDX1) _ pyruvate kinase, muscle 11 M23725 +
(PKM2) RAB, member of RAS" - 1 U18420 + + + +
oncogene family-like (RABL) .
Rat member RAS ' 3 M28209 + + + __ +
oncogene family (RAB1) RAB11A, member-RA-Sr - 2 - X56740 + + + + + high in spleen oncogene fam{ly (RAB11A) = RAB116, member RAS 1 045418 +
' +
oncogene family (Rab11B) -RAB27A, member RAS 3 038654 ' +
oncogene family (RAB27A) RAB5B, member RAS 1 X54871 ' + + + ' +
oncogene family (RAB5B) .
RAB6 member RAS 1 M28212 ' + +
oncogene family (RABB) RAB7, member RAS- 1 X93499 + ' + + + +
oncogene famil (RAB7) RAB7, memberRAS 2 084488 + + + +
oncogene family-like 1 (RAB7L1) RAB9, member RAS 1 044103 oncogene family (RAB9) RAD50 (S. cerevisiae) 2 063139 ' + + + - -homolog (RAD50) .
.
RAD5T (S. cereviStae) ' 1 ' AF029669 + - + + ' +
homolog C (RAD51C) Raclin blood group (RD T 2 L03411 - + - + + +
RAE1 (RNA export 1, ' 3 084720 + + + + + -I
S.pombe) homolog (RAE1) raIA-binding protein 2 L42542- + ' + + +
(RLIP76) RAN bindint protein 2-like 2 AF012086 1 (RANBP2 1) .
Ran GI Pase activating 3 X82260 + " + ' + + +
protein 1 (RANGAP1) _ RAN, member-RAS 1 M31469-oncogene family (RAN) (low match) R8nBP2 (Ran-binding T 042063 ' protein 2) (=U19248;
L41840 sapiens nucleoporin (NUP358)) . . .
ransforrning growth factor, 4 Db0683 + + + + +
beta receptor II (70-80kD) (TGFBR2) RAP1 A, member of RAS 10 M22995 +. _ + + + + + ..
oncogene family (RAP1A) RAR-refated orphan 1- U1699T ' +
receptor C (RORC) RAS guanyl releasing 1 Y12336- ' + +
protein 2 (calcium and DAG-regulated) ras homolog gene family, 12 IXObU2 4- + + ' + ' + -µ- + -highin ovary member A (AR HA) ras homolog gene family, 1- - X61587 + + + +
member G (rho G) (ARHG) ras homolog gene family, 2 '' Z35227 ' + +- + + _ + .
member H (ARHH) . 1 ras inhibitor (RINI) 2- - M37191 1 - + -Ras-GTPase activating 2 AF053535 + - + + - + - +
protein SH3 domain-binding protein 2 (KIAA0660) Ras-GTPase-activattng - 3- r-- U32519 + + + - + +
protein SH3-domain-binding protein (G3BP) .
ras-related C3 botulinum - 1-1 M2987-1 + - ' ' +
toxin substrate 2 (rho family, small GTP binding protein Rac2) (RAC2) .
_ .

RAP-16 (GTP-BINDING
PROTEIN SMG P21B) REIQ-1 1 - X85133 + + - + -rearranged T cell receptor 1 L06891 beta variable region (TCRB) (=X58810) _ regulator of Fas-induced 1- AF057557 B -' +
apoptosis (TOSO) i regulator of G protein " 1 AF073920 +
signaliing 6 (RGS6) .
regulator of G-protein 2 Ai-037195 + + + +
signalling 14 (RGS14) regulator of G-protein ' 6 L13391 " + + + + - +
signalling 2. 24k0 (RGS2) .
regulator of G-protein 1 015539 r signalling 5 (RGS5) (49%
aa) regulatory factor X, 4 " 1 M69297 + +
(influences HLA class II
expression) (RFX4) _ regulatory factor X, 5 r 2 X85786 T + + +
(influences HLA class II
expression (RFX5) replication protein A1 1 M63488 + - + ' + + - +
(RPA1) , replication protein A3 r 1 L0/493 ' (14kD) (RPA3) (low match) reproduction 8 (D8S2298b). 1 D83767¨ , + + +
. requiem, apoptosis 2 U94585 + + + + +
response zinc finger gene (REQ) - . -requiem, apoptosis 1 U94585 response zinc finger gene (REQ) (=AF001433) (low match) .
restin (Reed-Steinberg cell- 1 ' M97501 B, T ' + ' + ' expressed intermediate filament-associated protein) (RSN) retinoblastoma 1 (including 3 ' L11910 + ' + + " +
osteosarcoma) (RB1) rebnoblastoma binding 1 ' AF087481 protein 2 homolog 1 (RBBP2H1) . _ rebnoblastoma-binding 1 S66427 + +
protein 1 (RBBP1) retinoblastoma-binding 5- ' S66431" + + + + +
protein 2 (RBBP2) rebnoblastoma-binding 1 X71810 + + + +
protein 4 (RBBP4) rebnoblastoma-binding 1 ' X74262 ' + + + +
protein 4 (RBBP4) -retinoblastoma-binding " 1 ' U35143 protein 7 (RBBP7) . .
rebnoblastoma-like-2 1 X760 . 61 + + + +
(p130) (RBL2) retinoic acid receptor 1 AF060228 ' + + + +
responder (tazarotene nduced) 3 (RARRES3) rebnoic acid receptor, ' 1 ' X06'538 + ' + +
alpha (RARA) , I-retinoic acid responsive 1 U50383 + + +
(NN8-4AG) retinoid X receptor beta 2 X613424 + + + +
(RXR-beta) REV3 (yeast homolog)-like, 1 catalytic subunit of DNA
polymerase zeta,(REV3L) 'Rho GDP dissociation 23 L07916 + 4 + ' + - + ' + +
inhibitor (GDI) beta (ARHGDIB) Rho GTPase activating 2 X78817 + +
protein 4 (ARHGAP4) Rho GI Pase aCtivating 1 P98171 protein 4 (ARHGAP4) (low match) Rho-associated, coiled-coil 1 AB014519 containing protein kinase 2 (ROCK2) Tthonuclease 6 precursor 2 U85625 + - + - + - + +
" +
(RNASE6PL) , , ' ribonuclease 6 precursor - T U85625' (RNASE6PL) (low match) _.
nbonuClease, RNase A T X55988 +
family, 2 (liver, eosinophil-derived neurotoxin) (RNASE2) nbonuclease/angiogenin 3 M36717 + + + + +
inhibitor (RNH) nbonuaeoside dfphosphate 1 X65708 reductase M1 subunit .
ribonucleotide reductase 1 - F'31350 M2 polypeptide (non-exact 91%) _ nbophorin I (RPN1) 1 Y00281 + + + + +
nbophonn 11 (RPN2) - 1 Y00282 + + + + + +
ribosomal 188 rRNA 3 M10098 , n5osomal 28S RNA 1- ' M11167 -n5osomal priosphoprotein ' 1 0215418"
PO, 5'UTR (low match) , ..
Ribosomal protein 1 nbosomal protein L10 ' 30 L25899 + ' + +
+ + + high in many libraries (RPL10) ¨
111:10SUMAL PRO ruN 2 Pb3U25 L10A (CSA-19) , nbosomal protein L11 4 X79234 -1 + + + + + + Al-veolar (RPL11) rhabdomyosarcoma nbosomal protein L12 ' 2 L06505 + + + - + + +
(RPL19) ribosomal protein L13 1- P26373 + + + ' +' + + ' high in many libraries (PRL13) nb-osomal protein L14 4 -087735 ' + + + + + + high in many libraries (RPL14) .
ribosomal protein L17 4 -X53777 + blood only (RPL17) ribosomal protein L18 10- L11566 + + + + +
(RPL18) , nbosomal protein L18a 5 L05093 + + + + + High in-fetal adrenal (RPL18A) gland and skin ribosomal-protein 1.18a - 2 - mut + -homologue nbosomal protein L19 15 X63527 + + + + ' + +
(RPL19) nbosomal protein L21 6 1J14967 + - + + " + + - +
(RPL21) ribosomal protein L22 3 017652 + + + + + -(RPL22) ribosomal protein L23 -2 X55954 + + + + + + 'high in many Libraries (RPL23) nbosomal protein I.23a 5 U37230 + ' + +
+ + ' + high in many libraries (RPL23A) ..1 .
ribosomal protein-L.26 . 8 X69392- + - + + + + +
(RPL26) .
ribosomal protein L.27 6 L05094 + + + + +
(RPL27) .
nbosomarprotein L'Zia 10 U14968 + + + + + +
(RPI.27A) -4 nbosomal protein L28 6 - U14969 + + + ' + - +
(RPL28) .
ribosomal protein L29 6 - U10248 + + + + + +
(RPI.29) ribosomal protein 13 8I- - +
+ - + + + + high in many Ii5earies (RPL3) ribosorriii protein L3 81 ' X06323 -homologue =
ribosomal protein L30 6 X79238 + + + + + + high in lymphoma (RPL30) ribosomal protein L30 1 X79238 (RPL30) (low score) ribosomal protein L31 TO " X15940 ' + + + + + + High in alveolar (RPL31) rhabdomyosarcoma =

==
" ribosomal protein L32 -3 X03342 + + + + + __ +
(RPL32) ribosomal protein L33-like 1 AF047440 + + 4. +
(RPL33L) nbosomai protein L34 5 L38941 + + + + +
(RPL34) .
nbosomal protein L34 1 L38941 (RPL34) (low match) nbosomal protein L37 5 D2365I + + -'" + + + + high in barstead (RPL37)prostate ribosomal protein L371---------4-----766699 + + - + + - + - + high in many libraries ribosomal protein L38 1 Z26876 + + + - + + + high in many libraries (PRL38) ribosomal protein L4 27 D23660 ' + - + - + + + - + high in many libraries (RPL4) nbosomal protein L41 4 AF026844 ' + ' + + ' + - + ' + -high in many libranes (RPL41) .
ribosomal protein L5 14 U14966 + + ' + + + - + High in alveolar (RPL5) rhabdomyosarcoma , ribosomal protein L5 1 U14968 -(RPL5) (low match) ribosomal protein L6 ' 7 ' X59391 + ' + + + + +
high in many libranes (RPL6) nbosomal protein L7 14 X52967 + _ + + + + - + high in conorm (RPL7) ribosomal protein L7a 15 M36072 + " + + + + - + High in uterus, and (RPL7A) seminoma ribosomal protein L8 5 128407 + + + ' + ' + + high in ovary (RPL8) , 'ribosomal protein L9 10 U09953 + + + + +
(RPL9) nbosomal protein S10 5 1114972--- + ' + - + + ' + ' + high in many libraries (RPS10) nbosomai protein 611 4 -X06617 + ' + + + ' + + high in many libranes' (RPS11) .
, nbosomal protein 511 1 A8007152 (RPSI I) (low match) ribosomal protein 512 3 X53505 + + + + ' + + high in many libranes (RPS12) ribosomal protein S13 2 ' 101124 + + + + +
(RPS13) nbosomal protein S14 12 M13934 + + + + + +
(RPS14) ribosomal protein 515 2 - M32405 + + + + + +
(RPS15) nbosomal protein S15 3 M60854 + + + + - + ' + High in prostate (RPS16) invasive tumor nbosomal protein SIT 2 ' MI3932 + + - + ' + ' + + 'high in many libraries (RPS17) _ nbosomal protein 518 ' 8 - X69150 nbosomal protein S19 - 7 ' M81757--- + + ' + + + + high in many hbranes (RPS19) nbosomal protein-S2 4 X17206 + + ' + + + ' + high in many libraries' (RPS2) ' RIBOSOMAL FRO ['LIN S2 2 P15880 - .. . ... .
(RPS4) nbosomal protein S20 7 L06498 - + + - + ' + + + 'high in many libranes(RPS20) nbosomal protein 521 3 L04483 + - + + + - + + 'high in CD34+/CD38-(RPS21) hematopoietic cells and skin tumor ribosomal protein 57.3 3 014530 + + + - -- +
(RPS23) ribosomal protein S24 7 - M31520 + + . + + + - + high in uterus (RPS24) riEisomal protein S25 3 M64716 + - + + - + - +--- + -high in barstead (RPS25) prostate -ribosomal protein S26 2 X69654 ' + + ' + + +
(RPS26) ribosomal protein 527 5 U57847 + _ + + + + +
((metallopanstimulin 1) (RPS27) -, nbosomal protein 528 3 U58682 + + + + +
(RPS28) , ,-ribosomal protein S29 2 014973 + + + + + +
(RPS29) . ., . .
nbosomal protein 53 9 X5571-5 + + + + + + high in many libranes (RPS3) ribosomal protein 53 1 014990 (RPS3) (low match) nbosomal protein 53A 21 Z83334 - + ' + + + + high in many libraries (RPS3A) , nbosomafprotein S3A 1 N177234 (RPS3A) (low score) ribosomal protein 54, X- W ' N158458 + + + + + ' high in ovary and linked (RPS4X) Synovial sarcoma .
'ribosomal protein 54, Y- 2 -- M58459 . + + + - + - + +
linked (RPS4Y) ribosomal protein 55 4 1114970 - + + + + + + high in lymphoma (RPS5) (PHOSPHOPROTEIN
NP33) .
ri6osomai protein 56 22 1M20020 + + + + + +
(RPS6) nbosomal protein S6 1 M77232 (RPS6) (non-exact 86%) ribosomal protein 56 ' 3 L07597 + ' + + + + -kinase, 90kD, polypeptide 1 (RPS6KA1) ribosomal protein 56 1 - X85106 ' kinase, 90kD, polypeptide 2 (RPS6KA2) ribosomal protein 57 4 -Z25749 ' + ' += + ' + + ' (RPS7) nbosomarprotein 58 6 ' X67247 ' ' + + - + + +
(RPS8) _ ribosomal protein 59 8 U14971 colon tumor (RPS9) _ . .
M
nbosomal protein, large, PO- 1-13 -17885 T + +
(RPLPO) nbosomal protein, large, P1 ' 12 - M178136 T + + +
(RPLP1) nbosomal RNA 185 11 *- XU320b 1 (=M10098; K03432) (=poiyadenylating sequence) ribosomal RNA 285 2" ' M11167 nbosomas RNA, 165 1 - U2b123 ' - , _ _ nng finger protein (non- ' 1 ' AJ001019 -exact 58%) Ting finger protein 3 (liNF3) - 1 ' AJ001019 'ling finger protein 4 (RNF4) ' 3 ' AB000468 + " += +
' +
ring zinc-finger protein 3- U41315 + + + -+ -(ZNF127-Xp) RNA. (guanone=T-) r 1 AB007858 ' + + + +
methyltransferase (RNMT) RNA binding motif protein 5 4 1J23946 ' + + + + +
(RBM5) RNA binding motif, single 1 D2848 + .3 . + +
stranded interacting protein 2 (RBMS2) .
RNA helicase ("putative)", 1 "X98743 + ' + ' += ' +
+
(Myc-regulated DEAD box protein) (MRD8) RNA helicase-related- 1 AF083255 ' + ' + + +
protein MIA pol fi largest subunit 2 X74872 RNA polymerasel subunit" 1 ' AF008442 ' ' + + ' +
(RPA40) R11/P-1 protein 2 791911 + ' + + + +

=

' S100 calcium-binding 2 M81457 + + +
protein A10 (annexin 11 ligand, calpactin I, light polypeptide (p1 1)) (S100A10) 5100 calcium-binding 1 X80201 + + + +
protein A11 (calgizzarin) (S100A11) , S100 caictum-binding 3 - M80563 . 13 , - + +
protein A4 (calcium protein, caivasculin, metastasin, murine placental homolog)(S100A4) -S100 calcium-bindin9 7 M21005 + + - + 'high in bone marrow protein A8 (calgranulin A) (S100A8) 5100 calcium-binding 14 - X06233 ' + ¨ + -4 high in invasive protein A9 (calgranulin B) larynx squamous cell (S100A9) __________________________________________________ carcinoma S164 gene 1 AF 109illi t S-adenosylmethtonine - 3 - M88003 + + + + +
decarboxylase 1 (AMD1) SB classll 5 ' M27487 + + + + ' +
histocompatibility antigen alpha-chain 5C35-interacting protein 1 5 AF030234 + + + " + +
" +
(SRRP129) scaffold attachment factor 1 U72355 ' + + + + +
B (SAFB) . .
scaffold attachment-factor 1 U72355 ' B (SAFB) (non-exact 78%) _ scRNA molecule, 1 L13713 _ transcribed from Alu repeat SEC14 (S. cerevisiae)-like - 4 D67029 + + + " +
(SEC14L) ...
StC23-like protein 5 2 X97065 + ' + - + + - - +
(SEC23B) SK63 (SEC63) 1 AFT00141 ' + ' + +
secre . ted protein, acidic, " T M25746 - + + + - +
' + high in bone marrow cysteine-rich (osteonectin) stroma (SPARC) , . .
secretory carrier 1 AF038966 + + -membrane protein 1 (SCAMPI) secretory camer 1 ' AF005038 + + + + + - +
membrane protein 2 (SCAMP2) secretory carrier 1 - AF005039 membrane protein 3 (SCAMP3) secretory granule 1 M33649 proteoglycan core (clones lambda-PG[6,7,8)) .
selectm L (lymphocyte - 43 X17519 + ---.4 ' +
adhesion molecule 1) (SELL) . .
selectin P ligand (SELPLG) 13 U02297 + ' +
sema domain, 2 1J60800 + - + +
immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
(SEMA4D) , Ser/Arg-related nuclear 4 ' AF048977 + + + + +
matrix protein (plenty of prolines 101-like) (SRM160) senne palmitoyltransferase 1 Y08685 + + + +
subunit 1 (SPTI) senne palmitoyltransferase,- 1 - AB011098 + 4. 4 .4. +
subunit II (LCB2) serine protease 1 - J02907 serine protease inhibitor, 1 - U/8095 + ' + - + + ' " +
Kunitz type, 2 (SPINT2) 'sennerthreonfrie kinase 10 1 A8015718 + " + + - + +
(STK10) . _ serine/threonine kinase 19 1 ' L26260 - + + + +
(STK19) $
. .
sennerthreontne kinase 4 1 U18297 + +
(STK4) senne/threonine protein 1 " X66358 ' + + + +
kinase KKIALRE
(KKIALRE) sennerthreonine protein- 1 Y10256 + + +
kinase (NIK) PROTEIN KINASE

PRECURSOR (SKR3) serologically defined colon 2 AF039694 , cancer antigen 16 (NY-00-16) serologically defined colon 1 AF039698 8, T - + -- + - +
cancer antigen 33 (SDCCAG33) serologically defined colon 'I AI-039698 cancer antigen 33 (SDCCAG33) (low score) serologically defined colon 1 ' AF039698 "
cancer antigen 33 (SDCCAG33) (low score) _=.
serum deprivation 'I Al-085481.1.
response (phosphatidylserine-binding protein) (SDPR) (=S67386) serum/glucocorticoid 2 Y10032 + + - + ' + +
regulated kinase (SGK) SET domain, bifurcated 1 2 031891 + + + + ' (SETD81) , SH2 domain protein 1A, 1 AF073019 T +
Duncan's disease lymphoproliferative syndrome) (SH2D1A) . _ SH3 binding protein (SA8) 2 A8005047 + + + + +
i 5H3 domain protein 1B 4 U6115( + + ' ' +
(SH3D1B) .
SH3BGR 'ROTEIN (r-21- 1 ' P55822 GLUTAMIC ACID-RICH
PROTEIN;21-GARP) (non-exact 82%aa) , SH3-bindin9 domain ' 1 AF042081 + + + + +
glutamic acid-rich protein like (SH3BGRL) SH3-domain GR82-like 1 1 '" U65999 + + + + ¨ +
(SH3GL1) _ SRC (src homology 2 2 X68148 + + + +
domain-containing) transforming protein 1 (SHC1) siah binding protein 1 2 U51586 " + ' + + +
(SiahBP1) .
siah binding protein 1- 1 U51586 (SlahBP1) (non-exact, 69%) Sialomucin CD-164 9 014043 (CD184) .
sialophonn (gpL115, 2 J04536 leukosialin, C043) (SNP) = -'sialyltransferase "(S IHM) - 1 U14550 . + + +
-sialyltransferase 1 (beta- - 2 X17247 + + + + .+ +
galactoside alpha-2,6-sialytransferase) (SIAT1) $

sialyltransferase 4A (beta- 1 AF059321 - B - + + +
+
galactosidase alpha-2,3-sialytransferase) (SIAT4A) .
sialyltransferase 8 (alpha- 1 141680 +
2, 8-polysialytransferase) D
(SIAT8D) .
signal peptidase 25kDa 1 L38950 subunit signal recognition particle 1 X73459 + + + + + +
14kD (homologous Alu RNA-binding protein) (SRP14) .
signal recognition particle 1 - U51920 + + +
54kD (SRP54) , signal recognition particle 2- U20998 + + + + +
9kD (SRP9) L
signal recognition particle 5 X'06272 receptor ('docking protein') SRPR
signal regulatory protein, 5 Y1-0376 + ' +
beta, 1 (SIRP-BETA-1) .
signal sequence receptor, 2 Z12830 + +
alpha (translocon-associated protein alpha) (SSR1) signal sequence receptor, 2 XT4104 + + + + +
beta (transloc,on-associated protein beta) (SSR2) signal transducer and 4 ' L41142 + ' + + ' + + +
activator of transcription (STAT5A) ...
signal transducer and 1 U18671 + ' activator of transcription 2, 113KD (STAT2) . .
signal transducer and 3 L29277 activator of transcription 3 (acute-phase response factor) (STAT3) signal transducer and ' 2 '' 048730+ ,- -+ + + + +
activator of transcription 5A
(STAT5A) signal transducing adaptor 1 ' 043899 molecule (SH3 domain and ITAM motif) 1 (STAM) silencing mediator of 1 U3/146 retinoid and thyroid hormone action (SMRT) similar to beta-transducin 1 - U02609 + _ 4. +
4.
superfamily proteins (SAZD) similar to S. cerevisiae 1 - AB011169 + - + + +
SSM4 (TEB4) similar to yeast pre-mRNA 1 AF026031- + + + + +
splicing factors, Prp1/Zer1 and Prp6 SIT protein 1 ' AJ01005g.1 . .
Sjogren syndrome antigen 2 - M62800 - +
Al (52kD, ribonucleoprotein autoantigen SS-Allio) (SSA1) . -Sjogren syndrome antigen 1 - M62800 A1 (52kD, ribonudeoprotein autoantigen SS-A/Ro) (SSA1) (non-exact 63%) (match to zinc finger) .. _ SKAP55 homologue 1 ' AJ0CY4886 + + + +
(SKAP-HOM) skb1 (S. pombe)homolog 2 AF015913 + + + -+ +
(SKB1) skeletal muscle abundant 1 X87613 + + + + +
' protein STVIA3 (SMA3) 1 X83300 + + + ' +
'small acidic protein 3 U51678 + - + ' + + - +
small EDRK-nch factor 2 2 Y10351 + + + + + + high in fetal lung (SERF2) small inducible cytokine A5 - 2 M21121 + + ' + + + + high in many libraries (RANTES) (SCYA5) small inducible cytokine 1 063789 subfamily C, member 2 (SCYC2) small nuclear 2 - M15841 + + + +
ribonucleoprotein polypeptide B" (SNRPB2) small nuclear 4 J04615 + + " + + " + +
ribonucleoprotein polypeptide N (SNRPN) .
small nuclear 2 J04564 - + + ' + - + +
ribonucleoprotein polypeptides B and B1 (SNRPB) .
-small nuclear RNA 1 AF093593 + + + + +
activating complex, polypeptide 5, 19kD
(SNAPC5) smallest subunit of 1 D6bt536 + + + - + + + high in fetal lung ubiquinol-cytochrome c reductase .
SMC (mouse) homolog, X 1 L25270 + + + + +
chromosome (SMCX) SMI-3B protein (2) ' 2 X99585 + + + + + +
_., ____________ SNARL protein (YKT6) 1 U95735 (low match) SgC19 1 U20428 .
SNC73 protein (SNC73) ' 2 J00220 + + + ' + ' + high in many libraries solute carrier family 1 ' 2 U53347 + + +
(neutral amino acid transporter), member 5 (SLC1A5) ________________________________________________________________ Solute camer family 11 ' 7 ' D50403 + -(proton-coupled divalent metal ion transporters), member 1 (SLC11A1) . .
solute camer family 17 -' 1 -U90545 +
(sodium phosphate), member 3 (SLC17A3) solute carrier family 19 1 - U17566 B, I + - + ' (folate transporter), lymphoma member 1 (SLC19A1) solute camer family 2 1 K03195 ' + + + + + +
(facilitated glucose transporter), member 1 (SLC2A1) .
solute carrier family 23 3 087075 + - + + +-(nucleobase transporters), member 2 (SLC23A2) . .__. .
solute carner family 25 , 1 AF070548 - B, T + +
+ +
(mitochondrial owner;
oxoglutarate carrier), member 11 (SLC25A11) ____________________________________________________ solute carrier family 31 3 U83461 + +
(copper transporters), member 2 (SLC31A2) -solute earner family 4, 1 X62137 + + +
anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1) (SLC4A2) solute carrier family 4, 1 AB018282 ___________________ +

sodium bicarbonate cotransporter, member 8 (SLC4A8) = solute camer family 7 2 M80244 - T, W + - + 4- ' (cationic amino acid transporter, y+ system), member 5 (SLC7A5) .
solute carrier family 7 3 087432 + + _ + +
(cationic amino acid transporter, y+ system), member 6 (SLC7A6) , solute carrier family 7 1 087432 (cationic amino acid transporter, y+ system), member 6 (SLC7A6) (non-exact 77%) solute carrier family 9 ' 1 AF030409 .4. - + -"- +
+
(sodium/hydrogen exchanger), isoform 6 (SLC9A6) . . .
somatic cytochrome c 2 M22877 (HCS) SON-DRA binding protein 2 X63753 + + + ¨ + ' (SON) son of sevenless 1 L13858 + + + ' (Drosophila) homolog 1 (SOS1) sorcin (SRI) 1 M32886 sortiTin 1 (SOR11) 2 ' X98248 + + ' +
_ sortilin-related receptor, 6 Y08110 L(DLR class) A repeats-containing (SORL1) _ sorting nexin 1 (SNX1) 3 U53225 + + + + +
sorting nexin 2 (SNX2) 2 AF043453 sorting nexin 6 (SNX6) 1 AF121856.1 (=U83194.1 TRAF4-associated factor 2) Sp3 transcription factor 1 ' X68560 ' + + --1 + ' + +
(SP3) Sp3 transcription factor 4 M97191 _., + + + + +
(SP3) special AT-rich sequence 1 M97287 binding protein 1 (binds to nuclear matrix/scaffold-associating DNA's) (SATB1) speckle-type POZ protein 4 AJ000644 (SPOP) speckle-type POZ protein 1 AJ000644 (SPOP) (non-exact) spectnn 5H3 domain ' 6 087166 ' + + + + ' binding protein 1 (SSH3BP1) Speafin, alpha, non- 2 ¨ J05243 - + + " +
erythrocytic 1 (alpha-fodrin) (SPTAN1) , _ , spermichneispermine N1-11 M55580 acetyltransferase (SAT) . .. . .
-spermidine/spermine N1- 1 ¨ 040369 ' acetyltransferase (SAT) (non-exact, 84%) , spermine synthase (SUS) ¨ T A0001528 + + + + +
SPF31 (SPI-31) 1 AF083190 + + + + +
splungomyelin 1 X52679 + + +
phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) (SMPD1) , SPINDLIff HOMOLOG 1 Q99865 (PROTEIN DXF34) _ spinocerebellar ataxia 1 3 X79204 Er + +
(olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) (SCA1) _ spinocerebellar ataxia 2 - 1 1J70323 B __ +
, (olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2) (SCA2) _ spinocerebellar ataxia 7 2 AJ000517 +
(olivopontocerebellar atrophy with retinal degeneration) (SCA7) spliceosome associated 3 U41371 + + + + -- +
protein (SAP 145) .
splicing factor (CC1.3) 2 L10910 + ' + + + + +
(CC1.3) ....
splicing factor SRp40-1 7 U30826 + + + + + +
(SRp40) splicing factor, ' 3 M74002 B + + + +
arginine/serine-rich 11 (SFRS11) .
splicing factor, 4 L41887 + + + +
arginine/serine-rich 7 (35k0) (SFRS7) Src-like adapter protein - 1 U30473 (non-exact, 76%aa) Src-like-adapter (SCA) 6 D89077 + + + +
-Src-like-adapter (SLA) (low 1 D89077 match) .
Src-like-adapter (S1A) (low 1 - U44403 score) ' stannin (SNN) ' 2 AF030196 + - + - + + +
S'TAT induced STAT 1 ' ABOD4904 - + -inhibitor 3 (SSI-3) Si E20-like kinase 3 (MST- - 2 AF024636 + - + + + +
3) step 11 splicing factor SLU7 L 1 AF101074 + + ' + +
(SLU7) .
steroid sulfatase 1 M17591 ' ._ , steroid sulfatase ' 1 J04964 - + + +
(microsomal), arylsulfatase C, isozyme S (STS) , ..
sterol carrier protein 2 1 M55421 + + + + +
(SCP2) .
sterol 0-acyltransferase 1 Al-059202 +
(acyl-Coenzyme A:
cholesterol acyltransferase) 1 (SOAT1) stimulated trans-acting 6 X82200 + + +
factor (50 kDa) (STAF50) .
Stnabn, calmodulin-binding 1 U17989 -protein (STRN) (low match, 71%aa) Stromal antigen 2 (S I AG2) 2 ' L75331 + + + +
stromal interaction ' 3 ' U52426 " + + + +
+
molecule 1 (STIM1) structure specific 1 ' M86737 + + + +
recognition protein 1 (SSRP1) .
, succinate dehydrogenase 5 L21936 +
complex, subunit A, flavoprotein (Fp) (SDHA) .
, succinaie dehy-drogenase 1- U17248 + + + + +
complex, subunit B, iron sulfur (Ip) (SDHB) succinate dehydrogenase f U57877 + + + + +
complex, subunit C, integral membrane protein, 15kD (SDHC) succinate dehydrogenase 3 ' AB006202. + + +
complex, subunit D, Integral membrane protein (SDHD) succinate-CoA ligase, 1- F058954 + + + + +
GDP-forming, beta subunit (SUCLG2) _ = sucanyl CoA synthetase 1 Z68204 sudD (suppressor of 2 - AF013591 + + +
bimD6, Aspergillus nidulans) homolog (SUDD) , sulfotransferase family 1A, 1 L19999 + + +
phenol-preferring, member 1 (SULT1A1) sulfotransferase family 1A, ' 1 U37686 phenol-preferring, member 3 (SULT1A3) (non-exact 67%) superoxide dismutase 1, 4 X02317 + + + ' +
soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1) superoxide dismutase 2, 5 ' Y00985 + + + + +
mitochondriai (SOD2) , supervillin (SVIL) 2 AI-051851 + ' + +
suppression of 2 U15131 + + +
tumorigenicity 5 (ST5) ..
suppression of 1 U15779 tumorigenicity 5 (ST5) (non-exact 82 A) .
suppressor of K+ transport 1 AI-038960 + + ' defect 1 (SKD1) suppressor of Ty 1 A1-064804 + + + + +
(S.cerevisiae) 3 homolog (SUPT3H) suppressor of Ty 2 U38817 + + + - + ' +
(S.cerevisiae) 4 homolog 1 (SUPT4H1) suppressor of Ty ' 2 ' U56402 ' + - +
(S.cerevisiae) 5 homolog (SUPT5H) suppressor of Ty 2_._. .
U46691 + + + + + +
(S.cerevisiae) 6 homolog (SUPT6H) .
suppressor of variegation 1 AF019988 + + +
3-9 (Drosophila) homolog 1 (SUV39H1) survival of motor neuron 1, - 1 U18423 telomeric (SMN1) SVVI/SNF related, matrix 1 ' M88163 + " + ' +
associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1) (non-exact, 75%) SVVI/ali- related, matrix 2 D26155 +
associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARM) SVV1/SNF related, matrix 1 026156 + + + + + +
associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) SVV1/SNF related, matrix ' 4 U666I6 + + ' + + + +
associated, actin dependent regulator of chromatin, subfamily c, member 2 (SMARCC2) SVVI/SNF related, matrix 2 A1-035262 B, W + + + +
' associated, actin dependent regulator of chromatin, subfamily e, member 1 (SMARCE1) synaptobrevin-like 1 1 X95803 + + + +
(SYBL1) synaptosomal-associated 2 AJ011915 ' - + + + +
protein, 23kD (SNAP23) , syndecan binding protein 15 AF006636 + + + + +
(syntenin) (SDCBP) synovial sarcoma, 2 X79201 +
translocated to X
chromosome (SSXT) syntaxin 16 1 AF-038897 -syntaxin 3A (STX3A) 2 U32315 - + + ' +
_.
syniaxin 6 (STX6) 1 AJ002078.1 . _ PROTEIN 3 (UNC-18 HOMOLOG 3) (UNC-18C) syntaxin-16C 1 AF008937 SYT interacting protein 1 AF-080561 + + + ' +
(SIP) I cell activation, increased 4 M88282 + ' late expression (TACTILE) ' I cell receptor V alpha 2 X58744 gene segment V-alpha-7 (clone IGRa11) , I cell receptor V alpha 1 X58740 -gene segment V-alpha-w27 I 3 receptor-associating 5 S83890 - + + + + + +
cofactor-1 tafazzin (cardiomyopathy, 1 X92763 + + + +
_ dilated 3A (X-linked);
endocardial fibroelastosis 2; Barth syndrome) (TAZ) .
i AF 11100 protein (non- 1 - U80191 exact 53%) tankyrase, 1 RF1- 1 AF082556 + + + +
interacting ankyrin-related ADP-ribose polymerase (TNKS) ____________________________________________ , IAP1, I AP2, LMP2, LMP7 1 - X66401 _ and DOB
i AR UNA-binding protein- 6---- U23731 + - _ + + + +

i afinteractive protein 2 U40989 + 4. + + +
(60kD) (TIP60) i A 1 A box binding protein 1 000268 -(TBP)-associated factor, RNA polymerase II, Cl, 130kD (TAF2C1) (non-exact, 55%) ' 1A1A box binding protein 4 _____________ X97999 + + + + +
(TBP)-associated factor, RNA polymerase II, F, 55kD (TAF2F) . L._ .
I A TA-box binding protein 2 _____________ U21858 + + + + +
(TBP)-associated factor, RNA polymerase 11, G, 32kD (TAF2G) IAI A box binding protein 1 063705 + + + + +
(TBP)-associated factor, RNA polymerase II, I, 28kD
(TAF2I) i ax1 (humarit-cell 1 U33821 + ' + + ' + +
leukemia virus type I) binding protein 1 (TAX1BP1) .
i -box 2 ( i BX2) (non-exact 1 U28049 + + +
77%) I BP-associated factor 172 1 AJ001017 + + + ' (TAF-172) õ
.
i -celr-death-associated 1 U9o218 +
gene 8 (TDAG8) õ
I-cell leukemia/lymphoma 1 X82240 + ' 1A (TCL1A) _ I -cei1 leukemia/lymphoma 1 X82240 1A (TCL1A) (low match) .
I -cell receptor (delta 02- 1 M22197 J1-region) (clone K3B) i -cell receptor (V beta 5.1, 1 __ M97705 .
J beta 1.5, C beta 1) (low match) .
i -cell receptor alpha delta 2 AE000662 (=M94081) 'í-cell receptor alpha 1 839625 enhancer-binding protein, short form (=X58636 Mouse LEF1 lymphoid enhancer binding factor 1 (=D16503)) 1-cell receptor delta gene 1 M22197 D2-J1-region, clone K3B
, ________________________________________________________________________ i -cell receptor germline 1 M119ob beta chain gene V-region (V) V-beta-MT1-1 l -cell receptor germline 1 M14159 + ' only in blood beta-chain gene J2.1 exon .
I -cell receptor germline 2 M22152 delta-chain D-J region __________________________________________________ i-cell receptor interacting 2 AJ224878 +
molecule (TRIM) protein _________________________________________________ F-cell receptor rearranged 1 M21784 delta-chain, V-region (V-delta 3-J) 'I-cell receptor, alpha 3 AE000660 + + + ' + +
(V,D,J,C) (TCRA) I-cell receptor, beta cluster 3 L34740 + + + + + +
high in pancreas (TCRB) .
l -cell receptor, delta 2 X73617 + + - + "
(V,D,J,C) (TCRD) , i -cell, immune regulator 1 3 U45285 only found in-tumor (TCIRG1) , __________________ .
'iCi--1 mRNA for i cell 1 X59870 factor 1 .
i CF-I mRNA for I cell 1 X59870 factor 1 (splice form B) (low match) OMPLEX PROTEIN 1, 1 Q99832 1 ETA SUBUNIT (TCP-1-ETA) (CCT-ETA) (HIV-1 NEF INTERACTING
PROTEIN) ________________________________________________________________ I -COMPLEX PRO FEIN 1, 1 P50990 -THETA SUBUNIT (TCP-1-THETA) (CCT-THETA) (KIAA0002) i CR eta =T cell 1 - 694421 receptor(eta-exon) 'I CH V Beta 13.2 1 - X75419 i ERA 1 AC004472 'testis enhanced gene 33 X75861 - + + + - + - + +
transcript (TEGT) tetracycline transporter-like- 2 L11669 + + + +
protein (TETRAN) .
tetratncopeptide repeat 1 U46570 + + + + +
domain 1 (TTC1) fetratncopepticle repeat ' 1 - U465 /1 + + +
domain 2 (TTC2) retratncopeptide repeal 1 -084296 + + + + + -domain 3 (TTC3) , I Cil-B1-induced anti- 1 086970 + + 4. 4. +
apoptotic factor 1 (TIAF1) ______________________________________________ thioredoxin reductase 1 3 S79851 4.. 4. 4. +
(TXNRD1) i HIOREUOXIN- 1 P30048 -DEPENDENT PEROXIDE
REDUCTASE
PRECURSOR, mitochondria! (ANTI-OXIDANT PROTEIN 1) (AOP-1) -threonyl-tHNA synthetase 1 - M63180 + + + +
(TARS) thrombin inhifitor ' 1 - Z22658 thrombospondin 1 (1 HBS1) 2 X04665 + + + + +
thromboxane A synthase 1 1 M80647 + + + +
(platelet, cytochrome P450, subfamily V) (TBXAZ1) thymidine kinase 2, 2 - X76104 + + +
mitochondrial (TK2) thymidylate kinase (COGS) - 1 L16991 + ' + + +
thymine-DNA glycosylase 2 051166 + - + + + ' " +
(113G) i hymosin, beta 10 2 ' M20259 + + ____ + + + +
(TMSB10) thymosin, beta 4, X 29 " M17733 + ' + + " + ' chromosome (TMSB4X) .
thyroid autoantigen 70kD 7 J04611 (Ku antigen) (G22P1) thyroid hormone receptor - 1 AF016270 " + ' + +
coactivating protein (SMAP) thyroid hormone receptor 2 L40357 + ' + ' + + -interactor 7 (TRIP7) thyroid hormone receptor 4 - L40411 " ' +
interactor 8r (TRIP8) _ thyroid hormone receptor- 1 D83783 "
associated protein, 230 kDa subunit (TRAP230) thyroid receptor interacting 2 L403811 " + + + +
protein 15 (TRIP15) _ ' i I-22/H 1 050525 '. i -i IA1 cytotoxic granule- 1 M7,'142 + + + +
associated RNA-binding protein (TIA1) , tissue inhibitor of 1 X02598 + + + + + +
metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1) tissue inhibitor of ' 1 M32304 + + + " + ' +
high in placenta metalloproteinase 2 (TIMP2) i_ tissue specific 1 U58766 + + + + +
transplantation antigen P35B (TSTA3) titin (T1 N) 1 X64697 + ' + + + ¨ + ' high in muscle i Ni- receptor-associated 1 U12597 ' + ' + + ' +
factor 2 (TRAF2) I NI- receptor-associated 1 AI-110908.1 +
factor 3 (TRAF3) iN1- receptor-associated 1 U78798 - -factor 6 (TRAF6) (low match) , toll-like receptor 1 (TLR1) 1 - 1:18W40 +
toll-like receptor 2 (TLR2) 1 ' 1188878 + + + +
toll-like receptor 4 (TLR4) 1 U88880 L - + ' +
toll-like receptor 5 (T11..R5) 1 " AF051151 - 1 + +
_ _ topoisomerase (13NA)I 1 J03250 + + +
(TOP1) .
topoisomerase (DNA)1l 2 X68060 ' + - + + + ' + -beta (180kD) (TOP2B) _ . .
topoisomerase (DNA) III 3 ' D87012 +
beta (TOP3B) =
i N3beta 1 085245 ' +
iifkl-iamily member- 3 U63830 + + + + - + +
associated NF-kB activator (TANK) i FAIZALDULASE 1 P37837 transaldolase 1 (TALD01) 4 L1D437 + + + + + -' transaldolase-related r 1 ___________________ F010388 _ protein .
-transcobalamin li (TOD - 1- Ai-04 ib /b ' _ -transcription elongation - 2 Z47087¨* + ¨
+ + + +
factor B (SIII), polypeptide 1-like (TCEB1L) ' transcription elongation 1 L4/345 + + + + + +
factor B (5111), polypeptide 3 (110kD, elongin A) (TCEB3) _ transcription factor 12 1 ' M83233 + + + + +
(HTF4, helix-loop-helix transcription factors 4) (TCF12) transcription factor 17 ' 2 D89928 + _ +
(TCF17) transcription factor 4 2 X52079 + ¨ + ¨ + +
(TCR4) transcription factor 6-like 1 2 M62810 + + + +
(mitochondria, transcription factor 1-like) (TCF6L1) _ transcription factor 7-like 2 - 1 Y11306 + + + +
(T-cell specific, HMG-box) (TCF7L2) transcription factor binding 1 X96717 + + + + +
to IGHM enhancer 3 (TFE3 transcnption factor IL-4 7 AF06 /575 + + + + + +
Stat .
transcnption factor1L-4 1 U16031 Stat (low match) .
transcrip-tion factor 1SGF-3 4 M97935 , (=M97936) transcription factor-REST 1 A56138 -transcnption factor TFIID 1 ' Z22828 transcnptional adaptor 2 1 AF06094 _ (ADA2, yeast, homolog)-like (TADA2L) . .
transcriptional intermediary 1 AF009353¨
factor 1 (TIF1) (non-exact 72%) transducin (beta)-like 1 1 Y12781 + ' + + + +
(TBL1) .
transducin-like enhancer of . 1 M99438 ' + +
split 3, homolog of Drosophila E(sp1) (TLE3) i ransforrnation/transcriptio 1 AF076974 + + + +
+
n domain-associated protein (TRRAP) .
transformation-sensitive, 2 - M86752 4. - + + +
similar to Saccharomyces cerevisiae STIl (STI1L) transforming growth factor 1 AB009.356 beta-activated kinase 1 (TAK1) (non-exact 78%) transforming growlh factor 3 AJ222700 + -- + j + + " +
beta-stimulated protein TSC-22 (TSC22) transforming growth factor, - 1 L07594 + + + +
beta receptor III
(betaglycan, 300kD) (TGFBR3) transforming growth factor, 2 4507466 + ¨ + 7 + ..--1- + +
beta-induced, 68kD
(TGFBI) .
¨
t liANSFUHMING 2 Q15582 GROWTH FACTOR-BETA

PRECURSOR (BETA IG-H3) transforming, acidic coiled-. 1 AF049910 coil containing protein 1 (TACC1) (non-exact 70%) transgelin 2 (TAGLN2) 14 D21261 + + + - + + + -transgelin 2 (TAGLN2) 1 D21261 (non-exact) -trans-Golgi network protein ' 2 AI-029316 + +
(46, 48, 51kD isoforms) (TGN51) , transient receptor potential 1 X89066 + + + +
channel 1 (TRPC1) .
transketolase (VVemicke- 7 - L12711 + + + +
Korsakoff syndrome) (TKT) -translation factor surl 1 AF06460T + + + + +
homolog (GC20) translin (TSN) 3 X78627 + + + + +
translin-associated factor X 1 ' X9b073 + " + +
+
(TSNAX) , transmembrane ' 1 U79725 glycoprotein (A33) transmembrane protein 1 X89910 + ' + + + +
(63kD), endoplasmic reticulum/Golgi intermediate compartment (P63) transmembrane protein 1 1 ' A8001523 + + - +
(TMEM2) PROTEIN SEX
PRECURSOR (non-exact 65%) _ transmembrane trafficking - 2 X97442 + + + + + +
protein (TMP21) transporter 1, ABC- (ATP 3 L21208 + + ' + + +
binding cassette) (TAP1) !reacher Collins- 2 U40847 + + + + + high in many libraries Franceschetti syndrome 1 (TC0F1) triosephosphate isomerase 2 X69723 + + + + + +
1 (TPI1) . 1 tropomyosin - 2 X04201 ' + + + +
, tropomyosin 4 (TPM4) 2 X0b278 + + + + +
i liPM=2 protein 2 ' M63376 ' tryptase I precursor (non- 1 A35863 exact 64%)(=P20231) tryptophan rich basic 1 - Y12478 ' protein (VVRB) tryptophanyl-tRNA - 1 - X59892 + + + + + +
synthetase (WARS) I s translation elongation 1 ' L37936 + ' + + +
factor, mitochondria!
(TSFM) .. .
ttopoisomerase (DNA)11 1 ' -L1b115 + + +
beta (180kD) '1 u translation elongation 4 L38995 ' factor, mitochondrial (TUFM) _ tuberous sclerosis 1 ' 1 ''. AF013188 + + + +
(TSC1) tuberous sclerosis 2 1 ' X75621 + + + +
(TSC2) .
tubulin, alpha 1 (testis 1 - X06956 + +
specific) (TUBA1) .
tubulin, alpha, ubiquitous 11 - K00558 + - + + + + + ' high in many libranes (K-ALPHA-1) tubulin, alpha, ubiquitous 1 - K005b8 (K-ALPHA-1) (low match) tubulin-specific chaperone 1 U61234 + + + +
c (TBCC) , tumor necrosis factor ' 7 - 037518 + + + +
(ligand) superfamily, member 10 (INFSF10) tumor necrosis factor - 1 AF046888 + + + + -(ligand) superfamily, member 13 (INFSF13) tumor necrosis factor 1 AF036581 (ligand) superfamily, member 14 (TNFSF14) tumor necrosis factor 1 ' 038122 + ^ -Found only in library (ligand) superfamily, 386: T-cell lymphoma member 6 (TNFSF6) .
tumor necrosis factor 1 L09753 13 only (ligand) superfamily, member 8 (TNFSF8) .
tumor necrosis factor 1 AF061034 + 4. ' 4. +
alpha-inducible cellular protein containing leucine zipper domains (FIP2) i umor necrosis factor 2 M63928 + +
receptor superfamily member 7 (TNFRSF7) tumor necrosis factor 1 - AF016266 + + + + +
receptor superfamily, member 10b (TNFRSF10B) .
tumor necrosis factor 3 AF012629 +
receptor superfamily, member 10c, decoy without an intracellular domain (TNFRSF10C) _ tumor necrosis factor 1 AF023849- , found only in prostate receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D) (non-exact 84%) tumor necrosis factor 1 U94508 + + + + +
receptor superfamily, member 12 (translocating chain-association membrane protein) (TNFRSF12) .
tumor necrosis factor I U70321 + + + + +
receptor superfamily, member 14 (herpesvirus entry mediator) = (TNFRSF14) tumor necrosis factor ' 5 U52165 + + + + +
receptor superfamily, member 1B (TNFRSF1B) , tumor necrosis factor 1- X53717 B, W +
receptor superfamily, member 6 (TNFRSF6) .
, .
tumor necrosis factor T M63928 + +
receptor superfamily, member 7 (TNFRSF7) ¨
tumor necrosis factor, - 8 M92357 + + +
alpha-induced protein 2 (TNFAIP2) -tumor necrosis factor, Z M59465 alpha-induced protein 3 (TNFAIP3) , tumor protein 53-binding 1 AF078776 4. .4_ + +
protein, 1 (TP53BP1) .
tumor protein p53 (Li- ' 1- MI4695 + + - +
Fraumeni syndrome) (TP53) , i umor protein p53-binding 1 U82939 + + +
protein (TP53BPL) tumor protein, 1 35 - Xi-6064 translationally-controlled 1 (TPT1) .
tumor protein, _ 1 XT6064 , translationally-controlled 1 (TPT1) (low score) tumor rejection antigen 9 X15187 + + + + + +
(gp96) 1 (TRA1) ' tumorous imaginal discs 2 AF061749 +
(Drosophila) homolog (TID1) -i )0c-tyrosine kinase (l XK) 2 ' L2 /071 -type 11 integral membrane 1 AJ001685 +
found only in fetal protein (NKG2-E) liver/spleen l MU protein tyrosine 3 AF019562 +
kinase binding protein (T(ROBP) tyrosine 3- 1 X57346 + + + + + high in ecnorm monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3- 1 M86400 monooxygenase/tryptopha n 5-monooxygenase activation protein, zeta polypeptide ( YWHAZ) , I-tyrosine 3- 1 M86400 monooxygenase/tryptopha n 5-monooxygenase activation protein, zeta polypeptide (YVVHAZ) l yrosine kinase 2 (i YK2) ' 3 X54637 + + + +
_ , ' i YHOSINE:PtiU i EIN 2 P43403 KINASE ZAP-70 (70 KD
ZETA-ASSOCIATED
PROTEIN) (SYK-RELATED
TYROSINE KINASE) .
tyrosy)-tRNA synthetase 1 U89436 ' + + + + +
(YARS) U1 small nuclear RNA 1 M14387 . -UfgFI snoRNA (=M63485 1 AJ224166 R.norvegicus matrin 3) U2(RNU2) small nuclear 1 M96982 + + + +
RNA auxiliary factor 1 (non-standard symbol) (U2AF1) , -_ U22 snoRNA host gene 2 U40580 ' (UHG) U470-associated tiNA --' 4 AF016370 ' ' + + ' + +
splicing factor (HPRP3P) _ U49 small nuclear RNA 1 X96649 ' U5 snRNP-specific protein 1 ___________________________________________ + + + + +
(220 kD), ortholog of S.
cerevisiae Prp8p (PRP8) .
UTinRNP-specific protein,¨ 4 ' D21163 + + + ' +
+
116 kD (U5-116KD) .
' U5-inRNP-specific protein, 3 Z70200 ' 200 kDa (DEXH RNA
helicase family) (U5-200-KD) Uba80 mRNA for ubiquitin 4 579522 + - + + + + + high in ovary ubiquinol-cytochrome c 1 D55636 + + + + + + high in fetal lung reductase (6.4kD) subunit (UQCR) , CYTOCHROME C
REDUCTASE IRON-SULFUR SUBUNIT
PRECURSOR (RIESKE
IRON-SULFUR PROTEIN) (RISP) (low match) , _____________________________________ ubiquitin A-52 residue 2 X56999 ribosomal protein fusion product 1 (UBA52) .
, ________________________________________________________________________ ubiquitin activating enzyme 1 AF094516 + + +
E1-like protein (GSA7) __________________________________________________ ubiquitin C (UBC) - 5 AB009010 + + + + + high in ovary ubiquitin carboxyl-terminaf 1 M30496 + + + + +
esterase L3 (ubiquitin thiolesterase) (UCHL3) ubiquitin fusion degradation 1 LJ64444 + + + + +
1-like (UFD1L) ubiquitin protein ligase E3A 1 U84404 B ' + + +
(human papilloma virus E6-associated protein, Angelman syndrome) (UBE3A) ubiquitin specific protease 4 D80012 + + + + +
(USP10) ubiquitin specific protease 1 U44839 + + + + + +
11 (USP11) ubiquitin specific protease - 3 AB011101 + + + +
+
(USP15) ubiquitin specific protease 1 A13020698 +
19 (USP19) ubiquitin specific protease 1 AF017305 B + + ' + +
4 (proto-onc,ogene) (USP4) ubiquitin specific protease 1 AF017306 .
4 (proto-oncogene) (USP4) (non-exact, 66%) ubiquitin specifia protease ' 1 Z72499 - + + ' + +
7 (herpes virus-associated) (USP7) ubiquitin specific protease 5 D29956 + + - + +
8 (USP8) .
UBIQUI i INACTIVATING ' 1 P22314 .
ENZYME El (A1S9 PROTEIN) (56%) ubiquitin-activating enzyme 1 M58028 + + + + +
El (Al S9T and BN75 temperature sensitivity complementing) (UBE1) ubiquitin-activaling enzyme 1 L34170 + + ' + +
E1, like (UBElL) UBTQUITIN-BINDING 1 U41806 + + -PROTEIN P62;
phosphotyrosine independent ligand for the Lek SH2 domain p62 (P62) ubiquitin-conjugating 2 U49278 + + + + + +
enzyme E2 variant 1 (UBE2V1) ubiquitin-conjugating 1 - X98091 enzyme E2 variant 2 (UBE2V2) .
UBIQU1TIN= 1 06781 CONJUGATING ENZYME
E2-17 KD (UBIQUITIN-PROTEIN LIGASE) ubiquitin-conjugating 1 M74525 + + + ' + +
enzyme E2B (RAD6 homo19) (UBE2B) ubiquitin-conjugahng 1- AF032456 + + + + +
enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2) ubiquitin-conjugating 1 Z29328 + - + ' + + +
enzyme E2H (homologous to yeast UBC8) (UBE2H) ubiquitin-conjugating 1 X92962 + + +
enzyme E2L 1 (UBE2L1) ubiquitin-conjugating 3 AJ000519 - + + + .
+
enzyme E2L 3 (UBE2L3) ubiquitin-conjugating ' 4 AF031141 + + + + +
enzyme E2L 6 (UBE2L6) ubiquitin-like 1 (sentnn) 2 U61397 + _ + + + +
(UBL1) . ¨
UDP-N-acetyl-alpha-D- 2 X85019 galactosamine:polypeptide N-acetylgalactosaminyltransf erase 2 (GaINAc-T2) (GALNT2) ' UDP-N-acetyl-alpha-D-_ galactosamine:polypeptide N-acetylgalactosaminyltransf erase 3 (GaINAc-T3) (GALNT3) (non-exact 65%) unactive progesterone 2 L24804 + + + +
receptor, 23 Kd (P23) , unconventional myosin-ID 3 _____________________________ U5/LW
(MY01F) uncoupling protein 1 ..

homoloq (IJCP1-Q
uncoupling protein 1 U94592 -homolog (UCPH) (low match 67%) , Unknown gene product 1 Acoonio unknown mRNA (clone 1 AF070542 24514) unknown protein (clone 2 Z70223 ICRFp507L0677) unknown protein 1 AF070626 + + + ' + + +
(Hs.93832) unknown protein rria 1 AF040966 uppressor of Ty 1 , 079984 + + + + + +
(S.cerevisiae) 6 homolog upregulated by 1,25-_ 74 573591 .
+ + + + + high in heart dihydroxyvitamin 0-3 (VDUP1) .
. .
upregulated by 1,25- 1 573591 ..
dihydroxyvitamin D-3 (VDUP1) (low match) upregulated by 1,25- 1 ' 573591 _ dihydroxyvitamin D-3 (VDUP1) (low match) , upregulated by 1,25- 1 ' 573591 1 dihydroxyvitamin 0-3 (VDUP1) (low score) , _ upstream binding factor 1 X53461 + ' + + +
(hUBF) , UV radiation resistance 2- X99050 + + + +
associated gene (UVRAG) vacuolar proton-ATPase, 4- X71490 ' + + ' + + +
subunit D; V-ATPase, subunit D (ATP6DV) v-aki munne thymoma viral 1 M63167 + + + + +
oncogene homolog 1 (AKT1) Vanin 2 (VNN2) 3- AJ132100 ..
vasodilator-stimulated 3 Z46389 + + + +
phosphoprotein (VASP) vav 1 oncogene (VAV1) 1- M59834 +
, , .
vav 2 oncogene (VAV2) 1 576992 + +
v-crk avian sarcoma virus 1 D10656 - W + + ' +
CT10 oncogene homolog (CRK) v-erb-b2 avian ' 1 M29366 +
erythroblastic leukemia viral oncogene homolog 3 (ERBB3) , PROTEIN PRECURSOR .
Vesicle-associated ' 1 M36196 + + '+ +
membrane protein 1 (synaptobrevin 1) (VAMP1) vesicle-associated 1 1J64520 ' membrane protein 3 (cellubrevin) (VAMP3) _ v-fos FEiJ murine 26 K00650 + + + - + + 'high in aorta osteosarcoma viral oncogene homolog (FOS) _ v-fos I-13J munne 1 K00650 osteosarcoma viral oncogene homolog (FOS) (low match) 'viIlin 2 (ezrin) (VIL2) 1 X51521 + 4. 4. + +
= , villin-like protein l 088154 vimentin (VIM) 12 X56134 + + ' + + + ' high in many libraries vinculin (VCL) 4 ' M33308 + + + +
vitamin A responsive; 6 AFO __ /0523 + " + + +
cytoskeleton related (JWA) .
v-jun avian sarcoma virus 2 U65928 + + + + +
17 oncogene homolog (JUN) v-myb avian myeloblastosis 1 M15024 ' + + ' viral oncogene homolog (MYB) .
voltage-dependent anion 1 L06132 ' + + + ' + - +
channel 1 (VDAC1) .
voltage-dependent anion ' 4 U90943 + + + +
channel 3 (VDAC3) . , von Hippel-Lindau ' 1 L15409 + + 4. + ' syndrome (VHL) von VVillebrand factor ' 1- X06828 (vWF) (low matched) v-raf munne sarcoma 3611 - 2 L24038 + ¨ + ' + +
viral oncogene homolog 1 (ARAF1) v-rat-1 murine leukemia 1 X03484 + ' + + + +
viral oncogene homolog 1 (RAF1) . . .
oncogene homolog B (ras related; GTP binding protein) (RALB) V-rel avian - 1 L19067 + + + +
reticuloendotheliosis viral oncogene homolog A
(nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65)) (RELA) .
v-yes-1 Yamaguchi - 2 M16038 + + + +
sarcoma viral related oncogene homolog (LYN) 1/VD repeat domain -1 1 ¨ A8010427 + + ' + + + ' +
(WDR1) VVDR1 (=AI-020260) .

WD-repeat protein - 2 ' U94747 - 4. , + 1 _______ -4.
HAN11) Williams-Beuren syndrome 12 AF0455b5 ' + ' + ' + + + +
chromosome region 1 (WBSCR1) ________________________________________________________________ VViskott-Aldnch syndrome - 4 - X86019 + + + +
protein interacting protein (WASPIP) ________________________________________________________________ X (inactive)-specific -2 - M97168 transcript (XIST) .
ieroderma pigmentosum, - 3 - D21089 + + + +
complementation group C
(XPC) XIAP associated factor-1 ' 2 - X99699----- +
XIE- 1 ' X90392 + + ,+ +
_ ¨
X-linked anhidroitic 1 AF003528 ectodermal dysplasia _ = X-ray repair 1 M30938 + + + +
+ high in spleen complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80kD) (XRCC5) XRP2 protein 1 A..1007590 yeroid differentiation 1 U84408 + + + +
primary response gene (88) (MYD88) zeta-chain (TCR) 1 L05148 + +
associated protein kinase (70kD) (ZAP70) .
zeta-chain (TCR) 1 L05148 associated protein kinase (70kD) (ZAP70) (low match) zinc finger protein 2 U69274 + + + + +
(Hs.47371) zinc finger protein 1 U69645 + + ' + ' + +
(Hs.78765) , .
zinc finger protein 10 (KOX 1 X78933 + only 1) (ZNF10) LNG' FINUER PRO I bIN 1 U15973 124 (HZF-16) (non-exact 51%) zinc finger protein 124 1 S54641 (HZF-16) (ZNF124) (non-exact, 78%) ZINC FINUER PHU I UN 1 Pb/3b zinc finger protein 136 1 U09367 - ' + +
(clone pHZ-20) (ZNF136) zinc finger protein 140 1 ' U09368 - + + +
(clone pHZ-39) (ZNF140) zinc finger protein 140 1 AP-060865 (clone pHZ-39) (ZNF140) (non-exact 59%) zinc finger protein 140 1 U09368 -(clone pHZ-39) (ZNF140) (non-exact 73%) . ._ .
zinc finger protein 140 1 565508 (clone pHZ-39) (ZNF140) (non-exact 73%aa) zinc finger protein 140 1 009368 (clone pHZ-39) (ZNF140) (non-exact, 80%) zinc finger protein 143 2 009850 + + + + - + +
(clone pHZ-1) (ZNF143) zinc finger protein 143 1 U09850 (clone pHZ-1) (ZNF143) (low match) zinc finger protein 148 1 AF039019 + ' (pHZ-52) (ZNF148) ziNU FiNUER PHOTbIN 1 U13105 151 (MIZ-1 PROTEIN) (low match) zinc finger protein 173 1 ' U09825 B, T " + ¨ + +
(ZNF173) zinc finger protein 192 1 U57796 (ZNF192) (non-exact, 66%) _ zinc finger protein 198- 1 AJ224901 + + +
(ZNF198) zinc finger protein 2 (ZNF2) 1 X60152 (low match) zinc finger protein 200 1 Al- 06013Er + - +
(ZNF200) , zinc finger protein 207 6 ''. AF046001 + + - + + - + +
high in prosiate (ZNF207) zinc fi-nger protein 216 2 AF062072 + + + + +
(ZNF216) _ ' zinc finger protein 217 1- AF041259 T activated - +
(ZNF217) .

22 (ZINC FINGER
PROTEIN KOX15) (non-exact 58%) zinc finger protein 230 1 U95044 + -(ZNF230) 'Linc finger protein 239 1 L26914 + + "
(ANF239) zinc finger protein 261 1 ' A13002383 + + + _ + 1 (ZNF261) zinc finger protein 262 T ' AB007885 + + + ' +
(ANF262) . . .
zinc finger protein 263 1 088827 (ZNF263) zinc finger protein 264 1 A13007872 + +
+ - 1 (ZNF264) ' ZINC; HNGER PRO i EIN 1 Q06730 -33A (ZINC FINGER
PROTEIN KOX31) (KIAA0065) (HA0946) zinc finger protein 42 1 M58297 + + + ' + +
(myeloid-specific retinoic cid- responsive) (ZNF42) , zinc finger protein 43 1 ' X59244 ' (HTF6) (ZNF43) (low match) ' . , zinc finger protein 43 1 - X59244 ' (HTF6) (ZNF43) (non-exact, 54%) zinc finger protein 43 1 X59244 (HTF6) (ZNF43) (non-exact, 71%) 43 (ZINC PROTEIN HTF6) (non-exact 67%) zinc finger protein 45 (a 1 L75847 only found in testis Kruppel-associated box (KRAB) domain polypeptide) (ZNF45) LING' FINGER PROTEIN 1 P24278 46 (ZINC FINGER
PROTEIN KUP) (non-exact 62%) zinc finger protein 6 1 X56465 + ' + _ + , +
(CMPX1) (ZNF6) zinc finger protein 74 1 X71623 (Cos52) (ZNF74) (non-exact, 67%) zinc finger protein 76 ' 1 M91592 + - + + ' +
(expressed in testis) (ZNF76) J , 'LING I-INGER-PRO t LIN 1 P51522 83 (ZINC FINGER
PROTEIN HPF1) (non-exact 65%) zinc finger protein 84 1 M27878 T activated - + + +
(HPF2) (ZNF84) zinc finger protein 85 2 U35376 + ' + +
(ZNF85)) zincifriger profem 9 RNF13) 5 M28372 - + + + + +
, ________________________________________________________________________ 'ANC" i-INGER PROTEIN 1 P35789 93 (=ZINC FINGER
PROTEIN HTF34) (non-exact 70%) zinc finger protein C21-12-25 -3 - U38904 + = + " +
(ZNF25) .
zinc finger protein clone 1 ' AF024706 L3-4 .
zinc finger protein 4 ' M92843 + - blood only homologous to Zfp-36 in mouse (ZFP36) I _________________________________________________________________________ HRX (ALL-1) (71%a.a.) zinc finger protein HZF4 1 X78927 zinc finger protein RI4 1 D45132 + + +
zinc finer protein, 1 U40462 subfamily 1A, 1 (lkaros) (LYF1) zinc finger protein, 1 U40462 subfamily 1A, 1 (lkaros) (LYF1) (low match) zinc finger transcnptionat 1 M92844 regulator (G0S24) + + +
cn-15 related zinc finger 1 U22377 + + +
protein (r1f) Ln-15 related zinc finger 1 U22377 protein (r1f) (non-exact 56%) Efi\AJ long 1 X83497 terminal repeat ZW10 (Drosophila) 2 U54996 homolog, centromere/kinetochore protein (ZW10) zyxin (ZYX) 4 X95735 Column 1: List of unique genes derived from 6,283 known ESTs from blood cells.

Column 2: Number of genes found in randomly sequenced ESTs from blood cells.
Column 3: Accession number. Column 4: "+" indicates the presence of the unique gene in publicly available cDNA libraries of blood (B1), brain (Br), heart (H), kidney (K), liver (Li) and lung (Lu). **Comparison to previously identified tissue-specific genes was determined using the GenBank of the National Centre of Biotechnology Information (NCBI) Database.
Discussion Every cell and tissue comprising the human body share the necessary genetic information required to maintain cellular homeostasis. These "housekeeping"
genes function in basic cellular maintenance, including energy metabolism and cellular structure in all cell types. However, in certain situations, even the housekeeping genes show altered expression. Thus, it is necessary to define the use of these genes as internal controls from one investigation to another. Current results from the human blood cell EST database indicate that over 50% of the transcripts are widely expressed throughout the human body. Most of the cell or tissue specific genes are also detectable in blood cells by RT-PCR analysis.
For example, isoformic myosin heavy chain genes are known to be generally expressed in cardiac muscle tissue. In the rodent, the f3MyHC gene is only highly expressed in the fetus and in diseased states such as overt cardiac hypertrophy, heart failure and diabetes; the aMyHC gene is highly expressed shortly after birth and continues to be expressed in the adult heart. In the human, however, 13MyHC is highly expressed in the ventricles from the fetal stage through adulthood.
This highly expressed 13MyHC, which harbours several mutations, has been demonstrated to be involved in familial hypertrophic cardiomyopathy (Geisterfer-Lowrance et al.
1990).
It was reported that mutations of 13MyHC can be detected by PCR using blood lymphocyte DNA (Ferrie et al., 1992). Most recently, it was also demonstrated that mutations of the myosin-binding protein C in familial hypertrophic cardiomyopathy can be detected in the DNA extracted from lymphocytes (Niimura et al., 1998).
Similarly, APP and APC, which are known to be tissue specific and predominantly expressed in the brain and intestinal tract, are also detectable in the transcripts of blood. These cell- or tissue-specific transcripts are not detectable by Northern blot analysis. However, the low number of transcript copies can be detected by RT-PCR analysis. These findings strongly demonstrate that genes preferentially expressed in specific tissues can be detected by a highly sensitive RT-PCR
assay. In recent years, evidence has been obtained to indicate that expression of cell or tissue-restricted genes can be detected in the peripheral blood of patients with metastatic transitional cell carcinoma (Yuasa et al. 1998) and patients with prostate cancer (Gala et al. 1998).
Atrial natriuretic factor (ANF) and zinc finger protein (ZFP), which are known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients, are also detectable in the transcripts of blood.
Differential expression of zinc finger protein among the normal, diabetic and asymptomatic preclinical subjects may have additional value as a prophylactic early warning system". On a related note, there is now more attention/discussion in the cardiovascular disease field being focused on Syndrome X, loosely defined as a continuum of hypertension, increasing sugar levels, diabetes, kidney failure, culminating in heart failure, with the possibility of stroke and heart attack at any time in the continuum. The early identification of patients at risk of organ failure has been a challenge to the medical community for some time and the present method has the potential of resolving or, at least, ameliorating this challenge.
The present invention demonstrates that a simple drop of blood may be used to determine the quantitative expression of various mRNAs that reflect the health/disease state of the subject through the use of RT-PCR analysis. This entire process takes about three hours or less. The single drop of blood may also be used for multiple RT-PCR analyses. There is no need for large samples and/or costly and time-consuming separation of cell types within the blood for this method as compared to the methods described by Kimoto (1998) and Chelly et al. (1989; 1988). It is believed that the present finding can potentially revolutionize the way that diseases are detected, diagnosed and monitored because it provides a non-invasive, simple, highly sensitive and quick screening for tissue-specific transcripts. The transcripts detected in whole blood have potential as prognostic or diagnostic markers of disease, as they reflect disturbances in homeostasis in the human body. Delineation of the sequences and/or quantitation of the expression levels of these marker genes by RT-PCR will allow for an immediate and accurate diagnostic/prognostic test for disease or to assess the efficacy and monitor a particular therapeutic.
In addition to RT-PCR, other methods of amplifying may also be used for the purpose of measuring/quantitating tissue-specific transcripts in human blood.
For example, mass spectrometry may be used to quantify the transcripts (Koster et al., 1996; Fu et al., 1998). The application of presently disclosed method for detecting tissue-specific transcripts in blood does not restrict to subjects undergoing course of therapy or treatment, it may also be used for monitoring a patient for the onset of overt symptoms of a disease. Furthermore, the present method may be used for detecting any gene transcripts in blood. A kit for diagnosing, prognosing or even predicting a disease may be designed using gene-specific primers or probes derived from a whole blood sample for a specific disease and applied directly to a drop of blood. A cDNA library specific for a disease may be generated from whole blood samples and used for diagnosis, prognosis or even predicting a disease.
The following references were cited herein:
Claudio JO et al. (1998). Genomics 50:44-52.
Chelly J et al. (1989). Proc. Nat. Acad. Sci. USA. 86:2617-2621.
Chelly J et al. (1988). Nature 333:858-860.
Drews J & Ryser S (1997). Nature Biotech. 15:1318-9.
Ferrie RM et al. (1992). Am. i Hum. Genet. 51:251-62.
Fu D-J et al. (1998). Nat. Biotech 16: 381-4.
Gala JL et al. (1998). Clin. Chem. 44(3):472-81.
Geisterfer-Lowrance AAT et al. (1990). Cell 62:999-1006.
Groden J et al. (1991). Cell 66:589-600.
Hwang DM et al. (1997). Circulation 96:4146-4203.
Jandreski MA & Liew CC (1987). Hum. Genet. 76:47-53.
Jin 0 et al. (1990). Circulation 82:8-16 Kimoto Y (1998). MoL Gen. Genet 258:233-239.
Koster M et al. (1996). Nat Biotech 14: 1123-8.
Liew & Jandreslci (1986). Proc. Nat. Acad. Sci. USA. 83:3175-3179 Liew CC et al. (1990). Nucleic Acids Res. 18:3647-3651.
Liew CC (1993). J Mot Cell. Cardiol. 25:891-894 Liew CC et al. (1994). Proc. Natl. Acad. Sci. USA. 91:10645-10649.
Liew et al. (1997). Mol. and Cell. Biochem. 172:81-87.
Niimura H et al. (1998). New Eng. J. Med. 338:1248-1257.

Ogawa M (1993). Blood 81:2844-2853.
Santoro IM & Groden J (1997). Cancer Res. 57:488-494.
Yuasa T et al. (1998). Japanese J. Cancer Res. 89:879-882.
Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains.
One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

Claims (9)

CLAIMS.

1. A method of profiling gene expression in a human subject having diabetes, the method comprising for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from an unfractionated blood sample of the subject, wherein the set comprises the genes identified in Table 3-II, thereby profiling gene expression in a human subject having diabetes.

2. A method of screening the human genome to identify at least one marker for differentiating between subjects having diabetes and subjects not having diabetes, the method comprising.
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes, wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a marker for differentiating between subjects having diabetes and subjects not having diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby screening the human genome to identify at least one marker for differentiating between subjects having diabetes and subjects not having diabetes.

3. A method of screening the human genome to identify at least one potential marker for differentiating between subjects having diabetes and subjects not having diabetes, the method comprising (a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a potential marker for differentiating between subjects having diabetes and subjects not having diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby screening the human genome to identify at least one potential marker for differentiating between subjects having diabetes and subjects not having diabetes.

4. A method of identifying at least one marker for differentiating between subjects having diabetes and subjects not having diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a marker for differentiating between subjects having diabetes and subjects not having diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby identifying at least one marker for differentiating between subjects having diabetes and subjects not having diabetes.

5. A method of identifying at least one potential marker for differentiating between subjects having diabetes and subjects not having diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a potential marker for differentiating between subjects having diabetes and subjects not having diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby identifying at least one potential marker for differentiating between subjects having diabetes and subjects not having diabetes.

6. A method of screening the human genome to identify at least one marker of diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a marker of diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby screening the human genome to identify at least one marker of diabetes.

7. A method of screening the human genome to identify at least one potential marker of diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;

wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a potential marker of diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby screening the human genome for at least one potential marker of diabetes.

8. A method of identifying at least one marker of diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a marker of diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby identifying at least one marker of diabetes.

9. A method of identifying at least one potential marker of diabetes, the method comprising:
(a) for each gene of a set of genes, determining a level of RNA encoded by the gene in total blood cell RNA extracted from unfractionated blood samples of human subjects having diabetes; and (b) comparing the level of step (a) with a level of RNA encoded by the gene in blood of human subjects not having diabetes;
wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a potential marker of diabetes, and wherein the set comprises the genes identified in Table 3-II, thereby identifying at least one potential marker of diabetes.